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ABSTRACT 
Drug Induced Liver Injury (DILI) is associated with high morbidity and mortality 
rates. It is the leading cause of acute liver failure, accounting for 50% of all cases. 
Moreover, DILI is the most frequent cause of post marketing drug withdrawal and is 
often cited as a cause of compound attrition during the drug-development process. 
The High Mobility Group Box 1 (HMGB1) protein is an important inflammatory 
mediator which alters the immune system to tissue stress and injury. HMGB1 has 
been implicated in the pathogenesis of multiple inflammatory diseases including 
immune-mediated DILI. It has been identified as a potential biomarker of hepatic 
injury and a target for therapeutic intervention. Research is required to elucidate the 
pro-inflammatory role of HMGB1. HMGB1 has been reported to interact with a 
diverse range of endogenous (IL-1, DNA, nucleosomes, CXCL12) and exogenous 
(LPS) molecules to promote inflammation. However, the mechanisms responsible 
for these synergistic interactions remain poorly defined and therefore, the overall aim 
of this work was to characterise the interactions of HMGB1. Specifically, this work 
has focused on the interaction with IL-1β, which is of particular interest since both 
molecules often co-exist at the site of inflammation.  
The interaction between HMGB1 and IL-1β was investigated using combined 
cellular and Nuclear Magnetic Resonance (NMR) methodologies. LPS-free, 
isotopically labelled recombinant HMGB1 (full length protein, amino acids 1-215) 
and IL-1β proteins were expressed and purified from BL21 (DE3) cells. To facilitate 
these studies, three additional HMGB1 mutants were sub-cloned from the HMGB1 
plasmid: Δ30 (1-185), A box (1-85) and B box (89-163). The recombinant proteins 
were characterised using Mass Spectrometry (MS) and NMR spectroscopy.  
Synovial fibroblasts were isolated from synovial tissue obtained from rheumatoid 
arthritis patients undergoing joint replacement surgery. Cells were treated with 
HMGB1 (full length, Δ30, A box or B box) alone or combination with IL-1β. Cell 
supernatants were collected after 24hr and IL-6 levels were quantified by ELISA. 
Untreated fibroblasts or cells treated with any HMGB1 construct, or IL-1β alone had 
no detectable IL-6 release (<9.375pg/mL). In contrast, full length HMGB1, the Δ30 
and the B box domain (but not the A box domain) all acted in synergy with IL-1β to 
substantially enhance IL-6 production. In one patient, HMGB1, Δ30 and the B box 
in combination with IL-1β induced IL-6 levels of 28,473 ± 127pg/mL, 18,491 ± 
2388pg/mL and 18,710 ± 2792pg/mL, respectively. The synergistic interaction was 
mediated via the Interleukin-1 receptor (IL-1R) and could be inhibited when the cells 
were pre-treated with 5µg/mL anakinra, a selective IL-1R antagonist but not 
detoxified LPS, a TLR4 receptor antagonist.   
To investigate if there is a direct interaction between HMGB1 and IL-1β, a 
comprehensive biophysical analysis was performed using NMR methodologies. 
However, despite performing the experiments in various ways, no evidence of a 
direct interaction between IL-1β and either full length HMGB1, Δ30 or the B box 
was detected. This suggests that the synergistic interaction between HMGB1 and IL-
1β is mediated via an alternative cellular mechanism in which HMGB1 is required.  
In conclusion, the work presented in this thesis has identified that the B box domain 
of HMGB1 is critical for the synergistic effect observed with IL-1β. However, this is 
not due to the formation of a binary complex between HMGB1 and IL-1β. Instead, it 
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would appear that the synergistic effect is mediated via an alternative cellular 
mechanism in which HMGB1 is required and additional proteins are involved.  
Future work could focus on discovering what these other proteins might be. These 
findings help to elucidate the pro-inflammatory role of HMGB1 and provide a novel 
an insight into HMGB1 biology.  
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1.1. INTRODUCTION 
Adverse Drug Reactions (ADRs) are a major clinical problem impacting on patient 
morbidity and mortality rates. In the US, ADRs rank between the 4
th
 and 6
th
 leading 
cause of death (Lazarou et al., 1998; Zou et al., 2009). A prospective study 
conducted in UK found that 6.5% of all hospital admissions are directly related to an 
ADR (Pirmohamed et al., 2004). ADRs are also a significant financial burden for the 
pharmaceutical industry and are associated with high compound attrition and drug 
withdrawal rates (Kola and Landis 2004).  
ADRs can affect any organ system. However, the liver is highly susceptible to drug-
induced toxicity due to its central role in the metabolism and distribution of 
xenobiotics. To date, nearly 1000 drugs have been linked to an adverse hepatic 
reaction and Drug-Induced Liver Injury (DILI; hepatotoxicity) is the leading cause 
of acute liver failure (Ostapowicz et al., 2002). Moreover, it is the most frequent 
reason for post-marketing drug withdrawal and is often cited as a cause of compound 
attrition during the drug development process (Kaplowitz 2005) (Lasser et al., 2002).  
The cellular mechanisms leading to DILI are still not defined although two pathways 
appear to be involved: direct hepatotoxicity and adverse immune reactions. 
Chemically reactive drugs, or their metabolites, are able to damage cellular 
macromolecules, including proteins, lipids and nuclei acids, leading to hepatic 
cellular dysfunction and cell death. Emerging evidence suggests that hepatic cellular 
damage leads to activation of both innate and adaptive immunological responses. 
Inflammation, the first line innate immune response, has been identified as a key 
process involved in the modulation of liver injury during drug toxicity. Damaged or 
dying hepatocytes release proteins that are normally sequestered intracellularly into 
the extracellular environment (Iyer et al., 2009). These danger signals are termed 
Damage Associated Molecular Pattern Molecules (DAMPs) or alarmins. DAMPs 
activate neighbouring immune cells, triggering the production of multiple pro- and 
anti-inflammatory mediators. These mediators contribute to the progression of DILI 
by recruiting further innate and adaptive immune cells to the site of injury. The 
overall severity of the hepatic injury is determined by the balance of pro- and anti-
inflammatory mediators produced. To date, more than 20 DAMPs have been 
identified including the High Mobility Group Box 1 (HMGB1) protein, the Heat 
Shock Protein (HSP) family, DNA and ATP (Kubes and Mehal 2012).  
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HMGB1 is a ubiquitous, non-histone chromatin binding protein released following 
cell activation or cell death. Extracellular HMGB1 has a diverse range of biological 
activities that promote inflammation and tissue repair. HMGB1 mediates cytokine 
production (Andersson et al., 2000), chemotaxis (Orlova et al., 2007), cell 
proliferation, dendritic cell and T-cell activation (Dumitriu et al., 2005), cell 
differentiation (Melloni et al., 1995) and autophagy (Tang et al., 2010). HMGB1 has 
been reported to have a pathogenic role in multiple inflammatory diseases and has 
been implicated as a pro-inflammatory mediator of DILI. HMGB1 appears to 
interact with a diverse range of endogenous (Interleukin-1 (IL-1), DNA, 
nucleosomes and CXCL12) and exogenous (Lipopolysaccharide, LPS) molecules to 
initiate and enhance inflammation. However, despite intense research the 
mechanisms responsible for these synergistic interactions are still largely unknown. 
Investigations into these mechanisms will clarify the pro-inflammatory role of 
HMGB1 and may identify novel cellular pathways that can be targeted to reduce 
inflammation during DILI.  
1.2. ADVERSE DRUG REACTIONS (ADRs) 
ADRs are a major public health concern impacting on both patient mortality and 
morbidity rates (Lazarou et al., 1998; Moore et al., 2007). A prospective 
observational study conducted at two large Merseyside hospitals between 2001 and 
2002 concluded that 1225 (6.5%) out of 18,820 hospital admissions are due to an 
ADR. This accounted for 4% of the total bed capacity and was projected to cost the 
NHS up to £466 million per year (Pirmohamed et al., 2004). ADRs also contribute 
significantly to high compound attrition and drug withdrawal rates within the 
pharmaceutical industry (Kola and Landis 2004). Between 1975 and 1999, 548 New 
Chemical Entities (NCEs) were approved by the US Food and Drug Administration 
(FDA). 45 (8.2%) of these compounds were subsequently given a black box warning 
and 16 (2.9%) were withdrawn from the market (Lasser et al., 2002). 
ADRs can be categorised as ‘on’ or ‘off’ target reactions. ‘On target’ reactions are 
predictable and are directly related to the primary or secondary pharmacology of the 
drug. These reactions are dose-dependent and can be alleviated if the dose is reduced 
or the drug is withdrawn. ‘On target’ reactions are not generally associated with high 
mortality rates. An example of an ‘on target’ ADR is hemorrhage with 
anticoagulants, such as warfarin. In contrast, ‘off target’ ADRs cannot be predicted 
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as they are not related to the known pharmacological activity and are dose-
independent. ‘Off target’ ADRs are more commonly described as idiosyncratic 
reactions as patients display marked inter-individual susceptibility. Idiosyncratic 
reactions are less common than ‘on target’ ADRs but are more serious, normally 
occurring at therapeutic concentrations, and associated with higher mortality rates. 
These reactions usually occur after an initial delay or latency period which may 
range from a few days to several months. An example of an idiosyncratic reaction is 
hypersensitivity reactions with anticonvulsant drugs.   
Any organ system is susceptible to ADRs. The liver is the central organ responsible 
for the metabolism and distribution of all endogenous and exogenous compounds 
and thus, the liver is a frequent target of drug-induced toxicity. A three year 
prospective study conducted in France reported that the annual incidence of DILI 
was 13.9 per 100,000 inhabitants (Sgro et al., 2002). Moreover, DILI is the most 
frequently citied cause of post-marketing drug withdrawal (Kaplowitz 2005) and a 
leading cause of compound attrition during the drug-development process.   
1.3. DRUG INDUCED LIVER INJURY (DILI) 
A prospective study conducted by the US Acute Liver Failure Study Group 
concluded that DILI is responsible for more than 50% of all cases of acute liver 
failure (Ostapowicz et al., 2002). It is associated with high morbidity and mortality 
rates, with the survival rate in the absence of a liver transplant approximately 20% 
(Bernal et al., 2009; Verma and Kaplowitz 2009). To date, nearly 1000 drugs have 
been associated with DILI (Zimmerman 1999; Kaplowitz 2004). Acetaminophen 
(paracetamol, APAP) overdose accounts for a significant proportion of all cases of 
DILI (Ostapowicz et al., 2002) and is responsible for 200-500 deaths annually in the 
UK (Hawton et al., 1995; Makin et al., 1995).  
Idiosyncratic DILI is responsible for the majority of the remaining cases of acute 
liver failure (Ostapowicz et al., 2002). The mechanisms mediating idiosyncratic 
toxicities are largely unknown with a number of susceptibility factors implicated in 
the progression of these reactions including age, gender, metabolism and pre-existing 
inflammation. Idiosyncratic DILI reactions are rare and occur at a frequency of 1 in 
every 1000 to 1 in every 10,000 patients (Lee 2003). Due to the infrequent 
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occurrence of these reactions it is difficult to predict compounds that may cause 
idiosyncratic DILI during drug development and preclinical testing.  
Clinically, DILI can mimic various forms of naturally occurring liver disease 
including hepatitis and cholestasis. Symptoms can vary from mild asymptomatic 
biochemical changes to fulminant hepatic failure. It is difficult to predict and 
diagnose DILI in the clinic due to the occurrence of pre-existing liver injury or 
inflammation in some patients, an incomplete understanding of the underlying 
mechanisms, particularly during cases of idiosyncratic drug toxicity, and a lack of 
sensitive and informative clinical biomarkers that detect early liver injury. Currently, 
measurement of serum and plasma levels of aminotransferases, such as Alanine 
Amino-Transferase (ALT) and Aspartate Amino-Transferase (AST), is regarded as 
the ‘gold standard’ method to detect DILI. However, these enzymes are not organ 
specific and are only significantly elevated following overt liver damage.  
1.4. MECHANISMS OF DILI 
The exact mechanisms mediating DILI are not fully understood, although it appears 
that two pathways are involved: direct hepatotoxicity and immune-mediated damage 
(Figure 1.1). Most xenobiotic compounds are metabolised in the liver and in some 
instances, DILI can be initiated by the bioactivation of a drug to a chemically 
reactive metabolite. Unless detoxified, the parent drug or reactive metabolite may 
covalently bind to cellular macromolecules including proteins, lipids and nucleic 
acids resulting in protein dysfunction, lipid peroxidation, DNA damage and 
oxidative stress. Impaired hepatic cell function ultimately leads to cell death and 
liver injury (Park et al., 2011).  
APAP, a commonly used analgesic and antipyretic drug, is considered to be very 
safe at therapeutic doses (4 g/day) but causes acute liver failure during overdose. 
Metabolic activation has been demonstrated to be an essential pre-requisite for 
APAP-induced hepatotoxicity (Mitchell et al., 1973). APAP is bioactivated to the 
electrophilic intermediate N-acetyl-p-benzoquinonimine (NAPQI) (Dahlin et al., 
1984). The reactive NAPQI metabolite has been demonstrated to bind to a number of 
target proteins including glutamine synthestase, glutamate dehydrogenase and 
aldehyde dehydrogenase (Bulera et al., 1995; Halmes et al., 1996; Landin et al., 
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1996). APAP-induced hepatotoxicity has been widely studied and the APAP-mouse 
model is routinely used as a tool to investigate DILI.   
Hepatocyte cell stress and damage can trigger both innate and adaptive immune 
responses. Stressed or dying hepatocytes release danger signals that activate local 
cells, particularly those of the innate immune system including Natural Killer (NK) 
cells, Natural Killer T (NKT) cells and kupffer cells (KCs). Prototypical danger 
signals include Tumour Necrosis Factor α (TNFα), Interleukin-1β (IL-1β), 
Interferons (IFNs), ATP and HMGB1 (Matzinger 1994; Gallucci and Matzinger 
2001). The activation of local resident immune cells stimulates the release of 
multiple pro- and anti-inflammatory cytokines and chemokine mediators. These 
proteins activate and recruit further inflammatory cells to the liver with the overall 
severity of the hepatic injury depending on the balance of pro- and anti-inflammatory 
mediators produced. One type of cell recruited to the liver during DILI is the 
neutrophil cell (You et al., 2006). Neutrophils are critical to host defence as they 
phagocytose and digest foreign material. Depletion of these cells reduces 
susceptibility to liver injury induced by some drugs (You et al., 2006). 
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Figure 1.1 Mechanisms of DILI Schematic showing the pathways involved in DILI. Chemically reactive drugs or metabolites can interact with 
cellular macromolecules, including proteins, lipids and nucleic acids, leading to impaired hepatic cell dysfunction, cell death and possible liver 
injury. The severity of hepatic damage is determined by the balance of pro- and anti-inflammatory mediators produced. Figure adapted from 
(Kaplowitz 2005; Laverty et al., 2010).  
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1.5. IMMUNOLOGICAL RESPONSES IN DILI 
The immune system is composed of innate immunity and adaptive immunity. Cells 
of the innate immune system include macrophages, NK cells, NKT cells and 
leukocytes. The innate immune response provides rapid, non-specific, first-line 
defence to recognise and eliminate invading pathogens. Innate immune cells can also 
function as Antigen Presenting Cells (APCs) to activate the adaptive immune 
response, which is specific to the invading pathogen.  
Regulated physiological immune responses are important for tissue repair and 
regeneration. However, dysfunction of inflammatory pathways is associated with 
excessive cytokine production, tissue damage and a pathogenic role in multiple liver 
diseases. There is growing evidence to support the role of immune-mediated 
reactions in DILI caused by some drugs, particularly during idiosyncratic toxicity. 
Table 1.1 provides an overview of the drugs that cause idiosyncratic DILI with 
evidence of immune involvement.  
Table 1.1 Overview of drugs that cause idiosyncratic DILI with evidence of 
immune involvement 
+
Evidence for both allergic and non-allergic DILI reactions. 
Table adapted from (Kaplowitz 2005; Laverty et al., 2010). 
 
Drug class Drug name 
Anaesthetic Halothane 
Analgesic Diclofenac
+
 
 Sulindac 
Antibiotic Amoxicillin 
 Rifampicin
+
 
 Nitrofluantoin 
 Minocycline 
 Erthromycins 
Anti-convulsant Phenytoin 
 Phenothiazines 
Anti-epileptic Carbamazepine
+
 
Antihypertensive Dihydralazine 
 Methyldopa 
 Tienilic acid 
Anti-thyroid Propylthiouracil 
Antidepressant Tricyclic antidepressants 
Gout Allopurinol 
Hypertension ACE inhibitors 
 
Chapter 1 
 
10 
 
1.5.1. THE ROLE OF INNATE IMMUNE RESPONSES IN DILI 
1.5.1.1. Sterile inflammation and Damage Associated Molecular Pattern 
(DAMP) molecules  
Inflammation, the first line innate immune response to evading microbial pathogens, 
is a physiological process that promotes tissue repair and regeneration. However, if 
the inflammatory process is not tightly controlled, inflammation spreads and tissue 
damage can occur (Nathan 2002). Recent reports have shown that inflammation can 
occur in the absence of evading pathogens in response to necrotic cell death (Figure 
1.2) (Chen et al., 2007; Hoque et al., 2013). This phenomenon is termed sterile 
inflammation and can occur in all tissues. Hepatic cell necrosis is known to occur in 
response to toxic insults (Grattagliano et al., 2002) and sterile inflammation has been 
identified as a key process involved in DILI. Clinical features of inflammation 
include redness, swelling, heat, neutrophil infiltration and tissue damage (Kubes and 
Mehal 2012).  
Damaged or dying hepatocytes release proteins that are normally sequestered 
intracellularly into the extracellular environment (Figure 1.2). These host-derived 
proteins are termed DAMP molecules or alarmins as their extracellular release alerts 
the immune system to impending liver injury. HMGB1 (Scaffidi et al., 2002), ATP 
(Mariathasan et al., 2006), DNA (Jahr et al., 2001), hyaluronic acid and HSPs 
(Quintana and Cohen 2005) have all been identified as DAMPs that are able to 
trigger an immune response. DAMPs are recognised by the Pattern Recognition 
Receptors (PRRs), a group of highly conserved proteins that were initially identified 
as receptors for evading Pathogen Associated Molecular Pattern (PAMPs) molecules 
(e.g. LPS and polyinosinic: polycytidylic acid (poly: IC)). The most studied 
members of PRR family are the Toll-Like Receptors (TLRs), which are a family of 
transmembrane proteins expressed by cells of the innate immune system. Release 
and recognition of DAMPs by PRRs activates neighbouring cells of the innate 
immune system including macrophages, KCs, NK cells and NKT cells (Holt and Ju 
2006). This triggers the activation of two interrelated cell signalling pathways that 
up-regulate the production of multiple inflammatory mediators. The first pathway 
activates Nuclear Factor-κB (NF-κB)-mediated gene expression resulting in the up-
regulation of the transcription of a number of genes encoding pro-inflammatory 
cytokines, adhesion molecules, chemokines and growth factors (Siebenlist et al., 
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1994; Barnes and Karin 1997). Many of these newly transcribed proteins are 
involved in the second pathway and contribute to the formation of the 
inflammasome. The inflammasome is a cytosolic multi-protein complex, activated 
following a second signal, which is critical for caspase-1 (also known as the 
Interleukin-1 Converting Enzyme (ICE); (Alnemri et al., 1996)) dependent 
processing and secretion of many inflammatory mediators including IL-1 and IL-18 
(Martinon et al., 2002). Recent reports have demonstrated that the sterile 
inflammatory response to necrotic cells is mediated via the Nalp3 inflammasome 
(Iyer et al., 2009). Activated innate immune cells also secrete TNF, IFNγ, IL-6 and 
multiple chemokine mediators (Blazka et al., 1995; Ishida et al., 2002; Masubuchi et 
al., 2003). These proteins mediate the progression of DILI by promoting the 
recruitment of further innate and adaptive immune cells to the site of injury.   
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Figure 1.2 Overview of sterile inflammation and the effects of DAMPs on DILI 
Necrotic hepatocytes passively release their intracellular contents (DAMPs; 
HMGB1, HSPs, DNA & ATP) into the extracellular environment and blood, 
triggering the activation of local innate immune cells including macrophages, KCs, 
NK cells and NKT cells. Multiple inflammatory mediators, including HMGB1, are 
up-regulated via two interrelated pathways, which involve NF-κB-mediated gene 
transcription and inflammasome formation and activation. Inflammatory mediators 
promote the recruitment of innate and adaptive immune cells, contributing to the 
progression of inflammation and liver injury (Siebenlist et al., 1994; Barnes and 
Karin 1997; Martinon et al., 2002; Scaffidi et al., 2002; Holt and Ju 2006).  
1.5.1.2 The role of innate immunity as a promoter of DILI 
Genetic and environmental factors are known to influence susceptibility to drug 
toxicity. In particular, it has been hypothesised that cellular stress or inflammatory 
responses due to concurrent or pre-existing infection may increase the risk of DILI 
(the inflammatory stress hypothesis). There is clinical evidence to support this theory 
with studies showing that patients infected with the Human Immuno-deficiency 
Virus (HIV) or hepatitis C virus have an elevated risk of developing hepatic ADRs 
Chapter 1 
 
13 
 
(Levy 1997; Nguyen et al., 2008). The mechanism is not completely understood but 
it is known that cells of the innate immune system are activated during infection 
leading to the production of multiple pro-inflammatory mediators. It is generally 
believed that this lowers the threshold for drug toxicity, contributing to the 
development of many idiosyncratic ADRs. Recent testing into this hypothesis has 
resulted in the development of multiple animal models that appear to reproduce some 
of the idiosyncratic drug toxicities observed in the clinic. Most of these models have 
involved co-treating animals with non-toxic doses of LPS, a bacterial endotoxin, to 
replicate pre-existing or concurrent inflammatory stress. LPS (Figure 1.3) is a major 
component of the outer membrane of gram negative bacteria and a potent activator 
of the immune response, inducing systemic inflammation and septic shock via 
TLR4-mediated NF-κB signalling (Shakhov et al., 1990; Hoshino et al., 1999; 
Beutler and Rietschel 2003). LPS has been extensively used by researchers to induce 
and study inflammatory responses. Studies using rodent models have shown that co-
exposure to non-toxic doses of LPS increases the susceptibility to a number of 
hepatotoxic agents (Table 1.2).  
Figure 1.3 Structure of LPS The bacterial endotoxin, LPS, is present in the outer 
cell membrane of gram negative bacteria and is composed of polysaccharide and 
lipid moieties. (Hep, L-glycero-D-manno-heptose; KDO, 2-keto-3-deoxy-octulosonic 
acid; P, phosphate; GlcN, D-glucosamine). Figure adapted from (Beutler and 
Rietschel 2003).   
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Table 1.2 Drugs with increased hepatotoxic activities in the presence of 
moderate inflammatory stress. Compounds listed below had a reduced toxicity 
threshold when co-administered with bacterial or viral products.  
Hepatotoxin Drug Class/ Use Inflammagen(s) References 
APAP 
Analgesic/ 
antipyretic 
LPS & reovirus  (Maddox et al., 2010) 
Chlorpromazine Antipsychotic LPS  
(Buchweitz et al., 
2002) 
Diclofenac Analgesic LPS (Deng et al., 2006) 
Halothane  Anaesthetic LPS  (Lind et al., 1984) 
Ranitidine  
Histamine-2 receptor 
antagonist 
(Indicated for gastric 
disease) 
LPS 
(Luyendyk et al., 
2003) 
Sulindac Analgesic LPS  (Zou et al., 2009) 
Trovafloxacin  
Antibiotic 
(Restricted use due to 
hepatotoxicity)   
LPS   
(Waring et al., 2006; 
Shaw et al., 2007) 
   
1.5.2. THE ROLE OF ADAPTIVE IMMUNE RESPONSES IN DILI 
Adaptive immunological responses have been implicated in DILI reactions caused 
by some drugs including halothane, diclofenac and carbamazepine (Maddrey et al., 
2011). These reactions are often associated with fever, rash and eosinophilia, 
typically occurring after a short latency period of around 1-8 weeks.  
Despite intense research it is still not clear how drugs or their metabolites can 
activate adaptive immune responses. Two hypotheses have been postulated: the 
hapten hypothesis and the Pharmacological Interaction (p-i) hypothesis. The hapten 
hypothesis proposes that chemically reactive drugs or metabolites covalently bind to 
cellular proteins to form immunogenic drug-protein adducts. These adducts are 
recognised as foreign and induce specific immune responses (Park et al., 1998). 
Auto-antibodies directed towards drug-modified hepatic proteins have been detected 
in the sera of some patients, supporting this hypothesis (Satoh et al., 1989; Bourdi et 
al., 1994; Gunaratnam et al., 1995; Lecoeur et al., 1996). In contrast, the p-i 
hypothesis proposed by Pichler suggests that some drugs are able to directly bind 
and activate T cell receptors in the absence of drug metabolism or antigen 
presentation (Zanni et al., 1998; Pichler et al., 2006).   
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1.6. INTERLEUKIN-1 (IL-1) AS A CIRCULATING MEDIATOR OF 
INFLAMMATION  
The IL-1 sub-family consists of three proteins: Interleukin-1 alpha (Il-1α), 
Interleukin-1 beta (IL-1β) and the endogenous Interleukin-1 Receptor antagonist (IL-
1RA). IL-1α and IL-1β are potent pleiotropic cytokines that regulate a diverse range 
of biological activities including the pro-inflammatory response and hematopoiesis 
(Dinarello 1996) (Table 1.3). Specifically, IL-1β is a critical mediator of the acute-
phase response to tissue injury or inflammation (Zheng et al., 1995). A pathogenic 
role of IL-1β has been reported for many inflammatory diseases including 
autoimmune diseases, such as rheumatoid arthritis, type 2 diabetes and heart failure 
(Dinarello 2011).  
Table 1.3 Overview of the biological activities of the IL-1 protein Table adapted 
from (Dinarello 1991). 
Biological effects of IL-1  
Pyrogen  
Promotes synthesis of hepatic acute-phase proteins  
T-cell activation 
B cell activation  
Induces fibroblast differentiation  
Endothelial cell activation 
Modulation of gene expression: 
Increased expression of IL-1, IL-6, TNFα and IL-8 
Suppression of type 1 IL-1R and cytochrome P450 
expression  
 
The IL-1β protein is released by macrophages, monocytes and dendritic cells 
(Iwamoto et al., 1989; Eder 2009). Two signals are required for the production, 
processing and release of IL-1β. Firstly, PAMPs or DAMPs induce the transcription 
of the IL-1β mRNA and the subsequent translational of the IL-1β protein. IL-1β is 
initially synthesised as a 31kDa precursor protein (Pro-IL-1β) and a second signal is 
required to activate the inflammasome and caspase-1 dependent processing and 
release of mature IL-1β (17 kDa) (Kostura et al., 1989); (Thornberry et al., 1992).  
The mechanism of IL-1β secretion is not well defined, however as IL-1β lacks a 
secretory signal peptide it cannot be released via the classical ER-Golgi pathway. 
Instead, it has been suggested that IL-1β may be released from secretory lysosomes 
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or exosomes during exocytosis, by shredding of plasma membrane microvesicles or 
by active transport using specialised membrane transporters (Eder 2009).  
Extracellular IL-1 binds to the type I and II transmembrane IL-1 receptors (IL-1Rs) 
(Figure 1.4). The type I IL-1R is predominantly expressed on fibroblasts, endothelial 
cells, T cells and hepatocytes. IL-1 binds to the type 1 IL-1R and recruits the IL-1R 
accessory protein (IL-1RAcP) leading to the formation of a pro-inflammatory 
heterodimeric signalling complex (Greenfeder et al., 1995). The signalling complex 
activates the NF-κB pathway to induce the expression of a wide variety of genes 
including pro- and anti-inflammatory mediators (IL-1, IL-6, IL-8 and TNFα) and 
multiple inflammatory receptors, including the IL-1R (Dinarello 1996). In contrast, 
the type II IL-1R, located primarily on monocytes, neutrophils, B cells and bone 
marrow cells (Kuno and Matsushima 1994), contains a truncated cytoplasmic 
domain and cannot initiate intracellular signalling. Thus, the type II IL-1R acts as a 
decoy receptor, sequestering IL-1 and regulating the biological activity of the protein 
(McMahan et al., 1991). Furthermore, the endogenous IL-1RA can also bind to the 
IL-1R but cannot recruit the IL-1RAcP and therefore cannot initiate cell signalling 
and acts to regulate the pro-inflammatory activity of IL-1α and IL-1β (Arend et al., 
1990; Greenfeder et al., 1995). 
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Figure 1.4 Overview of IL-1-mediated cell signalling IL-1α and IL-1β form a 
heterodimeric signalling complex by binding to the IL-1R type I (IL-1RI) and the IL-
1RAcP. This results in NF-κB mediated gene transcription and up-regulation of 
multiple cell surface receptors including IL-1R and TLR4. In contrast, the IL-1R 
type II (IL-1RII) acts as a decoy receptor, as it contains a truncated cytoplasmic 
domain and cannot initiate intracellular signalling. The IL-1RA protein acts as a  
endogenous IL-1R antagonist as it can bind to the IL-1R but cannot recruit the IL-
1RAcP (McMahan et al., 1991; Greenfeder et al., 1995; Dinarello 1996).  
1.7. INTERLEUKIN-6 (IL-6) AS A CIRCULATING MEDIATOR OF 
INFLAMMATION  
IL-6 (previously termed the hepatocyte stimulating factor; (Van Snick 1990)) is a 
pleotropic cytokine with a central role in host defence (Table 1.4). Macrophages and 
monocytes secrete IL-6 following activation of the NF-κB pathway in response to 
PAMPs or DAMPs (Iwamoto et al., 1989; Ju et al., 2002; Luckey et al., 2002). It has 
both pro- and anti-inflammatory activities that regulate the immune response, 
hematopoiesis and acute phase reactions (Simpson et al., 1997). Overproduction of 
IL-6 is associated with a number of autoimmune and inflammatory diseases (Ishihara 
and Hirano 2002; Kishimoto 2006).   
IL-6 has important roles in liver repair and regeneration, protecting against APAP, 
ethanol and carbon tetrachloride induced hepatotoxicity (Kovalovich et al., 2000; 
Masubuchi et al., 2003; Bourdi et al., 2007). When subjected to acute carbon 
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tetrachloride treatment, IL-6 deficient mice have increased liver necrosis and 
impaired liver regeneration compared to wild-type animals (Kovalovich et al., 2000). 
Moreover, elevated IL-6 levels have been reported in animal models of APAP-
induced hepatotoxicity (James et al., 2003) and IL-6
-/-
 mice have an increased 
susceptibility to APAP-induced hepatic injury (Masubuchi et al., 2003).  
Table 1.4 Biological activities of the IL-6 protein   
Function Reference(s) 
Induction of B cell differentiation (Hirano et al., 1985) 
Hepatocyte stimulating factor:  
induces acute phase inflammatory response 
(Gauldie et al., 1987) 
T cell activation  (Lotz et al., 1988) 
Hematopoietic activity  (Ikebuchi et al., 1987) 
Induction of nerve cell differentiation  (Satoh et al., 1988) 
Stimulates secretion of nerve growth factor by 
astrocytes 
(Frei et al., 1989) 
 
1.8. HIGH MOBILITY GROUP BOX-1 (HMGB1) AS A CIRCULATING 
MEDIATOR OF INFLAMMATION  
1.8.1. Discovery and function of HMGB1 
The HMGB1 protein (previously referred to as HMG-1, amphoterin or P30; (Bustin 
2001)) is a ubiquitous and abundant non-histone chromatin binding protein first 
purified in the 1970s (Goodwin et al., 1973; Bustin 2001). The protein belongs to the 
HMG Box (HMGB) family, which also includes HMGB2 and HMGB3. The proteins 
have a highly conserved structure and were named after their ability to migrate 
quickly during electrophoresis. The average cell has up to 10
6
 HMGB1 molecules 
(Muller et al., 2004) and HMGB1-deficient mice die within hours of birth due to 
hypoglycaemia, demonstrating a vital role for HMGB1 in growth and development. 
(Calogero et al., 1999).  
HMGB1 has multiple, compartment-specific functions (Figure 1.5). HMGB1 is 
present in the nucleus of all eukaryotic cells where it acts as an ‘architectural’ DNA-
binding protein (Bustin et al., 1978; Travers and Thomas 2004). Nuclear HMGB1 
binds to the minor groove of double-stranded DNA in a sequence-independent 
manner. HMGB1 recognises distorted DNA structures like DNA-bulges, four-way 
junctions, kinks and cisplatin-modified DNA (Agresti and Bianchi 2003; Reeves 
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2010). HMGB1 induces bends into the DNA structure (Onate et al., 1994; Agresti 
and Bianchi 2003) which in turn facilitates the interaction between the DNA and 
various proteins, including the NF-κB and p53 transcription factors (Jayaraman et 
al., 1998; McKinney and Prives 2002; Rowell et al., 2012). HMGB1, therefore, 
facilitates gene transcription and DNA replication (Czura et al., 2001; Reeves 2010). 
Moreover, nuclear HMGB1 is also involved in cell replication, DNA repair and 
nucleosome assembly (Lange et al., 2008; Celona et al., 2011).  
Extracellular HMGB1 has a diverse range of biological activities that promote 
inflammation and tissue repair. HMGB1 mediates cytokine production (Andersson et 
al., 2000), chemotaxis (Orlova et al., 2007), cell proliferation, dendritic cell and T-
cell activation (Dumitriu et al., 2005), cell differentiation (Melloni et al., 1995) and 
autophagy (Tang et al., 2010). HMGB1 has been reported to have a pathogenic role 
in many diseases including arthritis (Kokkola et al., 2002), sepsis (Wang et al., 1999) 
and cancer (Lotze and Tracey 2005; Sims et al., 2010).  
HMGB1 has also been identified as an inflammatory mediator of liver injury. 
Elevated HMGB1 levels have been reported in experimental models of hepatic 
reperfusion injury and DILI (Ilmakunnas et al., 2008). Recent studies have identified 
HMGB1 as a potential early and sensitive mechanistic biomarker of DILI, with 
significant HMGB1 elevations reported during APAP-induced hepatotoxicity 
(Antoine et al., 2009; Martin-Murphy et al., 2010). Moreover, HMGB1 has been 
identified as a potential target for therapeutic intervention during DILI. 
Administration of neutralising HMGB1 antibodies has been reported to be beneficial 
in mice models of APAP-overdose and is associated with increased survival rates 
(Antoine et al., 2010).   
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Figure 1.5 Compartment-specific functions of the HMGB1 protein HMGB1 is a 
multifunctional cytokine with a diverse range of intra- and extra-cellular activities. 
HMGB1 is highly expressed in the nucleus where it acts as an architectural DNA-
binding protein that regulates gene transcription and chromatin structure. HMGB1 is 
also present in the cytoplasm where it is involved in autophagy and inflammasome 
activation. Membrane-bound HMGB1 promotes neurite outgrowth in cerebral 
neurons and platelet activation. Additionally, HMGB1 is released into the 
extracellular environment following cell activation (active secretion, requires 
HMGB1 acetylation) or cell death (passive secretion). Extracellular HMGB1 is an 
alarmin, promoting inflammation and tissue regeneration. Figure adapted from 
(Yang et al., 2013). 
 
1.8.2. The structure of the HMGB1 Protein  
The gene encoding human HMGB1 is located on chromosome 13q12 (Ferrari et al., 
1996). HMGB1 is a 25 kDa protein containing 215 amino acids organised into a 
tripartite domain structure consisting of 2 HMG box domains (Boxes A and B) and a 
polyacidic negatively charged tail (Figure 1.6). The HMG domains are highly 
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conserved DNA-binding motifs present in a variety of architectural proteins. The 
HMGB1 protein is highly conserved between species with 99% homology in the 
primary sequence of the rodent and human forms. The sequences differ in only 2 
amino acid residues located within the c-terminal tail: the glutamic acid at position 
189 and the aspartic acid at position 202 in human HMGB1 are substituted by 
aspartic acid and glutamic acid residues respectively in the rodent protein.   
 
 
 
Figure 1.6 Domain structure of HMGB1 HMGB1, a 25 kDa nuclear protein 
consisting of 215 amino acid residues, has a tripartite domain structure comprising of 
two highly conserved DNA-binding motifs (boxes A and B, residues 9-79 and 89-
163 respectively) and a polyacidic negatively charged tail (residues 186-215). The B 
box confers the pro-inflammatory activity whilst the A box is anti-inflammatory in 
vivo. The protein contains 2 NLS domains at residues 28-44 and 179-185 (as 
indicated). There are also two CRM1-dependent NES domains.  
 
Boxes A and B correspond to residues 9-79 and 89-163 respectively (Figure 1.7). 
The boxes, which are connected by a short nine-residue linker region, have a low 
sequence similarity (29%) but share a conserved global fold, consisting of three α-
helices arranged in an L-like structure (Weir et al., 1993; Hardman et al., 1995) 
(Figure 1.8). A 21-residue, unstructured and flexible linker region connects Box B to 
the 30-residue poly-acidic negatively charged tail. The tail is composed entirely of 
aspartic and glutamic acid residues (Residues 185-215; Figure 1.7) and interacts with 
the A and B boxes (Ramstein et al., 1999; Jung and Lippard 2003; Knapp et al., 
2004; Watson et al., 2007; Stott et al., 2010). The interaction is believed to shield the 
boxes and has important functional implications. It modulates the interaction with 
DNA (Sheflin et al., 1993; Štros et al., 1994; Lee and Thomas 2000; Muller et al., 
2001), is involved in the interaction with histones H1 and H3 (Cato et al., 2008; 
Watson et al., 2013) and modulates HMGB1 protein acetylation by histone 
acetyltransferases (Pasheva et al., 2004).  
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Figure 1.7 Linear representation of the amino acid structure of HMGB1 The HMGB1 protein contains 215 amino acid residues organised 
into three domains: the A (Blue) and B (Purple) boxes, at residues 9-79 and 89-163 respectively, and the negatively charged c-terminal tail 
composed of 30 acidic amino acid residues (Red;186-215).  Box A is anti-inflammatory and B box is pro-inflammatory, a 20-residue region 
within the B box (89-108) represents the minimal region required for TNF activation. The TLR4 and RAGE binding sites are indicated. HMGB1 
contains 43 lysine residues (20% of total amino acid content) and 8 of these, located within the NLS domains, are frequently acetylated in vivo 
(K) to aid active protein secretion. 
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Figure 1.8 3D structure of HMGB1 A and B box domains HMGB1 is composed 
of 2 HMG boxes (Boxes A and B, also known as DNA-binding domains) and a 
polyacidic negatively charged tail. The 3D structure of HMGB1 amino acids 1-167 
has been solved by solution NMR and is shown above. Image was prepared in 
PyMol using PDB entry 2YRQ (PyMoL).  
 
HMGB1 also contains two Nuclear Localisation Signal (NLS) domains and two non-
classical Nuclear Export Signal (NES) domains which allow the protein to 
continuously shuttle between the cell nucleus and cytoplasm.  
1.8.3. Extracellular release of HMGB1 
Under physiological conditions, HMGB1 is predominately localised to the nucleus 
but following cell injury or death it is released into the extracellular environment 
where it acts to initiate and amplify the inflammatory response. A number of 
mechanisms are involved in the regulation of HMGB1 release (Figure 1.9). HMGB1 
is constitutively expressed in all nucleated cells and can be passively released during 
necrotic cell death following the loss of the cell membrane integrity (Figure 1.9A) 
(Scaffidi et al., 2002; Rovere-Querini et al., 2004). In this context HMGB1 is 
regarded as an early marker of cell death.   
HMGB1 can also be actively secreted from innate immune cells in response to an 
inflammatory stimulus and in this context HMGB1 is regarded as a late mediator of 
cell activation (Figure 1.9B). Mouse macrophages stimulated with LPS, TNF or IL-1 
secrete large amounts of HMGB1 (Wang et al., 1999). Similar to IL-1β, HMGB1 
lacks a secretory signal peptide and cannot be secreted via the classical ER-Golgi 
pathway (Bonaldi et al., 2003). In resting cells, HMGB1 continually shuttles 
between the nucleus and cytoplasm. However, in activated macrophages and 
monocytes HMGB1 is post-translationally modified, preventing re-entry into the 
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nucleus and resulting in accumulation of HMGB1 into cytoplasmic vesicles (Bonaldi 
et al., 2003; Cato et al., 2008). HMGB1 is acetylated at lysine residues within the 
NLS domains, specifically lysine residues at positions 28, 29, 30, 180, 182, 183, 184 
and 185 are frequently acetylated in vivo (Figure 1.7). Additionally, hyper-
phosphorylation of HMGB1 has also been reported to occur in macrophages and 
monocytes (Youn and Shin 2006). The release of HMGB1 from the cytoplasmic 
vesicles into the extracellular environment is triggered by lysophosphatidylcholine 
(LPC) (Cato et al., 2008). LPC is a derived from phosphatidylcholine and is 
generated at the site of inflammation several hours after monocyte activation. Recent 
evidence suggests that active HMGB1 secretion from macrophages stimulated with 
LPS or polyI:C is dependent on the inflammasome and capase-1 activation 
(Lamkanfi et al., 2010; Lu et al., 2012).  
Active secretion of HMGB1 has also been reported from a number of other cells 
including neutrophils, dendritic cells, NK cells, pituicytes and hepatocytes (Wang et 
al., 1999; Chen et al., 2004; Dumitriu et al., 2005; Semino et al., 2005; Tsung et al., 
2007). Further investigation is required to fully elucidate the mechanisms that drive 
active release of HMGB1 from these cells. It has been reported that mono-
methylation of K42 may promote the cytoplasmic accumulation of HMGB1 in 
neutrophils (Ito et al., 2007).  
HMGB1 released from necrotic or activated cells, interacts with the TLRs and the 
Receptor for Advanced Glycation Endproducts (RAGE) to elicit an inflammatory 
response. It is not yet known if the different molecular forms activate distinct 
signalling pathways. In contrast, HMGB1 released from apoptotic cells undergoing 
secondary necrosis promotes immune tolerance (Figure 1.9C) (Kazama et al., 2008). 
During apoptosis, Reactive Oxygen Species (ROS) produced by the mitochondria 
oxidise HMGB1, at the C106 residue, preventing binding to the TLR4 and thereby 
neutralising the cytokine-inducing activity (Kazama et al., 2008; Yang et al., 2010). 
A study by Antoine et al illustrated the critical role of HMGB1 oxidation and 
subsequent immune tolerance during APAP-induced hepatotoxicity (Antoine et al., 
2010). In the APAP-induced hepatotoxicity mouse model, diet restriction inhibited 
caspase-driven apoptosis and prevented HMGB1 oxidation leading to enhanced 
inflammation and increased mortality (Antoine et al., 2010).  
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Figure 1.9 Mechanisms for the release of HMGB1 into the extracellular 
environment HMGB1 is released into the extracellular environment following cell 
death or injury where it may act to initiate and amplify the inflammatory response. 
A) Hypo-acetylated HMGB1 is passively released by necrotic cells. B) Hyper-
acetylated HMGB1 is actively secreted from activated immune cells. Both molecular 
forms can bind to the TLRs (TLR2, TLR4 and TLR9 have been implicated in 
HMGB1 signalling) and the RAGE on the target cell to promote inflammation. In 
contrast, oxidised HMGB1 released from apoptotic cells during secondary necrosis 
promotes immune tolerance (C).  Figure adapted from (Harris and Raucci 2006).  
1.8.4. Receptors mediating HMGB1 activity  
Extracellular HMGB1 interacts with multiple un-related receptors to mediate a 
diverse range of biological responses. A number of receptors have been identified for 
HMGB1 including RAGE, TLR2, TLR4, TLR9, Syndecan, Mac-1, and Siglec-10 
(Salmivirta et al., 1992; Hori et al., 1995; Yu et al., 2006; Tian et al., 2007; Chen et 
al., 2009; Gao et al., 2011).  
1.8.4.1. Receptor for Advanced Glycation Endproducts (RAGE)  
RAGE, a multi-ligand member of the immunoglobulin superfamily, was the first 
receptor to be identified for HMGB1 (Hori et al., 1995). A recent study by Huttunen 
et al, has mapped the RAGE binding site to residues 150-183 (Huttunen et al., 2002) 
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(Figure 1.7). HMGB1-RAGE signalling mediates chemotaxis and cell growth, 
differentiation of immune cells and the up-regulation of inflammatory cell signalling 
receptors, including RAGE and TLR4 (Orlova et al., 2007; Andersson and Tracey 
2011) (Figure 1.10).  
1.8.4.2. Toll-Like Receptors (TLRs) 
HMGB1 also interacts with TLR2, 4 and 9 (Figure 1.10) The interaction between 
HMGB1 and TLR4 is critical for HMGB1-induced cytokine release (Yang et al., 
2010). Macrophages from TLR4-deficient mice do not release TNF, IL-6, IL-1β or 
IL-10 when exposed to HMGB1 (Yang et al., 2010). In contrast, TLR2
-/-
 and RAGE
-
/-
macrophages secrete large amounts of cytokines in response to HMGB1 treatment, 
suggesting that these receptors are dispensable during HMGB1-induced cytokine 
production (Yang et al., 2010). Binding of HMGB1 to TLR4, activates the adaptor 
protein MyD88 which promotes the nuclear translocation of NF-κB and results in the 
up-regulation of multiple pro-inflammatory genes and inflammatory mediators (Park 
et al., 2004). HMGB1 signalling through TLR4 mediates macrophage activation, 
cytokine release and tissue injury (Andersson et al., 2000; Andersson and Tracey 
2011). The interaction between HMGB1 and TLR4 has been studied in detail using 
Surface Plasmon Resonance (SPR) and is mediated via the B box domain of 
HMGB1 (Yang et al., 2010). Specifically, the C106 residue is critical for the 
interaction and the C106A HMGB1 mutant does not bind to TLR4 and cannot 
induce cytokine production in human macrophages (Yang et al., 2010). 
1.8.5. HMGB1 as a pro-inflammatory cytokine mediator  
One of the main functions of extracellular HMGB1 is to induce the release of pro-
inflammatory cytokines. Human monocytes exposed to HMGB1 release TNF, IL-1, 
IL-6, IL-8, IL-1RA, Macrophage-Inflammatory Protein (MIP)-1α and MIP-1β 
(Andersson et al., 2000). HMGB1-induced cytokine production is mediated via two 
mechanisms of action. Firstly, HMGB1 is an endogenous cytokine mediator and 
secondly, HMGB1 is also reported to act in synergy with multiple unrelated 
molecules to promote and enhance inflammation (Figure 1.10).   
HMGB1 has intrinsic cytokine-inducing activity, interacting with TLR4 to activate 
NF-κB mediated gene transcription and cytokine production. Recent reports have 
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shown that the redox status of the C23, C45 and C106 residues is critical for the 
functional activity of HMGB1, with the pro-inflammatory molecular form requiring 
a C23-C45 disulphide bond and a reduced C106 residue (Yang et al., 2011). In 
contrast, fully reduced or fully oxidised HMGB1 does not induce cytokine-
production in human macrophages (Yang et al., 2011).   
Figure 1.10 HMGB1 signalling pathways Extracellular HMGB1 activates multiple 
signalling pathways to promote inflammation and tissue repair. HMGB1 induced 
cytokine-production occurs via two mechanisms of action: 1) HMGB1 acts as an 
endogenous cytokine mediator interacting with the TLR4/MD2 complex and 2) 
HMGB1 acts in synergy with multiple endogenous (IL-1, CXCL12 and 
nucleosomes) and exogenous (LPS and Pam3CSK4) ligands. It is generally believed 
that HMGB1-partner molecules interactions signal via the partner molecule receptor. 
HMGB1 also interacts with RAGE and CXCL12/CXCR4 to promote chemotaxis 
and cell growth. The signalling pathway under investigation in this thesis is shown in 
the boxed region. Figure adapted from (Harris et al., 2012). 
 
HMGB1 has also been demonstrated to act in synergy with a variety of endogenous 
and exogenous molecules to promote and enhance inflammation. Specifically, 
HMGB1 has been reported to interact with IL-1β, IL-1α, CXCL12, nucleosomes, 
LPS, CpG-DNA, Pam3CSK4 and lipoteichoic acid. A number of independent studies 
have shown that these synergistic interactions result in an enhanced inflammatory 
Chapter 1 
 
28 
 
response (Ivanov et al., 2007; Tian et al., 2007; Sha et al., 2008; Urbonaviciute et al., 
2008; Hreggvidsdottir et al., 2009; Qin et al., 2009; Cox et al., 2012; Schiraldi et al., 
2012). It has been proposed that these responses are mediated via the formation of 
highly active inflammatory complexes that interact with the partner molecule 
receptor. However, molecular studies are required to further characterise these 
interactions and to elucidate the mechanism of action. 
The first study to describe this mechanism was reported by Sha et al, in 2008. In this 
study FLAG-tagged HMGB1 was expressed alone or in the presence of IL-1β. 
Mouse macrophages exposed to HMGB1 cultured in the presence of IL-1β had 
enhanced TNFα and MIP-2 production when compared to cells treated with HMGB1 
alone (Sha et al., 2008). The authors proposed that this effect was mediated via the 
formation of a highly active pro-inflammatory complex between HMGB1 and IL-1β. 
To support this theory, they reported that FLAG-tagged HMGB1 and IL-1β could be 
co-isolated using a pull down assay. Additionally, several recent publications from 
independent groups support this hypothesis and demonstrate that HMGB1 and IL-1β 
also significantly enhance cytokine production in synovial fibroblasts (SFs) 
(Hreggvidsdottir et al., 2009; Ferhani et al., 2010; Garcia-Arnandis et al., 2010; 
Wähämaa et al., 2011). Moreover, HMGB1 has recently been shown to form similar 
complexes with CXCL12 and LPS (Schiraldi 2012, Youn 2008). 
HMGB1 and IL-1β are circulating mediators of inflammation that often co-exist at 
the site of inflammation and signal via a common pathway. Both proteins have been 
implicated in the pathogenesis of DILI and thus, the synergistic interaction between 
HMGB1 and IL-1β is of particular interest. However, detailed cellular and 
biophysical studies characterising the interaction are lacking within the current 
literature and this project will make extensive use of Nuclear Magnetic Resonance 
(NMR) to probe the interactions between HMGB1 and IL-1β in the presence and 
absence of LPS. Further details of the NMR method are given in Chapter 2. 
1.9. AIMS OF THESIS  
HMGB1 has been described as a pathogenic mediator of immune-mediated DILI. It 
has been identified as a potential biomarker of hepatotoxicity and a target for 
therapeutic intervention. Further investigations are required to elucidate the pro-
inflammatory role of HMGB1. HMGB1 interacts with a diverse range of unrelated 
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molecules to enhance inflammation. However, despite considerable research the role 
of HMGB1-partner molecule interactions in modulating the inflammatory response 
remain poorly defined and further investigations are needed. The overall aim of the 
work presented in this thesis was to characterise the interactions of HMGB1 using 
combined cellular and NMR methodologies. Specifically, this work has focused on 
the interaction with IL-1β, which is of particular interest, as both molecules often co-
exist at the site of inflammation and have been implicated in the pathogenesis of 
DILI.   
The specific aims of this work were to:  
 Develop and optimise methods for the expression, purification and 
characterisation of LPS-free and isotopically labelled recombinant HMGB1 
and IL-1β proteins (Chapter 1) 
 Characterise the cellular response to HMGB1/IL-1β synergy (Chapter 2):   
 Identify which domain(s) of HMGB1 mediates the interaction with 
IL-1β 
 Explore the dynamics and kinetics of the HMGB1/IL-1β interaction 
to establish the clinical relevance of HMGB1/IL-1β synergy  
 Test the hypothesis that HMGB1 and IL-1β directly interact to form a binary 
complex and, if appropriate, identify the residue(s) involved in the binding 
interaction (Chapter 3) 
The findings from this work will help to elucidate the function of HMGB1 and will 
provide a novel insight into the biology of the HMGB1 protein.  
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2.1. MATERIALS 
The HMGB1 I.M.A.G.E full length cDNA clone was purchased from Imagenes 
(Berlin, Germany) (Clone ID: IRAUp96H0588D). The I.M.A.G.E full length cDNA 
clone for IL-1β was obtained from Source Biosciences (UK) (Clone ID: 
IRATp970B129D). PCR primers used for cloning purposes were synthesised by 
Sigma Aldrich (UK). All PCR reagents were purchased from New England BioLabs 
(NEB, Hertfordshire, UK). XLI-blue E.coli cells were from Stratagene (San Diego, 
USA) and BL21 (DE3) cells were from Novagen (Merck Chemicals Ltd, 
Nottingham, UK). Kanamycin was purchased from Sigma Aldrich (UK) and used at 
a final concentration of 32 μg/mL. Ampicillin was from Melford (UK) and was used 
at a final concentration of 100 μg/mL. AKTA columns were from GE Healthcare 
(Buckinghamshire, UK). All AKTA buffers were passed through a 0.22 μM filter 
and de-gassed prior to use. SFs were cultured from synovial tissue isolated from 
Rheumatoid Arthritis (RA) patients at the Karolinska Institute, Stockholm, Sweden. 
Unless otherwise stated, all other reagents were purchased from Sigma Aldrich 
(UK).   
 
2.2. GENERAL MOLECULAR BIOLOGY METHODS 
2.2.1. Amplification of full length human HMGB1 DNA by Polymerase Chain 
Reaction (PCR) 
The DNA sequence for the human HMGB1 protein (648 bp) was obtained from the 
NCBI website (BC008492.1). Forward and reverse primers were designed to clone 
the DNA encoding the full length protein from the I.M.A.G.E cDNA clone. Primer 
sequences are detailed in Table 2.1; Nco1 and EcoR1 restriction sites were 
incorporated into the forward and reverse primers respectively, as underlined. PCR 
reactions were set up in a final volume of 50 µL and contained 750 ng cDNA 
template, 1x polymerase buffer, 0.5 µM forward and reverse primers, 0.2 mM
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Table 2.1 Sequences and technical information of the PCR primers used for the cloning of the HMGB1, Δ30, A box and IL-1β DNA 
from the respective cDNA clones Important features are underlined and include the Nco1 and EcoR1 restriction sites, added to the HMGB1 
forward and reverse primers respectively, and the primer extension regions added to the IL-1β primers to aid the In-fusion cloning reaction.  
Protein Primer Sequence (5’ to 3’) 
Melting 
temperature (
o
C) 
GC 
content 
HMGB1 
Forward ATATCCATGGGCAAAGGAGATCCTAAGAAGCCGAGAG 78.8 48.7 
Reverse TATAGAATTCTTATTCATCATCATCATCTTCTTCTTCATC 69.4 27.5 
A box 
FL GGAGACATGAAAGAAGTTCAAGGATCCCAATGCACCCAAGAG 82.7 47.7 
FS CAAGGATCCCAATGCACCCAAGAG 73.1 54.2 
RL AACTTCTTTCATGTCTCCCCTTTGGGAGGGATATAGGTTTTC 78.2 42.9 
RS CCTTTGGGAGGGATATAGGTTTTC 65.3 45.9 
Δ30 
FL AAAAAGAAGTGAGAAGAGGAGGAAGATGAGGAAGATGAAGAG 76.3 40.5 
FS GAGGAAGATGAGGAAGATGAAGAG 63.3 45.9 
RL GTCAAGGCTGAAAAAAGCAAGAAAAAGAAGTGAGAAGAGGAG 77.8 40.5 
RS GTCAAGGCTGAAAAAAGCAAGAAA 66.2 37.5 
IL-1β Forward AAGTTCTGTTTCAGGGCCCGGCACCTGTACGATCACTGAAC 84.7 53.7 
 Reverse ATGGTCTAGAAAGCTTTATTAGGAAGACACAAATTGCAT 72.6 33.4 
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dNTPs, 0.1 mM betaine and 0.5 units Phusion Hot Start polymerase. PCR reactions 
were carried out in an Eppendorf Mastercycler
®
 as described in Table 2.2.  
Table 2.2 PCR cycling conditions used to amplify HMGB1 DNA for the 
I.M.A.G.E cDNA clone 
 Step Temperature Time 
1 Polymerase activation 98
o
C 2 min 
2 Denaturation 98
o
C 20 sec 
3 Annealing 55
o
C 30 sec 
4 Extension 72
o
C 30 sec 
 Steps 2-4 were repeated for 24 cycles 
 
2.2.2. Analysis of DNA products using agarose gel electrophoresis 
PCR products were analysed using agarose gel electrophoresis. 0.6% or 1% (w/v) 
agarose gels were prepared by dissolving 300 mg or 500 mg agarose respectively in 
50 mL 1xTris-Acetic acid-EDTA (TAE) buffer (40mM Tris acetate, 20 mM Acetic 
acid, 1 mM EDTA). The mixture was heated until the agarose had fully dissolved 
and then allowed to cool to 40-50
o
C. Ethidium bromide to a final concentration of 1 
µM was added; the gel was poured and left to set at room temperature. Agarose gels 
were run in 1 x TAE buffer. For each sample, 5 µL of the PCR products were mixed 
with 5 µL of loading buffer (30% glycerol, 0.25% bromophenol blue in dH2O). 5 µL 
of the DNA ladder (1Kb ladder, NEB; N3232) and 10 µL of each sample was loaded 
to the wells and the gel was run at 80V for approximately 40 min. DNA bands were 
visualised under UV light.    
2.2.3. Construction of the pETM-11-HMGB1 plasmid 
PCR products were purified using the GenElute PCR Clean-Up Kit (Sigma Aldrich) 
according to the manufacturer’s instructions. To obtain cut linear DNA the reaction 
products were digested using 10 U NcoI and 10 U EcoRI in a total volume of 60 µL 
dH2O supplemented with 1 x NEBuffer EcoRI (NEB, Hertfordshire, UK). Reactions 
were allowed to proceed at 37
o
C for 1 h. Cut DNA was purified using the GenElute 
PCR Clean-Up Kit. A purified and pre-cut pETM-11 expression vector was supplied 
by Dr Robert Gibson, Institute of Integrative Biology, University of Liverpool. 
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Ligation of HMGB1 DNA into the pETM-11 vector was carried out at an insert: 
vector molar ratio of 5:1 at 20
o
C for 25 min using the T4 DNA ligase (Invitrogen, 
UK) (Figure 2.1). Plasmid concentration was quantified using a ND-100 
Spectrophotometer (NanoDrop®).    
 
Figure 2.1 Schematic representation of the pETM-11-HMGB1 vector map 
HMGB1 was cloned into the pETM-11 plasmid at the NcoI and EcoRI restriction 
enzyme sites, as indicated, generating a recombinant vector with 5989 bp. The DNA 
for the Δ30, A box and B box mutants was cloned into the vector at the same sites 
generating plasmids of 5902 bp, 5602 bp and 5575 bp respectively. The key features 
of the plasmid are indicated and include the kanamycin resistance gene (KanR) and 
the T7 promoter region. * indicates the position of the 6-residue his tag incorporated 
into the N-terminus of all constructs for purification purposes. The vector map was 
created using SnapGene®.  
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2.2.4. Cloning of HMGB1 mutants using Site-Directed Ligase Independent 
Mutagenesis (SLIM) 
The A box (residues 1-85) and Δ30 (residues 1-185) HMGB1 mutants were sub-
cloned using the Site-directed Ligase Independent Mutagenesis (SLIM) method 
described by Chiu and colleagues (Chiu et al., 2004).  An overview of the technique 
is shown in Figure 2.2. Briefly, SLIM comprises of a single inverse PCR reaction 
that uses four primers (Forward Long [FL], Forward Short [FS], Reverse Long [RL] 
and Reverse Short [RS]) to incorporate the desired substitution, insertion or deletion 
into the target DNA and produce complementary overhangs. This results in the 
generation of four PCR products and following subsequent denaturation and re-
annealing 16 different hybrids are formed; two of these hybrids contain the correct 
complementary overhangs and can form stable, non-covalently joined DNA circles. 
When transformed into Escherichia coli (E.coli), in this case XL1-blue cells, only 
the circular DNA can produce colonies on the appropriate antibiotic selective agar 
plate.   
To generate the A box and Δ30 mutants a stop codon (TGA) was inserted into the 
target DNA at positions 86 and 186 respectively. Sequences for the PCR primers 
used to incorporate this mutation are given in Table 2.1. pETM-11-HMGB1 plasmid 
DNA (prepared as previously described in Section 2.2.3) was used as the template 
DNA for the PCR reactions. Reactions contained 5 ng DNA template, 0.2 mM 
dNTPs, 100 mM betaine, 10 pmol of each primer, 1 x polymerase buffer and 0.5 U 
Phusion Hot start Fidelity DNA polymerase (NEB, UK) in a total volume of 25 µL 
dH2O. PCR reactions were carried out in an Eppendorf Mastercycler
®
 as detailed in 
Table 2.3.    
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Figure 2.2 An overview of the Site-directed Ligase Independent Mutagenesis 
(SLIM) method used to clone the Δ30 and A box mutants SLIM is a novel PCR-
based mutagenesis technique used for the insertion, substitution or deletion of 
nucleotides in plasmid DNA. SLIM comprises of an inverse PCR reaction that 
utilises four primers (Forward Long [FL], Forward Short [FS], Reverse Long [RL] 
and Reverse Short [RS]) to incorporate the desired modification into the target DNA 
and produce complementary overhangs. The FL and RL primers incorporate the 
described modification and the FS and RS primers amplify the region immediately 
prior to the mutation point. 4 PCR products are generated; products 1 and 2 are 
considered to be productive as they contain complementary overhangs. Subsequent 
denaturation and re-annealing of the PCR products results in the formation of 16 
hybrids; 2 of these hybrids can form stable, non-covalently joined DNA circles. 
When transformed into E.coli only the circular DNA can produce colonies on the 
appropriate antibiotic selective agar plate. Figure was adapted from Chui et al, 2004  
(Chiu et al., 2004).   
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Table 2.3 PCR conditions used to sub-clone the ∆30 and A box mutants from 
the petM-11 plasmid DNA using Site-directed Ligase Independent Mutagenesis 
(SLIM)  
 Step Temperature Time 
1 Polymerase activation 98
o
C 2 min 
2 Denaturation 95
o
C 25 sec 
3 Annealing 50
o
C 30 sec 
4 Extension 68
o
C 7 min 
 Steps 2-4 were repeated for 29 cycles 
 
To remove the template DNA, PCR products were digested using Dpn1. 20 µl of the 
PCR products were incubated with 10 U Dpn1 in 1 x NEB buffer 4 (B7004S, NEB, 
Hertfordshire, UK) at 37
o
C for 1 h. The reaction was terminated using 30 µl of a 
solution of 50 mM Tris HCl (pH 8), 300 mM NaCl and 20 mM EDTA. The products 
were denatured at 99
o
C for 3 min. To anneal the complementary overhangs of the 
DNA strands, thermo hybridisation was performed as described in Table 2.4. This 
resulted in the formation of circular hybrids that contained the desired mutation.  
Table 2.4 Thermocycler conditions used for the thermo hybridisation of the 
linear Dpn1 digested pETM-11-Δ30 and pETM-11-A box PCR products  
Step Temperature Time 
1 99
o
C 3 min 
2 65
o
C 5 min 
3 30
o
C 15 min 
Steps 2-3 were repeated for 3 cycles 
 
2.2.5. Construction of the pETM-11-B box plasmid 
The B box domain was synthesised and sub-cloned into the pETM-11 vector (at the 
Nco1 and EcoR1 restriction sites) by GeneArt, Regensburg, Germany.  
2.2.6. Amplification of the DNA encoding human IL-1β protein by PCR 
The DNA sequence for the human IL-1β protein (459 bp) was obtained from the 
NCBI website (BC008678.1). Forward and reverse primers were designed to amplify 
the DNA from the I.M.A.G.E full length cDNA clone (Table 2.1). PCR reactions 
Chapter 2  
41 
 
contained 100 ng of the template DNA, 1x polymerase buffer, 0.6 μM forward and 
reverse primers, 0.2 mM dNTPs, 1 mM MgCl2 and 1 U of KOD polymerase in a 
final volume of 50 μl. Reactions were carried out in an Eppendorf Mastercycler® as 
outlined in Table 2.5.   
Table 2.5 An overview of the PCR cycling conditions used to amplify IL-1β 
DNA 
 Step Temperature Time 
1 Polymerase activation 94
o
C 2 min 
2 Denaturation 94
o
C 30 sec 
3 Annealing 60
o
C 30 sec 
4 Extension 68
o
C 2 min 
Steps 2-4 were repeated for 29 cycles 
5 Final elongation 72
o
C 2 min 
 
PCR products were analysed using agarose gel electrophoresis as previously 
described (Section 2.2.2).  
2.2.7. Construction of the pOPINf-IL-1β recombinant plasmid 
IL-1β DNA was expressed using the pOPINf vector system (Figure 2.3). The 
pOPINf plasmid was prepared as follows: a commercial glycerol stock of the 
plasmid was used to inoculate 5 mL of LB supplemented with 100 µg/mL ampicillin 
and incubated overnight at 37
o
C in a shaking incubator at 200 rpm. The following 
day the overnight culture was transferred to 100 mL ampicillin selective Lysogeny 
Broth (LB) medium and returned to the incubator for a further 24 h. The plasmid was 
purified using the GenElute™ HP Plasmid Midiprep kit (Sigma Aldrich) according 
to the manufacturer’s instructions. Plasmid concentration was quantified using a ND-
1000 Spectrophotometer (NanoDrop®) and was only used when the A260:A280 ratio 
was between 1.8-2.1.  
To obtain cut linear plasmid DNA, 5 µg of DNA was incubated with 1 x BSA, 50 U 
KpnI, 50 U HindIII and 1 x NEbuffer 2 (NEB, UK) in a total volume of 190 µL of 
dH2O at 37
o
C for 2 h. The digested plasmid was purified using the GenElute PCR 
Clean-Up Kit (Sigma Aldrich) according to the manufacturer’s instructions. The 
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purity of the plasmid DNA was analysed using agarose gel electrophoresis as 
described in Section 2.2.2.  
Ligation of IL-1β DNA into the cut pOPINF vector was carried out using the In-
Fusion® HD Cloning Kit (Clontech, Saint Germain-en-Lave, France) according to 
the manufacturer’s instructions at an insert: vector molar ratio of 7:1.  
2.2.8. Confirmation of gene insertion by DNA sequencing  
To confirm that the recombinant plasmids contained the correct gene of interest, 1 
mL bacterial cell cultures were sent to Source Bioscience, UK, for forward and 
reverse DNA strand sequencing using the T7 primer.  
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Figure 2.3 Schematic representation of the pOPINf-IL-1β vector map IL-1β 
DNA was cloned into the pOPINf plasmid using an In-Fusion® HD cloning Kit at 
the KpnI and HindIII restriction sites, as indicated, resulting in the formation of a 
recombinant plasmid of 5657 bp. Key features of the plasmid are indicated and 
include the ampicillin resistance gene (AmpR) and the T7 promoter region. The 
vector map was created using SnapGene®.  
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2.3. PREPARATION OF RECOMBINANT PROTEINS FROM 
ESCHERICHIA COLI (E.COLI): PROTEIN EXPRESSION AND 
PURFICATION METHODS  
2.3.1. Preparation of chemically competent E.coli cells for the cloning and 
expression of recombinant plasmids 
Two types of chemically competent E.coli cells were used: XL1-blue cells for 
cloning and BL21 (DE3) cells for expression purposes. Chemically competent cells 
were prepared using a variant of the Hanahan method (Hanahan 1983). The 
procedure was conducted in a sterile environment and all glass and plasticware used 
throughout was pre-chilled. Briefly, the commercial glycerol cell stock was streaked 
onto a LB-agar plate with the appropriate antibiotic resistance (XLI-blue = 20 µg/mL 
tetracycline & BL21 (DE3) = antibiotic free) and the plate was incubated overnight 
at 37
o
C. A single colony from the plate was used to inoculate 5 mL LB and the 
medium was incubated overnight at 37
o
C in a shaking incubator at 200 rpm. The 
following day, the 5 mL cell culture was added to 250 mL of Super Optimal Broth 
(SOB) medium and the cells were returned to the incubator until an OD600 of 0.3 was 
achieved. The cell culture was centrifuged at 3000g for 10 min at 4
o
C; the 
supernatant was decanted and the cell pellet was gently resuspended in 80 mL ice 
cold CCMB80 buffer (10 mM KOAc pH7.0, 80 mM CaCl2.2H2O, 20 mM 
MnCl2.4H2O, 10 mM MgCl2, 10% glycerol). The cells were incubated on ice for 20 
min and centrifuged for a further 10 min. The cell pellet was resuspended in 
CCMB80 buffer to yield a final OD600 of 1.0-1.5 and cells were stored in 50 μl 
aliquots at -80
o
C until required.  
2.3.2. Transformation of recombinant plasmids into competent E.coli cells 
Transformation of all recombinant plasmids (pETM-11-HMGB1, pETM-11 Δ30, 
pETM-11-A box, pETM-11-B box and pOPINF-IL-1β) into competent E.coli cells 
followed the same standard protocol. Briefly, 50 µL aliquots of competent cells were 
thawed on ice prior to the addition of 50 ng of plasmid DNA. The cells were 
incubated on ice for a further 30 min, heat shocked at 42
o
C for precisely 1 min and 
returned to ice for a further 2 min. 300 µL of Super Optimal broth with Catabolite 
repression (SOC) medium was added and the cells were incubated at 37
o
C for 1 h in 
a shaking incubator. Following this 100 µL of the cells were plated out onto 
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kanamycin or ampicillin selective agar plates and were incubated overnight at 37
o
C 
in a non-shaking incubator. Colonies on the plate represented bacteria with antibiotic 
resistant that were successfully transformed with the desired plasmid.  
2.3.3. Expression of recombinant HMGB1, HMGB1 mutants and IL-1β in LB 
media 
Single discrete colonies were cultured overnight in 50 mL LB, supplemented with 
the appropriate antibiotic, at 37
o
C in a shaking incubator at 200 rpm. The overnight 
culture was used to inoculate 500 mL LB to give a starting OD600 between 0.07-0.1. 
The cells were incubated at 37
o
C at 200 rpm until an OD600 between 0.8-1.0 was 
achieved. Protein expression was induced with the addition of Isopropyl β-D-1-
thiogalactopyranoside (IPTG) and cells were incubated at 200 rpm, as outlined in 
Table 2.6. Induced cells were harvested by centrifugation at 3000g for 15 min at 4
o
C; 
the cell pellet was retained and stored at -80
o
C prior to protein purification.  
Table 2.6: An overview of the expression conditions used for the production of 
recombinant proteins in E.coli Recombinant plasmids were transformed into BL21 
(DE3) cells and cultured in antibiotic selective LB or M9 media. Protein expression 
was induced using Isopropyl β-D-1-thiogalactopyranoside (IPTG) as indicated.  
Construct 
Antibiotic 
resistance 
IPTG final 
concentration (mM) 
Incubation 
conditions  
HMGB1 Kanamycin 0.5 37
o
C, 4 h 
∆30 HMGB1 Kanamycin 1 18oC, overnight 
A box  Kanamycin 1 24
o
C, overnight 
B box Kanamycin 1 24
o
C, overnight 
IL-1β Ampicillin 1 37oC, 4 h 
 
2.3.4. Expression of 15N and/or 13C-labelled recombinant proteins in minimal 
(M9) Medium 
15
N and/or 
13
C enriched proteins were prepared in minimal medium (also referred to 
as M9 media) using 
15
N ammonium chloride and/or 
13
C glucose as the sole sources 
of nitrogen and carbon respectively. Proteins were expressed as described in Section 
2.3.3 with the following modifications: the M9 medium consisted of 88 mM 
Na2HPO4 and 55 mM KH2PO4 adjusted to pH7.2 and supplemented with 22 mM 
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13
C-labelled glucose, 18 mM 
15
NH4Cl, 1 mM MgSO2.7H2O, 140 µM CaCl2.2H20 
and 30 µM thiamine HCl. Discrete colonies were incubated in 2 mL LB, with the 
appropriate antibiotic, for 5 h at 37
o
C in a shaking incubator set at 200 rpm. Cells 
were centrifuged at 3000g for 10 min and the cell pellet was re-suspended in 500 µL 
M9 media. 50 mL of M9 media, supplemented with the appropriate antibiotic, was 
inoculated with 250 µL of the resuspended cells and incubated overnight at 37oC at 
200 rpm.  The following day, cells were centrifuged at 3000g for 10 min; the cell 
pellet was retained and re-suspended in 3-5 mL M9 media and used to inoculate 500 
mL M9 media to give a starting OD600 between 0.07-0.1. Protein expression was 
induced as previously described (Table 2.6) with the following exemption; IL-1β 
was induced overnight at 18
o
C.   
2.3.5. Lysis of bacterial cell pellets 
The bacterial cell pellets were allowed to gently thaw on ice and re-suspended in 10 
mL of lysis buffer per 1 g of cell pellet. The lysis buffer consisted of 25 mM Tris 
HCl pH7.8, 350 mM NaCl, 250 mM sucrose, 0.5 mg/mL lysosyme and 0.1% (v/v) 
Triton X100. 12.5 µg/mL DNase 1 from bovine pancreas was added to the 
resuspended cells. The pellets were incubated on ice for 15-30 min prior to the 
addition an equal volume of 25 mM Tris HCl (pH7.8) supplemented with 350 mM 
NaCl. The cells were returned to the ice for a further 5 min. Cells were lysed using a 
Pressure Cell Homogeniser (Stansted Fluid Power Ltd, UK) at 1 bar. Lysed cells 
were centrifuged at 23-24,000g for 30 min at 4
o
C to remove the bacterial debris and 
the lysate was retained and passed through a 0.22 µM syringe filter. 
2.3.6. Purification of recombinant proteins by Ni2+ affinity chromatography 
A cleavable 6 residue histidine (His) tag was incorporated into the N-terminus of all 
protein constructs for purifications purposes. His-tagged proteins were purified using 
a variation of the method originally described by Hochuli and colleagues (Hochuli et 
al., 1988) on a ÄKTApurifier system equipped with a P-960 sample pump and a 
frac-920 fraction collector. A 5 mL HisTrap HP column pre-charged with Ni
2+
 
Sepharose beads was equilibrated with 15 mL buffer A (25 mM Tris HCl, 350 mM 
NaCl and 20 mM imidazole, pH7.8) at a constant flow rate of 3.5 mL/min. The 
lysate was loaded onto the column and the column was washed with a further 25 mL 
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of buffer A to remove any proteins that had formed non-specific interactions with the 
Ni
2+
 resin. Proteins of interest, interacted specifically with the Ni
2+
 mediumand were 
eluted using an increasing concentration of buffer B (25 mM Tris HCl, 250 mM 
NaCl and 0.5 M imidazole, pH7.8)  delivered by a linear gradient over 90 mL (or 18 
column volumes). Proteins were collected in 5 mL fractions and analysed using SDS 
gel electrophoresis as described in 2.3.7. Fractions containing the protein of interest 
were pooled and subjected to further purification.  
All recombinant proteins were  purified using Ni
2+
 affinity chromatography as 
described above with the following exception: for the IL-1β purification, buffers A 
and B consisted of 50 mM Tris HCl, 350 mM NaCl, 20 mM imidazole, pH 8.0 and 
50 mM Tris HCl, 350 mM NaCl, 0.5 M imidazole pH 8.0 respectively. 
2.3.7. SDS-PAGE gel electrophoresis analysis of protein samples  
SDS-PAGE gel electrophoresis was used to analyse the purity of bacterially 
expressed recombinant proteins. Proteins were resolved on 12.5% (HMGB1 and 
Δ30) and 15% (A box, B box and IL-β) bis-acrylamide SDS-PAGE gels using the 
standard method described by Laemmli (Laemmli 1970) in  a  Bio-Rad gel 
electrophoresis system. Gel samples were prepared as indicated using a 4x SDS-
PAGE loading buffer (200 mM Tris-HCl, pH6.8 supplemented with 400 mM DTT, 
8% SDS, 0.4% bromophenol blue and 40% glycerol). Gels were run at 100 V for 10 
min to allow the samples to stack evenly and then at 180 V for 45-60 min or until the 
loading dye had reached the bottom of the gel plate.  
SDS-PAGE gels were stained using Coomassie R250 stain (0.25% [w/v] Coomassie 
R250 stain, 45% methanol and 10% acetic acid in dH2O) at room temperature for 30 
min. Stained gels were placed in a solution of 40% methanol, 10% acetic acid until 
the background was completely de-stained. 
2.3.8. Cleavage of the 6-his tag from HMGB1 and HMGB1 mutants using 
TEV protease 
The 6 residue poly-histidine tag, which was incorporated into the N-terminus of all 
HMGB1 constructs for purification purposes, was cleaved following the Ni
2+
 affinity 
chromatography using the Tobacco Etch Virus (TEV) protease. For optimal TEV 
cleavage, the protein was desalted into 25 mM Tris HCl, 50 mM NaCl, pH 7.8 using 
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a HiPrep 26 10 desalting column (GE Healthcare, Buckinghamshire, UK) according 
to the manufacturer’s instructions. Incubations were conducted overnight at 4oC at a 
TEV: protein ratio of 1:20 (w/w).  
The cleaved protein was isolated by “reverse” Ni2+ affinity chromatography. Protein 
samples were adjusted to 300 mM NaCl and loaded onto a pre-equilibrated 5 mL 
HisTrap HP column at 3.5 mL/min. The flow through, containing the cleaved protein 
was retained. The cleaved his-tag and his-tagged TEV protease, which interacted 
specifically with the Ni
2+
 beads were eluted using 25 mM Tris HCl, 250 mM NaCl 
and 0.5 M imidazole, pH 7.8.  
2.3.9. Cleavage of the 6-his tag from IL-1β using 3C protease 
The 6 residue poly-histidine tag, incorporated into the N-terminus of the IL-1β 
protein, was cleaved after the Ni
2+ 
affinity chromatography, using the 3C protease. 
The protease, produced in-house and kindly provided by Dr Thomas Zacharchenko, 
recognised the LEVLFQ-GP sequence and specifically cleaved between the 
glutamine (Q) and glycine (G) residues. For optimal cleavage, the protein was 
desalted into 50 mM TrisHCl, 50 mM NaCl, pH 8 using a HiPrep 26 10 desalting 
column (GE Healthcare, Buckinghamshire, UK) according to the manufacturer’s 
instructions. Incubations were conducted overnight at 4
o
C at a 3C: protein ratio of 
1:25 (w/w).  
The cleaved protein was isolated by “reverse” Ni2+ affinity chromatography. Protein 
samples were adjusted to 300 mM NaCl and loaded onto a pre-equilibrated 5 mL 
HisTrap HP column at a flow rate of 3.5 mL/min. The flow through, containing the 
cleaved protein was retained. The cleaved his-tag and his-tagged 3C protease bound 
specifically to the Ni
2+
 beads and were eluted using 50 mM Tris HCl, 350 mM NaCl 
and 0.5 M imidazole, pH 7.8.  
2.3.10. Purification of recombinant proteins by Ion Exchange (IEX) 
chromatography 
All recombinant proteins were subjected to Ion Exchange (IEX) chromatography 
following the reverse affinity purification. IEX chromatography separates molecules 
by exploiting the difference in their overall net surface charge. A protein has no net 
charge at a pH equivalent to its Isoelectric Point (pI). However, at a pH greater than 
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its pI a protein will have a negative net charge and will interact with positively 
charged medium or an anion exchanger (HiTrap Q FF column). At a pH lower than 
its pI a protein will have a positive net charge and interact with negatively charged 
medium or a cation exchanger (HiTrap S FF column). 
The HMGB1 protein had a pI of 5.62 and was purified using anion exchange on a 5 
mL HiTrap Q FF column (GE Healthcare, Buckinghamshire, UK). To allow optimal 
binding, the protein was desalted into buffer A (25 mM Tris HCl, 50 mM NaCl, pH 
7.8) prior to IEX purification, using a HiPrep 26 10 desalting column (GE 
Healthcare, Buckinghamshire, UK) according to the manufacturer’s instructions. The 
HiTrap Q FF column was pre-equilibrated with buffer A and the sample was loaded 
at constant flow rate of 3.5 mL/min. The protein was eluted using an increasing 
concentration of buffer B (25 mM Tris HCl, 1 M NaCl, pH 7.8) delivered over 90 
mL (or 18 column volumes) and collected in 5 mL fraction. Fractions were analysed 
using SDS gel electrophoresis as described previously (Section 2.3.7). Fractions 
containing the protein of interest were pooled and purified further using size 
exclusion chromatography.  
The cleaved IL-1β protein had a pI of 5.91 and was purified using anion exchange as 
described above but using the following buffers; Buffer A: 50 mM Tris HCl, 50 mM 
NaCl, pH 8.5  and buffer B  contained 50 mM Tris HCl, 0.5 M NaCl, pH 8.5.   
The cleaved Δ30, A box and B box had pI values of 9.87, 9.67 and 9.38 respectively 
and were purified by cation exchange using a 5 mL HiTrap S FF column, as 
described above but with the following modifications; Buffer A consisted of 50 mM 
potassium phosphate, 50 mM NaCl, pH 6.5 and buffer B contained 50 mM 
potassium phosphate, 1 M NaCl, pH 6.5.   
2.3.11. Purification of recombinant proteins using size exclusion 
chromatography  
The fractions retained from the IEX chromatography were subjected to size 
exclusion purification. Proteins were concentrated to approximately 5-8 mL using 6 
or 20 mL Vivaspin centrifugal concentrators with a 5 kDa Molecular Weight Cut Off 
(MWCO) according to the manufacturer’s instructions (Sigma Aldrich, UK).  
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The sample was loaded onto a Superdex 75 26 10 column (GE Healthcare, 
Buckinghamshire, UK), which was pre-equilibrated with PBS pH 7.2.   
The column was washed with 320 mL (or 1 column volume) of PBS, delivered at 
constant flow rate of 1 mL/min and the protein was collected in 5 mL fractions. The 
retention time was determined by the size of the molecule. Proteins were analysed 
using SDS gel electrophoresis as described in Section 2.3.7.   
Purified proteins were concentrated to an appropriate working concentration using 
the Vivaspin centrifugal concentrators according to the manufacturer’s instructions.   
2.3.12. Removal of contaminating endotoxin from recombinant protein 
preparations using the Triton-X114 protocol 
Contaminating LPS was removed from bacterially expressed recombinant protein 
preparations using the Triton-X114 two phase extraction protocol originally 
described by Aida and Pabst (Aida and Pabst 1990). Briefly, Triton-X114 was added 
to the proteins at a final concentration of 1% (v/v) and the solution was gently 
inverted to ensure thorough mixing. Tubes were rotated at 4
o
C for 30 min, heated to 
37
o
C for 10 min and centrifuged at 18,000g at 25
o
C for 10 min. This resulted in the 
formation of a bi-layer and the top layer, containing the protein, was carefully 
aspirated into a sterile tube. The entire process was repeated 3 times. After the final 
spin, the samples were passed through a 0.22 µM syringe filter.  
Protein aliquots (10 g/mL) were sent to the Karolinska Institute in Stockholm, 
Sweden for endotoxin level quantification using the chromogenic LAL endotoxin 
assay. Proteins used for experiments had LPS levels of less than 5 Endotoxin Unit 
(EU)/mL.   
2.3.13. Determining the total molecular mass of recombinant HMGB1 and IL-
1β proteins using Electrospray Ionization Mass Spectrometry (ESI-MS) 
analysis  
Recombinant proteins were prepared at 1 pg/μL in dH2O for Electrospray Ionization 
Mass Spectrometry (ESI-MS) analysis.  Samples were kindly analysed by Dr Mark 
Prescott at the Institute of Integrative Biology, University of Liverpool. Samples 
were analysed using a Waters Micromass Quadrupole Time of Flight (QToF) mass 
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spectrometer operated in the positive ion electrospray mode. The samples were 
dissolved in 50% aqueous acetonitrile (ACN), and infused into the mass 
spectrometer via a syringe pump. The mass range scanned was: m/z 2-80 kDa. Data 
were analysed using Waters MassLynx MS software.  
2.3.14. Western blot analysis of the recombinant HMGB1 protein   
5 µl of 4 x SDS-PAGE loading buffer was added to 1 µg of the recombinant 
HMGB1 protein in a final volume of 20 µl dH2O. Proteins were resolved on a 10% 
bis-acrylamide SDS-PAGE gel using the standard method described by Laemmli 
(Laemmli 1970) in  a  Bio-Rad gel electrophoresis system. Gels were run at 100 V 
for 10 min to allow the samples to stack evenly and then at 180 V for 45-60 min or 
until the loading dye had reached the bottom of the gel plate. The proteins were 
transferred onto nitrocellulose membrane (Hybond ECL, GE Healthcare) in ice-cold 
transfer buffer (25 mM Tris base, 200 mM Glycine and 20% methanol in dH2O) at 
100 V for 1 h.  The membrane was blocked in 10% milk (Bio-Rad, Hertfordshire, 
UK) for 30 min at room temperature. The membrane was washed four times using 
Tween-TBS buffer (0.1% Tween in 1 x TBS buffer. 1 x TBS buffer contained 20 
mM Tris base and 137 mM NaCl). The membrane was incubated with a polyclonal 
rabbit anti-HMGB1 antibody (Abcam, UK) for 1 h at room temperature. The anti-
HMGB1 antibody was diluted 1/5000 in 2% milk. The membrane was washed four 
times using Tween-TBS buffer. The membrane was incubated with an anti-rabbit 
IgG antibody (Sigma, A0545) for 1 h at room temperature. The anti-rabbit antibody 
was diluted 1/1000 in 2% milk. Protein bands were visualised using the Western 
Lightning™ Chemiluminescence Plus-ECL reagent (Perkin Elmer, UK) according to 
the manufacturer’s instructions.     
2.3.15. Determination of the redox status of HMGB1 using LC-ESI-MS/MS 
100 μg of his-tagged HMGB1 was incubated with 50 μl of Ni2+ affinity beads for 15 
min at room temperature. The beads were centrifuged at 13,000 rpm for 1 min; the 
pellet was retained and washed with PBS. The beads were re-suspended in 55 mM 
iodoacetamide (Figure 2.4A) and incubated at room temperature for a further 15 min. 
The beads were centrifuged at 13,000 rpm for 1 min; the pellet was retained and 
washed with PBS. The beads were re-suspended in 1 mM DTT and incubated for a 
further 15 min. The beads were centrifuged at 13,000 rpm for 1 min; the pellet was 
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retained and re-suspended in 20 mM N-ethylmaleimide (NEM; Figure 2.4B). The 
beads were incubated for a further 15 min at room temperature. The beads were 
centrifuged at 13,000 rpm for 1 min; the pellet was retained and washed with PBS. 
The his-tagged HMGB1 protein was digested on the Ni
2+
 beads using Glu-c (NEB, 
Hertfordshire, UK) at a final protein: Glu-c ratio of 1:100. The mixture was 
incubated for 16 h at 25
o
C in a total volume of 100 μl in PBS. The following day, the 
beads were centrifuged at 13,000 rpm for 1 min and the supernatant was retained. 
The peptides were dried down using a speed vac and re-suspended in 20 μl 0.1% 
TFA. The peptides were purified using ZipTip C18 pipette tips (Millipore, UK) 
according to the manufacturer’s instructions. Briefly, 1 µl 1% TFA was added to 10 
µl of the peptides and the sample was vortexed. The C18 ZipTip was washed twice 
with 100% ACN and three times with 0.1% TFA. The sample was loaded onto the 
column and the tip was washed five times with 0.1% TFA. Peptides were eluted in 
10 µl 0.1% TFA/60% ACN.     
 
Figure 2.4 Chemical structures of (A) NEM and (B) iodoacetamide  
Samples were kindly analysed using LC-ESI-MS/MS by Dr Rosalind Jenkins in the 
Centre for Drug Safety Science at the University of Liverpool. The alkylation with 
iodoacetamide generated a carboxyamidomethyl adduct resulting in a mass shift of 
57 amu (atomic mass units). The alkylation with NEM yielded a mass shift of 125 
amu. 
2.3.16. Determination of the cytokine-inducing activity of rHMGB1 proteins on 
Peripheral Blood Mononuclear Cell (PBMC) cultures 
PBMCs were purified using Ficoll centrifugation (Ficoll-Paque Plus, GE Healthcare) 
from the blood of a healthy volunteer drawn into sodium heparin tubes. Briefly, 18 
mL of blood was collected and added to an equal volume of PBS along with 8 mL of 
Ficoll reagent. The mixture was immediately centrifuged at 440g for 20 min at 20
o
C. 
Chapter 2  
53 
 
The PBMC layer was retained and cells were washed using 40-45 mL PBS. Cells 
were centrifuged at 300g for a further 7 min. The pellet was retained and the wash 
was repeated. Cells were counted and the viability with assessed  using trypan blue; 
cells were only used when the viability > 95%.  
Cells were plated at 100,000 cells/mL in a 96-well plate in OPTIMEM supplemented 
with 100 U/mL Penicillin and 100 μg/mL streptomycin and cultured at 37oC with 
5% CO2. Cells cultures were stimulated with HMGB1, Δ30, A box and B box at a 
final concentration of 0, 0.625, 1.25, 2.5, 5 and 10 μg/mL for 16 h. Cell supernatants 
were collected and stored at -20
o
C. IL-6 levels were quantified by ELISA as 
described in Section 2.4.8.  
2.4. IN VITRO ASSAYS TO INVESTIGATE THE INTERACTIONS OF 
HMGB1  
2.4.1. Culturing of SFs isolated from RA patients 
SFs were cultured from synovial tissue isolated from arthritic patients undergoing 
joint replacement surgery at the Karolinska Institute, Stockholm, Sweden as 
previously described (Wahamaa 2011). Cells were cultured in DMEM supplemented 
with 10% heat-inactivated FCS (PAA Laboratories, Linz, Austria), 100U/mL 
penicillin, 100 µg/mL streptomycin and 1 x HEPES (Life Technologies, Paisley, 
Scotland, UK) at 37
o
C with 5% CO2.  
Cells were sub-cultured when they were 80% confluent using 0.05% trypsin-EDTA 
(Gibco, UK). Briefly, cells were washed twice with PBS before 0.05% trypsin-
EDTA was added (4 and 2 mL trypsin solution was added to T175 and T75 flasks 
respectively) and cells were incubated at room temperature for approximately 5 min 
or until all the cells had detached from the flask. The detached cells were diluted to 
15 mL using DMEM medium and were centrifuged at 300g for 5 min at room 
temperature. The cell pellet was retained and re-suspended in DMEM. Cell viability 
was assessed using trypan blue (Merck, Darmstadt, Germany) and was between 95-
100%. As a general rule, cells were sub-cultured at a ratio of 1:3.  
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2.4.2. Investigating the synergistic activity of HMGB1 and IL-1β in SFs  
SFs were plated at 6,000 cells/well in a 96-well plate and allowed to rest for 15-17 h. 
The medium was discarded and the cells were washed with OPTIMEM (Invitrogen, 
UK), supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin 
(Invitrogen, UK). Cells were treated with a final concentration of 100 ng/mL 
HMGB1 and 0.5 ng/mL or 0.05 ng/mL IL-1β. Proteins were pre-incubated as a 50 x 
stock solution in PBS (without CaCl2 and MgCl2, pH7.2; Invitrogen, UK) for 16 h at 
4
o
C prior to the experiment. For the simultaneous addition the diluted HMGB1 and 
IL-1β stocks were incubated separately overnight at 4oC and were combined 
immediately prior to dosing. The proteins were diluted in OPTIMEM immediately 
prior to cell treatment to provide the final indicated concentrations. Cells were dosed 
for 24 h and the cell supernatants were collected and stored at -80
o
C until analysis.  
2.4.3. HMGB1 and IL-1β dose response in SFs 
SFs were plated at 6,000 cells/well in a 96-well plate and allowed to rest for 15-17 h. 
The medium was discarded and the cells were washed with OPTIMEM (Invitrogen, 
UK), supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin 
(Invitrogen, UK). HMGB1 and IL-1β were prepared as a 50 x stock solution and 
incubated for 16 h at 4
o
C. Proteins were diluted in OPTIMEM immediately prior to 
cell dosing to provide a final concentration of 3.25-100 ng/mL HMGB1 and 0.5 
ng/mL IL-1β. Cells were dosed for 34 h and the cell supernatants were collected and 
stored at -80
o
C until analysis.  
2.4.4. Investigating the kinetics of the synergistic interaction between 
HMGB1 and IL-1β in SFs  
SFs were plated at 6,000 cells/well in a 96-well plate and allowed to rest for 15-17 h. 
The medium was discarded and the cells were washed with OPTIMEM (Invitrogen, 
UK), supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin 
(Invitrogen, UK). Fibroblasts were treated with a final concentration of 100 ng/mL 
HMGB1 and 0.5 ng/mL IL-1β. The proteins were prepared as 50 x stock solutions 
using freshly made dilutions and pre-incubated at 4
o
C, room temperature or 37
o
C for 
0-24 h. Stock solutions were diluted in OPTIMEM immediately prior to cell dosing. 
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Cells were dosed for 24 h and the cell supernatants were collected and stored at -
80
o
C until analysis. 
2.4.5. Investigating the synergistic interaction between IL-1β and the 
different HMGB1 domains (Full length HMGB1, Δ30, A box or B box) 
SFs were plated at 6,000 cells/well in a 96-well plate and allowed to rest for 15-17 h. 
The medium was discarded and the cells were washed with OPTIMEM (Invitrogen, 
UK), supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin 
(Invitrogen, UK). Cells were treated with HMGB1, Δ30, A box or B box in 
combination with IL-1β. Proteins were prepared as a 50 x stock solution and 
incubated for 16 h at 4
o
C. Stock solutions were diluted in OPTIMEM immediately 
prior to dosing to provide a final concentration of 100 ng/mL HMGB1, 86 ng/mL 
Δ30, 40 ng/mL A box or 35 ng/mL B box with 0.05 or 0.5 ng/mL IL-1β. Different 
concentrations of the HMGB1 constructs were used to maintain the same molar ratio 
(1:137 or 1:1370, IL-1β: HMGB1/Δ30/A box or B box). Cells were dosed for 24 h, 
the supernatants were collected and stored at -80
o
C until analysis. 
2.4.6. Determining if the synergy between HMGB1, Δ30 or B box and IL-1β 
is mediated via the IL-1R or TLR4 receptor  
SFs were plated at 6,000 cells/well in a 96-well plate and allowed to rest for 15-17 h. 
The medium was discarded and the cells were washed with OPTIMEM (Invitrogen, 
UK), supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin 
(Invitrogen, UK). Cells were pre-treated with 5 µg/mL anakinra (Kineret®; a 
synthetic IL-1R antagonist) or 10 µg/mL detoxified LPS for 1-2 h. The cells were 
treated with HMGB1, Δ30, A box or B box in combination with IL-1β. Proteins 
were prepared as described in Section 2.4.5. Cells were dosed for 24 h, the 
supernatants were collected and stored at -80
o
C until analysis. 
2.4.7. Investigating the effect of LPS on HMGB1 and IL-1β synergy  
SFs were plated at 6,000 cells/well in a 96-well plate and allowed to rest for 15-17 h. 
The medium was discarded and the cells were washed with OPTIMEM (Invitrogen, 
UK), supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin 
(Invitrogen, UK). The HMGB1, IL-1β and LPS used to dose the cells were prepared 
as 50 x stock solutions. 5 µg/mL HMGB1 was pre-incubated with 1.25 ng/mL LPS 
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for 1 h at 4
o
C. 25 ng/mL IL-1β was added to the mixture and the proteins were 
incubated for a further 16 h at 4
o
C. The proteins were diluted in OPTIMEM 
immediately prior to cell dosing. Additionally, 5 µg/mL HMGB1 and 25 ng/mL IL-
1β were incubated for 16 h at 4oC. Following the overnight incubation, 1.25 ng/mL 
LPS was added to the proteins for 2, 1, 0.5 or 0 h. The stock solutions were diluted 
1/50 in OPTIMEM immediately prior to cell stimulations to provide a final cellular 
concentration of 100 ng/mL HMGB1, 0.5 ng/mL and 25 pg/mL LPS. Cells were 
dosed for 24 h; supernatants were collected and stored at -80
o
C until analysis. 
2.4.8. Quantification of IL-6 levels in synovial fibroblast cell supernatants by 
ELISA  
IL-6 cytokine levels were quantified using the Human IL-6 DuoSet ELISA kit (R & 
D systems) according to the manufacturer’s instructions. The limit of quantification 
was 9.37 pg/mL and samples below this limit were assigned a value of 0.1 for 
statistical analysis. 
2.4.9. Statistical analysis   
All data are provided as absolute IL-6 values ± SD, with the following exception: for 
Figure 4.2, data are expressed as mean IL-6 value ± SEM. The limit of quantification 
for the IL-6 ELISA was 9.37 pg/mL and samples below this limit were assigned a 
value of 0.10 for statistical analysis. Data were analysed for normality using a 
Shapiro Wilk test. For normal data statistical significance was determined using a T-
test. Non-normal data were analysed using a Kruskal Wallis one-way ANOVA on 
ranks test.  
2.5. NMR METHODS TO INVESTIGATE HMGB1 PROTEIN 
INTERACTIONS 
2.5.1. An Introduction to NMR spectroscopy  
(The following references were used throughout this section (Cavanagh et al., 2006; 
Muskett 2011; Takeda and Kainosho 2011)).  
In 1957, Saunders et al recorded the first 
1
H NMR spectrum for the pancreatic 
ribonuclease protein using a 40 MHz spectrometer (Saunders et al., 1957). Since 
then, NMR tools have developed considerably with the introduction of two-
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dimensional (2D) spectroscopy in the 1970s allowing for the study of multiple nuclei 
within a single experiment.  
All molecules are composed of atoms, which in turn consist of a nucleus that 
contains protons and neutrons and is surrounded by orbital negatively charged 
electrons. Nuclei have an intrinsic quantum mechanical property known as the 
nuclear spin angular momentum, which is defined by the nuclear spin quantum 
number (I). As a result, when certain atomic nuclei are exposed to a strong magnetic 
field they will align parallel to the applied field. It is important to note that nuclei 
with I = ½ are commonly studied by NMR spectroscopy. This includes the 
1
H, 
15
N 
and 
13
C isotopes, which have a natural abundance of 99.99%, 0.37% and 1.11% 
respectively. As such, enrichment of the 
15
N and 
13
C isotopes is required for the 
production of labelled proteins for heteronuclear NMR experiments.   
NMR experiments utilise a stable magnetic field and when the sample is placed into 
the spectrometer the nuclei align to this resting state. During the experiment, 
radiofrequency pulses perturb the alignment and the resulting signal is detected. The 
signal is measured until the nuclei have re-aligned to the magnetic field (resting 
state). The amplified and digitised signal is known as the Free Induction Decay 
(FID) signal and is a measurement of the intensity of the signal over time (intensity 
vs. time). The FID signal must be processed prior to data analysis and this is 
achieved using a mathematical process known as Fourier transformation. The FID 
signal is converted from a plot of the intensity vs. time to intensity vs. frequency 
(frequency may also be referred to as chemical shift), with the frequency measured 
in MHz. However, the MHz signal is dependent upon the magnetic field strength and 
is not a standardised measurement across different spectrometers. To compensate for 
this, the signal is converted to parts per million (ppm) and expressed relative to a 
reference peak and the final NMR spectrum is a plot of the chemical shift (ppm) vs. 
intensity.  
2.5.2. Protein NMR spectroscopy: Types of experiments and their applications 
Protein NMR spectroscopy has many practical applications; it can be employed to 
elucidate three dimensional (3D) protein structures and can be used to investigate 
and characterise macromolecular interactions. For the work described within this 
thesis, standard 1D, 2D and 3D experiments were employed. One dimensional (1D) 
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1
H NMR spectroscopy can provide vital information about a protein; for example it 
can be used to determine if the protein of interest is correctly folded and to identify 
any small molecule contaminants. 2D Heteronuclear Single Quantum Coherence 
(HSQC) experiments are used to obtain more detailed information about the protein 
of interest. HSQC experiments measure the chemical shift of both the proton and the 
heteronuclear atom (
15
N or 
13
C). They are used to obtain one-bond correlation 
spectra and each peak on a HSQC spectrum is a plot of the proton frequency (direct 
dimension) vs. the frequency of the corresponding heteronuclei (indirect dimension). 
2D HSQC experiments are an extremely useful tool for investigating protein 
interactions. If two macromolecules interact to form a binary complex then the 
electronic environment of the atoms involved or affected by the interaction will be 
changed and the peaks on the HSQC spectrum will be perturbed. For the purpose of 
this work, protein NMR spectroscopy has been utilised to investigate HMGB1 
interactions. Specifically, this work was performed to determine if a direct 
interaction occurs between HMGB1 and IL-1β.  
A combination of 2D and 3D NMR experiments were performed for the assignment 
of the A box domain of HMGB1. Standard HSQC-based 3D triple resonance (
1
H, 
15
N and 
13
C) experiments were used to assign the backbone residues (Clubb et al., 
1992; Grzesiek and Bax 1992; Grzesiek and Bax 1992). Briefly, 3D HNCO and 
HNCACO experiments were used to sequentially assign the backbone NH via the 
carboxyl group and CBCACONH and HNCACB experiments were used to assign 
the backbone NH via the backbone Cα and side-chain Cβ groups (Figure 2.5). 
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Figure 2.5 Overview of the experiments carried out for the assignment of the A 
box domain of HMGB1 Standard HSQC-based 3D triple resonance experiments 
were used to assign the backbone NH groups of the A box domain. A) HNCO and 
HNCACO spectra were used to sequentially assign the backbone NH via the 
carboxyl group. B) CBCACONH and HNCACB experiments were used to assign 
the backbone NH via the backbone Cα and side-chain Cβ groups. Circled nuclei 
represent resonances assigned using each experiment via i NH root resonances.  
2.5.3. Preparation of NMR samples 
For NMR analysis
 15
N and/or 
13
C-labelled recombinant proteins were expressed in 
minimal medium and purified as previously described in Section 2.3. Detailed 
information on the samples used for NMR experiments is provided in Table 2.7. As 
a general rule, NMR samples were prepared at 10-100 μM in PBS, pH 7.2, and 
contained a final concentration of 10% D2O (Deuterium oxide, 
2
H2O). For NMR 
experiments, the samples were placed in either standard 5 mm NMR tubes (Sample 
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volumes of >500 μL; Goss Scientific, UK) or Shigemi reduced volume NMR tubes 
(Sample volume between 300-500 μL; Sigma Aldrich, UK). Between samples, NMR 
tubes were cleaned using 100% nitric acid overnight and washed thoroughly with 
ultrapure water prior to use.  
2.5.4. NMR data collection 
All NMR spectra were collected on Bruker Avance II 600 or 800 MHz spectrometers 
equipped with triple (TCI) resonance cryoprobes at 25
o
C (298 K) unless otherwise 
stated.   
2.5.5. NMR data processing and analysis 
All NMR data were processed using Topspin 3.1 (Bruker) and analysed using CCPN 
analysis.  
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Table 2.7 An overview of the NMR sample preparation and experimental acquisition parameters NMR spectra were collected on 600MHz 
or 800MHz Bruker Advance spectrometers equipped with triple resonance cryoprobes at 25
o
C (298K) unless stated otherwise. All samples 
contained a final concentration of 10% D20. (PBS; 8.06mM Na2HPO4.7H2O, 1.47mM KH2PO4, 137.93mM NaCl and 2.67mM KCl, pH7.2) 
Thesis 
figure(s) 
Sample LPS Free 
(<0.05EU/ 
mL) 
Buffer/pH  Field 
strength 
(MHz) 
Number of 
scans (NS) 
T1 
Increments 
Resolution in 
the indirect 
dimension 
(Hz) 
3.4 23 μM unlabelled HMGB1 
 
Yes PBS, pH 7.2 600 512 - - 
3.6 100 μM 15N his-tagged Δ30  
 
Yes PBS, pH 7.2 600 64 160 18.24 
3.7 50 μM 15N A box 
 
Yes PBS, 10 mM DTT, pH 7.2  800 16 150 21.80 
3.8  
 
10 μM 15N B box  Yes PBS, pH 7.2 800 192 256 15.80 
3.9 
 
25 μM 15N IL-1β Yes PBS, pH 7.2 600 32 160 21.00 
3.11 
 
100 μM 15N A box  
pH titration from 5.5 to 7.2 
No 20 mM potassium phosphate, 
100 mM potassium chloride 
and 10 mM DTT, pH 5.5 
to7.2 
800 8 150 21.09 
3.13 
 
50 μM 15NA box ± 10 mM DTT Yes PBS, pH 7.2  800 16 150 21.08 
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3.14 Pre-LPS removal: 40 µM 
15
N his-
tagged Δ30 
Post-LPS removal 100 µM 
15
N his-
tagged Δ30 
No 
Yes 
PBS, pH 7.2 600 64 160 18.24 
3.15 Pre-LPS removal: 77 µM 
15
N A 
box 
Post-LPS removal 50 µM 
15
N A 
box 
No 
Yes 
PBS, 10 mM DTT, pH 7.2 800 16 150 21.08 
3.16 Pre-LPS removal: 10 µM 
15
N B 
box 
Post-LPS removal 10 µM 
15
N B 
box 
No 
Yes 
PBS, pH 7.2 800 192 256 15.80 
5.1 & 5.2 25 μM IL-1β (Apo) 
12.5 μM 15N IL-1β ± 11.5 μM 
HMGB1 (IL-1β: HMGB1 1:1) 
Yes PBS, pH 7.2 600 32 160 21.00 
5.3 & 5.4 100 μM 15N IL-1β (Apo) 
50 μM 15N IL-1β ± 195 μM 
HMGB1 (IL-1β: HMGB1 1:4) 
Yes PBS, pH 7.2 600 
10
o
C  
(283 K) 
64  
256 
250 
384 
12.67 
12.67 
5.6 10 μM 15N his-tagged Δ30 ± 90 μM 
IL-1β 
(Δ30: IL-1β ratio = 1:9) 
Yes PBS, pH 7.2 800 192 256 15.80 
5.7 100 μM 15N IL-1β ± 300 μM Δ30 Yes 20 mM Phosphate, 100 mM 
potassium chloride, 10 mM 
DTT, pH 6.8 
800 4 210 16.99 
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5.8 10 µM 
15
N B box ± 100 µM IL-1β  
(B Box: IL-1β ratio = 1:10) 
Yes PBS, pH 7.2 800 192 256 15.80 
5.9 100 μM 15N A box ± 500 μM IL-1β 
(A box: IL-1β ratio = 1:5) 
Yes 20 mM Phosphate, 100 mM 
potassium chloride, 10 mM 
DTT, pH 6.8 
800 8 150 21.09 
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3.1.  INTRODUCTION 
HMGB1 was first isolated from calf thymus in 1973 by Goodwin and colleagues 
(Goodwin et al., 1973). Originally HMGB1 was discovered as a nuclear protein that 
is involved in the regulation of protein transcription (Travers and Thomas 2004). 
However, subsequent studies have demonstrated that HMGB1 has multiple distinct 
functions in the nucleus and cytoplasm (Figure 1.5).  
Increasingly, HMGB1 is reported to be an important cytokine mediator in both 
sterile and infectious inflammation. Studies have identified HMGB1 as a pathogenic 
mediator of sepsis, autoimmune diseases including arthritis, pancreatitis, respiratory 
disorders, gastrointestinal inflammation, ischemia-reperfusion injury and cancer 
(Andersson and Tracey 2011). Additionally, HMGB1 has been identified as an 
important inflammatory mediator in animal and clinical studies of DILI (Antoine et 
al., 2009; Antoine et al., 2010; Craig et al., 2011; Antoine et al., 2012). Recently, a 
study by Antoine and colleagues has identified acetylated HMGB1 as a prognostic 
indicator of acute liver injury during acetaminophen hepatotoxicity (Antoine et al., 
2012).  
To initiate and enhance inflammation, HMGB1 signals alone or via an unidentified 
mechanism to act in synergy with other endogenous or exogenous molecules. The 
overall aim of this thesis was to investigate and characterise the molecular 
interaction between HMGB1 and IL-1β using both cellular and NMR methodologies. 
To facilitate these studies, this chapter describes the development and optimisation 
of methods for the expression, purification and characterisation of the human 
HMGB1 and IL-1β proteins. This chapter also reports the successful sub-cloning of 
three human HMGB1 mutants (Table 3.1). The individual A and B box domains 
(corresponding to residues 1-85 and 89-163 respectively) and the Δ30 protein, which 
contains residues 1-185 and does not incorporate the 30-residue C-terminal 
polyacidic tail. The different HMGB1 domains will be used to further investigate the 
cellular and biophysical interaction between HMGB1 and IL-1β and to identify 
which domain(s) of HMGB1 is critical for the synergistic response.    
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Table 3.8 Domain structure of recombinant HMGB1, Δ30, A box and B box 
proteins produced in this thesis. 
 
As discussed in Section 1.8.2, HMGB1 is a 25 kDa protein consisting of 215 amino 
acid residues organised into a tripartite domain structure (Figure 1.6 & Figure 1.7). 
The expression and purification of recombinant cytokine-inducing rat HMGB1 in 
E.coli has been previously reported and is associated with low protein yields 
(Bianchi 1991; Li et al., 2003). A further complication associated with the 
production of recombinant HMGB1 proteins is the presence of LPS contaminants in 
the purified protein sample. LPS is a major component of the outer membrane of 
gram negative bacteria and a potent activator of the innate immune system. LPS 
induces septic shock in humans and studies have demonstrated that LPS-treated 
macrophages release large quantities of TNF (Beutler et al., 1985). HMGB1 and LPS 
both signal via the TLR4 to increase nuclear translocation of NF-KB (Andersson and 
Tracey 2011). It has been reported that HMGB1 and LPS act synergistically to 
enhance the inflammatory response and it is proposed that this is mediated via the 
formation of a highly active pro-inflammatory complex (Youn et al., 2008; 
Hreggvidsdottir et al., 2009). Efficient removal of LPS contaminants is essential 
(Wakelin et al., 2006) particularly since HMGB1 is reported to have a high affinity 
for LPS (Youn et al., 2008). A number of removal methods have been described 
including Triton-X 114 phase extraction, polymyxin B treatment and anion-exchange 
purification (Petsch and Anspach 2000). 
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The production of isotopically labelled recombinant proteins is required for 
heteronuclear NMR experiments and backbone assignment. For the purpose of this 
work, the proteins were uniformly labelled using the 
15
N and/or 
13
C isotopes. Isotope 
labelling increases the sensitivity and peak resolution and additionally helps to 
simplify the complexity of the NMR spectra (Lian and Middleton 2001). The 
production of isotopically labelled HMGB1 constructs has been previously reported. 
However, published NMR studies have not considered the effect of LPS 
contaminants and their removal. An additional aim of this work was to investigate 
the effect of LPS removal on the NMR spectra for the HMGB1 proteins.  
This chapter describes the development and optimisation of methods for the 
expression, purification and characterisation of LPS-free and isotopically labelled 
recombinant human HMGB1 and IL-1β proteins.   
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3.2.  MATERIALS AND METHODS 
Recombinant HMGB1, Δ30, A box, B box and IL-1β proteins were expressed, 
purified and characterised as described in Chapter 2, Sections 2.2 and 2.3. A 
schematic overview of the methods employed is provided in Figure 3.1.  
 
Figure 3.5 Schematic overview of the cloning, expression, purification and 
characterisation protocols   
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3.3.  RESULTS 
3.3.1. Production of recombinant human HMGB1 proteins from E.coli  
The pETM-11/HMGB1 plasmid was transformed into E.coli BL21 (DE3) cells and 
the protein was expressed in LB medium at 37
o
C for 4 h, as this was determined to 
be the optimal expression conditions. The bacterial cell lysate was initially purified 
using Ni
2+
 affinity chromatography and SDS-PAGE gel electrophoresis analysis of 
the purification fractions identified two over expressed protein bands (Figure 3.2A). 
The two bands were successfully separated using anion exchange chromatography 
(Figure 3.2B), which exploited the difference in the overall net surface charge. ESI 
MS analysis determined that the upper band had a molecular weight (MW) of 28.03 
kDa (Figure 3.2C). The predicted MW of his-tagged HMGB1 was 28.02 kDa and the 
MS analysis confirmed that the upper band was full length HMGB1. Furthermore, 
western blot analysis confirmed this finding (Figure 3.2D). The lower band was 
found to have a MW of 25.80 kDa by ESI-MS and represented a C-terminal 
truncated HMGB1 protein (Figure 3.2C). Predicted MW data suggests that the final 
18 residues of the polyacidic C-terminal tail are absent in the truncated HMGB1 
protein (corresponding to residues 198-215; EEEEDEEDEDEEEDDDDE).  
In future preparations, the 6 residue poly-his tag was cleaved using TEV protease 
prior to the ion-exchange purification as described in Section 2.3.8. Additionally, to 
increase the purity the HMGB1 protein was further purified using size exclusion 
chromatography (as described in Section 2.3.11). Purified HMGB1 was visualised as 
a single band on a SDS-PAGE gel. In LB medium, the final yield of purified protein 
was approximately 0.75 – 1 mg/L. Due to the low protein yield, full length HMGB1 
was not expressed in minimal medium.  
The Δ30, A box and B box proteins were sub-cloned from the pETM-11/HMGB1 
plasmid using SLIM as described in Chapter 2, Section 2.2.4. Recombinant plasmids 
were transformed into BL21 (DE3) cells and the proteins were expressed in LB and 
minimal medium. The purification protocol used for the mutants was identical to the 
HMGB1 purification strategy. Purified proteins were visualised as a single band on a 
SDS-PAGE gel. In comparison to HMGB1 the yields of protein obtained for the 
mutants were significantly higher (Table 3.2).   
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Figure 3.6 Production of recombinant human HMGB1 in BL21 (DE3) cells The 
pETM-11/HMGB1 plasmid was transformed into BL21 (DE3) cells and expressed in 
LB medium at 37
o
C for 4 h. The cell lysate (lane 2) was purified using Ni
2+
 affinity 
chromatography and the fractions of interest (lanes 4-9) were analysed on a 12.5% 
SDS-PAGE gel (A). Two over-expressed protein bands were detected (lanes 8 & 9) 
and were separated using anion exchange chromatography (lower band lanes 3-7, 
upper band lanes 11-12) (B). ESI-MS analysis confirmed that the upper band 
corresponded to the full length HMGB1 and the lower band was a C-terminal 
truncated HMGB1 protein (C). Western blot analysis confirmed that the upper 
HMGB1 band was HMGB1 (D).  
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Table 3.9 Typical yields of LPS-free proteins obtained from BL21 (DE3) cells 
expressed in 1L of LB or minimal medium
*
 
Construct LB medium (mg/L) Minimal medium (mg/L) 
HMGB1 0.75 - 1 - 
Δ30 3 - 5 1.5 – 2.5 
A box 8 - 10  4 – 5 
B box 8 - 10 4 – 5 
IL-1β 36 20 
3.3.2. Production of recombinant human IL-1β from E.coli  
The DNA for the human IL-1β protein was sub-cloned into the pOPINF vector using 
the In-Fusion® reaction. A 6-residue his tag was incorporated into the N-terminus 
for purification purposes (Figure 2.3). The pOPINF/IL-1β plasmid was transformed 
into BL21 (DE3) cells and the protein was expressed in LB medium at 37
o
C for 4 h. 
The bacterial cell lysate was purified using Ni
2+
 affinity chromatography and the 
fractions were analysed using SDS-PAGE gel electrophoresis (Figure 3.3B). A high 
yield of the IL-1β protein was obtained and contaminating proteins were removed 
using anion exchange chromatography (Figure 3.3C). ESI-MS analysis confirmed 
that the IL-1β protein had a total molecular weight of 19.39 kDa (predicted 
molecular weight = 19.5 kDa). 
In future preparations, the 6 residue poly-his tag was cleaved using the 3C protease 
prior to the ion-exchange purification as described in Section 2.3.9. For NMR 
experiments, the protein was further purified using size exclusion separation. 
Purified IL-1β was visualised as a single band on a SDS-PAGE gel. In LB medium, 
the final yield of purified protein was approximately 36 mg/L of cell culture (Table 
3.2). For the production of 
15
N-labelled IL-1β, transformed E.coli cells were grown 
in minimal medium to an OD of 0.8-1.0 and after induction with IPTG, protein 
expression was carried out overnight at 18
o
C. The purification of labelled proteins 
was identical to the protocols used for the purification of LB expressed proteins.  
Approximately 20 mg of purified IL-1β protein was obtained from 1L of minimal 
medium.  
                                               
* For a description of the LPS removal see Section 3.3.3 
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Figure 3.7 Production of recombinant IL-1β from BL21 (DE3) cells DNA for the 
human IL-1β protein was cloned into the pOPINF vector. A cleavable 6-residue his 
tag was incorporated into the construct for purification purposes (A). The plasmid 
was transformed into BL21 (DE3) cells and the protein was expressed in LB medium 
at 37
o
C for 4 h. The cell lysate (lane 3) was purified using Ni
2+
 purification and the 
fractions of interest (lane 5-14) were analysed using SDS-PAGE gel electrophoresis 
(B). Protein contaminants were removed using anion exchange chromatography 
(lanes 2-12) over an increasing salt concentration (C). For NMR experiments, the 
protein was further purified using size exclusion separation.  ESI-MS analysis 
confirmed that the total molecular weight of his-tagged IL-1β protein was 19.39 kDa 
(D).  
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3.3.3. Removal of LPS from recombinant protein preparations  
LPS is a major component of the outer membrane of gram negative bacteria and a 
potent stimulator of the TLR4. Contaminating LPS was removed from protein 
preparations using a Triton X-114-based two-phase extraction protocol (Aida and 
Pabst 1990). It has previously been shown that this method is more effective at 
removing LPS from recombinant HMGB1 preparations than polymyxin B 
purification (Li et al., 2004). LPS levels in protein preparations were determined 
before and after Triton-X114 purification. LPS molecules vary considerably between 
different species and strains of bacteria (Erridge et al., 2002) and to account for this 
variation the LPS levels are expressed as EU/mg of protein (EU/mg). This is a 
standardised measurement that describes the biological activity or potency.  
The level of LPS in bacterially expressed recombinant full length HMGB1 was 
typically greater than 500 EU/mg (Table 3.3). Considerably less LPS was detected in 
the Δ30 (approx. 126 EU/mg) and A box (Approx. 52 EU/mg) preparations. The 
LPS content in the B box preparation before LPS removal was not determined but 
previous studies have demonstrated that both HMG boxes have a similar affinity for 
LPS (Li et al., 2004). Importantly, the LPS content after the Triton X-114 
purification in all protein preparations was consistently less than 5 EU/mg. 
Recombinant IL-1β protein preparations were also subjected to Triton X-114 
extraction and consistently exhibited levels of less than 5 EU/mg after purification.   
Table 3.10 Typical LPS content in recombinant protein preparations before and 
after Triton X-114 purification (LPS levels are expressed as Endotoxin Units per 
mg of protein (EU/mg). 1EU/mg is approximately equal to 100 pg endotoxin) 
Construct Typical LPS before (EU/mg) Typical LPS after (EU/mg) 
HMGB1 > 500 < 5 
Δ30 Approx. 126 < 5 
A box  Approx. 52 < 5 
B box - < 5 
IL-1β - < 5 
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3.3.4. NMR characterisation of recombinant proteins 
3.3.4.1. 1D NMR characterisation of full length HMGB1 
The full length HMGB1 protein was characterised using 1D NMR analysis. A
 1
H 
NMR spectrum was collected on a 23 µM unlabelled HMGB1 sample in PBS at pH 
7.2 using a 600 MHz Bruker Avance II spectrometer at 25
o
C (Figure 3.4). Peaks 
were detected between 0.5 to 10 ppm and the spectral dispersion is characteristic of a 
folded protein (Figure 3.4). As previously described, LPS contaminants were 
removed using a Triton-X114 two phase extraction protocol and residual Triton-
X114 impurities were identified in the 
1
H HMGB1 spectrum. 
The 
1
H spectrum for full length HMGB1 was compared with the 
1
H spectrum for the 
15
N-labelled Δ30 and B box proteins.  As indicated in Figure 3.5, conserved peaks 
were identified in the different spectra and, as expected, all three constructs appear to 
express proteins with folded regions, rather than being random coil.    
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Figure 3.8 
1
H NMR spectrum for full length HMGB1 The NMR spectrum was 
collected on a 23 µM HMGB1 sample on a 600 MHz Bruker spectrometer equipped 
with triple resonance cryoprobes at 25
o
C (298 K) in PBS, pH 7.2. The full 
1
H 
spectrum for HMGB1 is presented with typical 
1
H chemical shifts highlighted (A). 
An expanded section of the amide region is shown in (B) and an expanded section of 
the aliphatic region is displayed in (C). For (B) and (C) the spectrum was baseline 
corrected using the auto-correct spectra range function between -1–3 ppm and 6-10 
ppm to reduce the effect of water suppression.   
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Figure 3.9 Comparison 
of 
1
H NMR spectra for 
full length HMGB1, 
Δ30 and B box An 
expanded section of the 
aliphatic region is 
presented for full length 
HMGB1 (A), Δ30 (B) 
and B box (C). An 
example of a conserved 
peak is shown (---). 
Based on the line-
widths of the peaks all 
three domains appear to 
contain folded regions. 
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3.3.4.2. 2D NMR characterisation of Δ30, A box, B box and IL-1β proteins  
The HMGB1 constructs were characterised using 2D NMR analysis. 
1
H-
15
N HSQC 
spectra were collected for 
15
N-labelled LPS-free Δ30, A box and B box proteins in 
PBS, pH 7.2 at 25
o
C. The number of expected peaks for each spectrum was 
calculated as follows: number of backbone amides (total number of residues with 
proline deducted) plus the number of asparagine and glutamine side-chain amides 
(Table 3.4). Under these conditions, 159 peaks were detected on the 
1
H-
15
N HSQC 
spectrum for the 
15
N-labelled his-tagged Δ30 (Figure 3.6). The peaks were well 
dispersed and resolved and the spectrum was indicative of a folded protein. 
However, 22% of the expected peaks were missing from the spectrum, probably due 
to the fast chemical exchange with the solvent, as expected from the pH used for the 
solution. 
On the 
1
H-
15
N HSQC spectrum for the reduced 
15
N-labelled A box 67 out of 84 
predicted peaks were detected (Figure 3.7). The peaks were well resolved and the 
spectral dispersion indicated that the protein was folded.  
On the 
1
H-
15
N HSQC spectrum for the 
15
N-labelled B box, 69 out of 73 expected 
peaks were detected (5% missing) (Figure 3.8). The peaks were well resolved and 
dispersed. The spectrum indicated that the protein was folded.   
The IL-1β protein was also characterised using 2D NMR analysis. A 1H-15N HSQC 
spectrum was collected on a 25 µM LPS-free 
15
N-labelled Il-1β protein in PBS, pH 
7.2 at 25
o
C. The spectral dispersion was indicative of a folded protein and the peaks 
were well resolved. In total, 161 peaks were resolved out of an expected 168 (4% 
missing). 
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Table 3.11 Number of peaks detected on the 
1
H-
15N HSQC spectra for the Δ30, 
A box, B box and IL-1β proteins at pH 7.2 NMR spectra were collected in PBS, 
pH 7.2. The number of predicted peaks was calculated as follows: N
o
 of backbone 
amides (total residues with proline deducted) plus Asn and Gln side-chain amides.  
Construct Predicted peaks N
o 
of resolved peaks % of peaks missing 
His-Δ30 204 159 22 
A box  84 67 20 
B box  73 69 5 
IL-1β 168 161 4 
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Figure 3.10 
1
H-
15
N HSQC 
spectrum for 100 µM LPS-
free his-tagged Δ30 at pH 
7.2 A 
1
H-
15
N HSQC 
spectrum was collected for 
100 µM LPS-free 
15
N-
labelled his-tagged Δ30 
protein in PBS at pH 7.2 at 
25
o
C. The spectrum was 
recorded on a 600 MHz 
spectrometer using 64 scans 
with 160 increments and 
with a resolution in the 
indirect dimension of 18.24 
Hz. Under these conditions 
159 peaks were identified 
(22% of predicted peaks 
were absent). The well 
resolved and dispersed 
peaks indicate a folded 
protein.  
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Figure 3.11 
1
H-
15
N 
HSQC spectrum for 
50 µM 
15
N-labelled 
A box at pH 7.2 The 
1
H-
15
N HSQC 
spectrum for 50 µM 
15
N-labelled A box 
was collected in PBS, 
10 mM DTT at pH 
7.2. The spectrum 
was collected on an 
800 MHz 
spectrometer using 16 
scans and 150 
increments with a 
resolution in the 
indirect dimension of 
21.80 Hz. Under 
these conditions 67 of 
the 84 predicted 
peaks were detected 
(20% missing). All of 
the peaks were well 
resolved and 
dispersed and the 
spectrum is indicative 
of a folded protein.  
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Figure 3.12 
1
H-
15
N HSQC 
spectrum for B box The 
1
H-
15
N 
HSQC spectrum for 10 µM LPS-
free B box was collected in PBS 
at pH 7.2 using a 800 MHz 
spectrometer. The spectrum was 
recorded at 25
o
C using 192 scans 
with 256 increments and with a 
resolution in the indirect 
dimension of 15.80 Hz. Under 
these conditions 69 out of 73 
predicted peaks were detected 
(5% missing). All peaks were 
well resolved and dispersed and 
the spectrum is indicative of a 
folded protein.  
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Figure 3.13 
1
H-
15
N 
HSQC spectrum for 
25 µM 
15
N-labelled 
IL-1β at pH 7.2 The 
1
H-
15
N HSQC 
spectrum for 25 µM 
LPS-free 
15
N-labelled 
IL-1β protein was 
collected in PBS at pH 
7.2. The spectrum was 
collected on an 600 
MHz spectrometer at 
25
o
C using 32 scans 
with 160 increments 
and with a resolution 
in the indirect 
dimensional of 21.00 
Hz. Under these 
conditions 161 of 168 
predicted peaks were 
detected (4% missing). 
All peaks were well 
resolved and dispersed 
and the spectrum is 
indicative of a folded 
protein.
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3.3.4.3. Characterisation of the 1H-15N HSQC spectrum for the reduced A box 
domain of HMGB1  
A partial assignment of the A box domain of HMGB1 was performed using a 
combination of 2D and 3D experiments. Spectra were collected on a 350 µM 
15
N-
13
C-labelled A box sample in 20 mM potassium phosphate, 100 mM potassium 
chloride and 10 mM DTT at pH 6.8. In total, it was predicted that there should be 84 
peaks observed on the 
1
H-
15
N HSQC spectrum (82 backbone and 2 side-chain 
amides). Under these conditions, 70 peaks were detected and 63 residues were 
assigned (Figure 3.10).   
1
H-
15
N HSQC spectra were collected on a 100 µM A box sample in 20 mM 
potassium phosphate, 100 mM potassium chloride and 10 mM DTT at a pH range of 
5.5 to 7.2. Spectra were acquired on an 800 MHz Bruker spectrometer at 25
o
C using 
comparable NMR parameters (8 scans with 150 increments at a resolution in the 
indirect dimension of 21.08 Hz).  
An overlay of the spectra is presented in Figure 3.11. At pH 5.5 83 of the 84 peaks 
were detected. However, up to 20% of the peaks disappeared with increasing pH 
conditions (Table 3.5) and as previously noted at pH 7.2 only 67 of the 84 peaks 
were detected. It was possible to identify 8 of the 17 residues that are missing from 
the spectrum at pH 7.2 using the partial A box assignment as M1, G2, G4, D5, S35, 
V36, A54 and K55. As shown in Figure 3.12, these residues are surface exposed and 
are dispersed across the molecule.  
Table 3.12 Percentage of peaks missing from the A box 
1
H-
15
N HSQC spectra at 
pH 5.5-7.2 NMR spectra were collected on a 100 µM A box sample in 20 mM 
potassium phosphate, 100 mM potassium chloride and 10 mM DTT at pH 5.5 – 7.2. 
Expected peaks were calculated as follows: number of backbone amides (total 
number of residues with proline deducted) plus the number of asparagine and 
glutamine side-chain amides. 84 peaks were expected for the A box.  
pH N
o
 of peaks % of peaks missing 
5.5 83 1 
6.0 78 7 
6.5 75 11 
6.8 70 17 
7.2 67 20 
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Figure 3.14 Chemical Shift Index (CSI) for A box assignment The A box domain (residues 1 -85) was assigned using sequential assignment. 
A change from the random coil chemical shift provides information on the structural identify of each amino acid residue. Based on the partial 
assignment, the majority of the secondary structure is alpha helical. (Black = assigned residues, Blue = residue not assigned).
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Figure 3.15 
1
H-
15
N HSQC 
spectra for reduced A 
box at pH 5.5 to 7.2 
Spectra were collected on a 
100 µM A box sample in 
20 mM potassium 
phosphate, 100 mM 
potassium chloride and 10 
mM DTT on a 800 MHz 
spectrometer at 25
o
C using 
comparable NMR 
acquisition parameters. 
Spectra were recorded at 
pH 5.5 (black), 6.0 (pink), 
6.5 (blue), 6.8 (green) and 
7.2 (red). For clarity an 
expanded section of the 
amine region is presented. 
No significant chemical 
shift perturbations were 
observed from some 
residues (S17). Some 
residues were not detected 
at every pH (S37). Some 
residues exhibited 
significant chemical 
perturbations at every pH 
point (*).  
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Figure 3.16 3D structure of A box highlighting the residues that disappear from 
the 
1
H-
15
N HSQC spectrum at pH 7.2 At pH 7.2 20% of the predicted peaks are 
missing from the 
1
H-
15
N HSQC spectrum for 
15
N-labelled A box. A partial backbone 
assignment of the A box domain has identified 8 (M1, G2, G4, D5, S35, V36, A54 
and K55) of these residues and these are highlighted on the 3D structure of A box. 
The V36 residue is not visible at this angle. Image was produced in PyMOL 
(PyMoL) using PDB entry 2YRQ.  
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3.3.4.4. NMR characterisation of the reduced and un-treated A box domain  
1
H-
15
N HSQC spectra were recorded for the reduced and un-treated A box domain. 
NMR spectra were recorded on an 800 MHz spectrometer at 25
o
C in 20 mM 
potassium phosphate and 100 mM potassium chloride at pH 6.8. Spectra were 
collected in the absence and presence of 10 mM DTT using identical acquisition 
parameters; 16 scans with 150 increments and with a resolution in the indirect 
dimension of 21.08 Hz. As can be seen in Figure 3.13, the spectra for reduced and 
non-reduced A box differ considerably with significant chemical shift perturbations 
observed in the majority of peaks following the addition of 10 mM DTT. The 
formation of a di-sulphide bond between the C23 and C45 residues has been 
previously reported and is critical for TLR4 receptor binding (Yang et al., 2010; 
Yang et al., 2011). Using the partial A box assignment it was possible to identify 
these two residues in the reduced A box spectra (Figure 3.13).  
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Figure 3.17 
1
H-
15
N 
HSQC spectra for 
reduced and non-treated 
A box Spectra were 
recorded for a 50 μM A 
box sample in PBS, pH 
7.2, with (black) and 
without (red) 10 mM 
DTT. Samples were 
analysed on a Bruker 
Avance II 800 MHz 
spectrometer at 25
o
C (298 
K) using identical NMR 
parameters: 16 scans with 
150 increments with a 
resolution in the indirect 
dimension of 21.08 Hz. 
Following the addition of 
DTT significant chemical 
shift perturbations were 
observed for some 
residues (For example, 
K52 & F62), while no or 
minor perturbations  were 
observed for some 
residues (S17 & K5). The 
C23 and C45 in reduced 
A box are also indicated.  
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3.3.4.5. Investigating the effect of LPS removal on the NMR spectra for Δ30, A 
box and B box 
As discussed previously, LPS contaminants were successfully removed using Triton-
X114 purification (Section 3.3.3). To ensure that this process did not alter the NMR 
spectra, 
1
H-
15
N HSQC spectra were collected for 
15
N-labelled HMGB1 proteins 
before and after LPS removal. Overlays of the spectra for 
15
N-labelled Δ30, A box 
and B box are presented in Figure 3.14, Figure 3.15 and Figure 3.16, respectively. 
Prior to purification, the levels of LPS in the Δ30 and A box proteins were 
approximately 126 EU/mg and 52 EU/mg. The LPS content after the Triton-X114 
purification in all protein preparations was consistently less than 5 EU/mg. No 
significant chemical shift perturbations were detected for any of the proteins 
following LPS removal although some minor perturbations were observed in the 
1
H-
15
N HSQC spectra for the B box (Figure 3.16). 
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Figure 3.18 Effect of LPS 
removal on the Δ30 1H-15N 
HSQC spectra A 
1
H-
15
N 
HSQC spectrum was 
collected on a 40 µM 
15
N-
labelled his-tagged Δ30 
sample before the sample was 
subjected to Triton-X114 
purification to remove 
contaminating LPS (Black). 
A 
1
H-
15
N HSQC spectrum 
was collected on a 100 µM 
15
N-labelled his-tagged Δ30 
sample after (red) 
purification. The spectra were 
collected in PBS at pH 7.2 on 
an 600 MHz spectrometer 
using 64 scans with 160 
increments and with a 
resolution in the indirect 
dimension of 18.24 Hz. The 
LPS level was approximately 
126 EU/mL before LPS 
removal and < 3 EU/mL after 
removal. No significant 
chemical shift perturbations 
were detected. 
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Figure 3.19 Effect of LPS 
removal on the A box 
1
H-
15
N HSQC spectra 
1
H-
15
N 
HSQC spectra were 
collected on a 50 μM A box 
sample in PBS with 10 mM 
DTT, pH 7.2 at 25
o
C (298 
K) on a Bruker Avance II 
800 MHz spectrometer using 
identical acquisition 
parameters (NS = 16, 
increments = 150 and 
15
N 
resolution = 21.08). HSQC 
spectra were collected before 
(black) and after (red) the 
sample was subjected to a 
specific LPS removal step 
using a Triton-X114 based 
two phase extraction 
protocol. The LPS content in 
the sample was > 50 EU/mL 
before LPS removal and < 3 
EU/mL after removal. No 
significant chemical shift 
perturbations were detected. 
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Figure 3.20 Effect of 
LPS removal on the B 
box 
1
H-
15
N HSQC 
spectra 
1
H-
15
N HSQC 
spectra were collected 
on a 10 μM B box 
sample in PBS, pH 7.2 
at 25
o
C (298 K) on a 
Bruker Avance II 800 
MHz spectrometer 
using identical NMR 
parameters (NS = 192, 
increments = 256 and 
15
N resolution = 15.80). 
Spectra were collected 
before (black) and after 
(red) the sample was 
subjected to a specific 
LPS removal step using 
a Triton-X114 based 
two phase extraction 
protocol. Some minor 
chemical shift 
perturbations were 
observed.  
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3.3.5. Analysis of the cytokine-inducing activity of the recombinant HMGB1 
proteins 
The cytokine-inducing activity of the recombinant HMGB1 proteins was assessed  in 
PBMCs isolated from a healthy volunteer. Un-induced cells or cells treated with PBS 
(vehicle control) had minimal IL-6 release. 10 µg/mL recombinant HMGB1, Δ30, A 
box or B box also failed to induce IL-6 production in the PBMCS with low or un-
detectable IL-6 levels recorded (< 154 pg/mL). However, the positive control, a 
recombinant HMGB1 with known cytokine-inducing activity, (supplied by Peter 
Lundbäck, Karolinska Institute, Stockholm, Sweden) induced IL-6 levels of 27,612 ± 
836 pg/mL.   
 
 
Figure 3.21 Induction of IL-6 release in PBMCs by bacterially expressed 
rHMGB1 constructs Cells were isolated from a healthy volunteer and treated with 
PBS (Vehicle control), HMGB1, Δ30, A box or B box at a final concentration of 10 
µg/mL. Cell supernatants were collected after 16 h and IL-6 levels were quantified 
by ELISA. Recombinant HMGB1 with known cytokine-inducing activity was used 
as a positive control (n = 1 experiment performed in triplicate wells). +VE control = 
recombinant HMGB1 with known cytokine-inducing activity.  
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3.3.6. LC-ESI-MS/MS characterisation of the redox state of the C23, C45 
and C106 residues in full length HMGB1 
Recent evidence has shown that the redox status of the three cysteine residues (23, 
45 and 106) in HMGB1 is critical for the interaction with the TLR4 (Yang et al., 
2010; Yang et al., 2011). The redox status of the three residues was determined using 
LC-ESI- MS/MS analysis. Reduced cysteine residues within his-tagged HMGB1 
were initially capped using iodoacetamide. The alkylation with iodoacetamide 
generates a carboxyamidomethyl adduct resulting in a mass shift of 57 amu (atomic 
mass units). Next, the protein was incubated with 1 mM DTT and newly reduced 
cysteine residues were capped using NEM. The alkylation with NEM yields a mass 
shift of 125 amu. The protein was digested using Glu-C and peptides were analysed 
using LC-ESI-MS/MS analysis. A thiol-capped NEM adduct was detected in the 
peptide containing residues 2-26 (Figure 3.18A). This corresponded to the C23 
residue. The same adduct was detected in a second peptide which contained residues 
17-26 (Figure 3.18B). A thiol-capped NEM adduct, corresponding to the C45 
residue, was detected in the peptide containing amino acids 41-47 (Figure 3.18C). 
Furthermore, in a peptide comprising residues 103-108 a thiol-capped NEM adduct 
was detected that corresponded to the C106 residue.  Collectively, these results show 
that all three cysteine residues were oxidised in the E.coli expressed his-tagged 
HMGB1 protein, prior to the addition of DTT.     
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Figure 3.22 Mass spectrometric identification of C23, C45 and C106 redox state 
LC-MS/MS spectra of Glu-C-derived peptides confirming that the C23 (A and B), 
C45 (C) and C106 (D) residues in his-tagged HMGB1 are all oxidised.   
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3.4.  DISCUSSION 
For the purpose of this work, human HMGB1 and three HMGB1 domains were 
expressed in E.coli BL21 (DE3) cells. Approximately 0.75-1 mg of full length 
human HMGB1 protein was obtained from 1 L of LB medium. Expression of 
recombinant HMGB1 in bacterial cells has been previously associated with low 
protein yields (Bianchi 1991; Lee et al., 1998; Li et al., 2003). This has been partially 
attributed to the toxicity of the 30-residue C-terminal polyacidic tail, which is 
composed entirely of repeating aspartic and glutamic acid residues. Additionally, it 
has been reported previously that the HMGB1 protein may be toxic to the E.coli 
cells and may interact with the bacterial DNA (Bianchi 1991). Degradation of 
HMGB1 by bacterial cells has been previously reported (Bianchi 1991) and a C-
terminal truncated HMGB1 protein was also over expressed in the BL21 (DE3) cell 
cultures (Figure 3.2). Li et al demonstrated that both full length and truncated 
HMGB1 can induce comparable TNF-release in mouse macrophages (Li et al., 
2003). Three recombinant HMGB1 mutants, Δ30, A box and B box, were also 
generated for use in the cellular assays and NMR characterisation. In comparison to 
the full length protein, the yields of protein obtained for the HMBG1 domains and 
truncated mutant were considerably higher (Table 3.2). Typically 3-5 mg of Δ30 and 
8-10 mg of the A and B box proteins was obtained for 1 L of LB medium. All of the 
proteins were visualised as a single band on a SDS-PAGE gel. 
Efficient removal of LPS contaminants from recombinant protein preparations was 
of critical importance as contaminating LPS can activate TLR4 and induce a similar 
biological response to HMGB1 (Hoshino et al., 1999). Until recently, it was believed 
that the Heat Shock Protein (HSP) 60 and HSP70 induced TNF secretion and APC 
activation via the TLR4. However, it has now been demonstrated that these effects 
were in fact a direct result of low amounts of endotoxin contamination (Bausinger et 
al., 2002; Gao and Tsan 2003; Gao and Tsan 2003). In comparison to other proteins, 
HMGB1 is reported to have a high affinity for LPS, binding to both the 
polysaccharide and lipid-A moieties (Youn et al., 2011). Additionally, HMGB1 and 
LPS have been demonstrated to act synergistically to enhance cytokine production in 
SFs and it is proposed that this effect is mediated via the formation of a highly active 
pro-inflammatory complex (Hreggvidsdottir et al., 2009; Wähämaa et al., 2011). 
Consequently, in agreement with previous findings bacterially expressed HMGB1 
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had high levels of contaminating LPS (<500 EU/mL) (Bianchi 1991). In comparison, 
the HMGB1 mutants had considerably less LPS contamination. This suggests that 
the C-terminal tail of HMGB1 is involved in the interaction and that the HMGB1 
mutants have a reduced affinity for LPS (Table 3.2). LPS contaminants were 
successfully removed using a two-phase Triton-X114 extraction protocol which 
consistently reduced LPS levels to less than 3 EU/mg of protein.  
The work presented in this chapter also describes the NMR characterisation of the 
recombinant HMGB1 and IL-1β proteins. Uniformly 15N and/or 13C -labelled 
proteins were expressed and purified in minimal media with final yields of 
approximately half of that obtained from LB media (Table 3.2). 
1
H-
15
N HSQC 
spectra were collected for the 
15
N-labelled Δ30, A box, B box and IL-1β proteins. 
All of the peaks were well resolved and the spectral dispersions were indicative of 
folded proteins. However, up to 22% of the predicted peaks were missing from the 
spectrum at pH 7.2 (Table 3.4) due to chemical exchange of the amide protons with 
water. The removal of contaminating LPS did not alter the Δ30, A box and B box 
NMR spectra and no significant chemical shift perturbations were observed 
following Triton-X114 purification (Figure 3.14, Figure 3.15 and Figure 3.16).  
Further NMR characterisation was performed for the A box domain and a partial 
assignment of the 
1
H-
15
N HSQC spectrum was undertaken. A pH titration was 
conducted and NMR spectra were collected at pH 5.5 to 7.2. A total of 84 peaks 
were expected on the 
1
H-
15
N HSQC spectrum and at pH 5.5 only 1% of the peaks 
were undetectable. In comparison, at pH 7.2 20% of the peaks were missing from the 
spectrum (Figure 3.11 and Table 3.5). These residues were dispersed across the 
protein and did not cluster to a specific region. Future NMR spectra were collected at 
pH 7.2 as this is more physiologically relevant. Additionally, Li et al have 
previously reported that at pH 6.0 the cytokine-inducing activity of HMGB1 is 
inhibited (Li et al., 2004).  
Previous studies have reported conflicting results on the intrinsic pro-inflammatory 
activity of HMGB1 (Andersson et al., 2000; Rouhiainen et al., 2007; Sha et al., 
2008). Recently, Yang et al have demonstrated that the redox status of the C23, C45 
and C106 residues is critical for the functional activity of the protein. The pro-
inflammatory molecular form requires a C23-C45 disulphide bond and a reduced 
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C106 residue, with other forms of HMGB1 unable to induce cytokine-production 
(Yang et al., 2011). LC-ESI-MS/MS characterisation of the bacterially expressed 
recombinant his-tagged HMGB1 protein identified that the C23, C45 and C106 
residues were all oxidised (Figure 3.18). However, it was not possible to deduce the 
specific cysteine modification using this method. HMGB1 expressed in BL21 (DE3) 
cells is unlikely to contain any post-translational modifications and it can be 
assumed that the oxidation occurred during the purification procedure. 
Consequently, the recombinant HMGB1 proteins did not induce IL-6 cytokine 
production in PBMCs (Figure 3.17). However, evidence within the literature also 
supports the hypothesis that HMGB1 acts synergistically with endogenous and 
exogenous molecules to initiate and amplify the inflammatory response and 
emerging evidence suggests that this mechanism may be independent of the 
oxidation state (Wähämaa et al., 2011; Leclerc et al., 2013). The synergistic potential 
of the recombinant HMGB1 has not been examined within this chapter but will be 
the focus of future experiments.        
In conclusion, this chapter describes the successful optimisation of methods to 
express, purify and characterise recombinant HMGB1, Δ30, A box, B box and IL-1β 
proteins in E.coli. The recombinant proteins contain minimal endotoxin 
contamination (< 5 EU/mg of protein) and the NMR characterisation has indicated 
that they are well folded. However, the recombinant HMGB1 proteins did not induce 
IL-6 cytokine production in PBMCs and this requires further investigation. Previous 
studies have suggested that HMGB1 and IL-1β act synergistically to promote 
inflammation. It is proposed that this response is mediated by the formation of a 
highly active pro-inflammatory complex in which HMGB1 and IL-1β directly 
interact. However, the molecular interaction between the two proteins requires 
further investigation; the folded, purified and LPS-free proteins generated in this 
chapter will be used to elucidate the cellular and biophysical interaction between 
HMGB1 and IL-1β.  
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4.1.   INTRODUCTION 
In 1999, Wang and colleagues identified HMGB1 as a late cytokine mediator of 
lethal endotoxemia (Wang et al., 1999). Subsequent studies have demonstrated that 
HMGB1 has a board range of immunological activities. Extracellular HMGB1 
promotes inflammation and tissue regeneration by mediating the production of 
multiple cytokine mediators from macrophages and monocytes, chemotaxis, 
angiogenesis, cell proliferation and autophagy (Andersson et al., 2000; Orlova et al., 
2007; Tang et al., 2010; Andersson and Tracey 2011).  
As discussed in Section 1.8.5, human monocytes exposed to recombinant HMGB1 
secrete multiple cytokine mediators including TNFα, IL-1α, IL-1β, IL-1RA, IL-6, 
IL-8 and the MIP (Andersson et al., 2000). It has been proposed that HMGB1 
induced cytokine production is mediated via the formation of highly active pro-
inflammatory complexes with both endogenous and exogenous molecules (Figure 
1.10) (Ivanov et al., 2007; Tian et al., 2007; Sha et al., 2008; Urbonaviciute et al., 
2008; Youn et al., 2008; Hreggvidsdottir et al., 2009; Schiraldi et al., 2012).  
Specifically, HMGB1 has been shown to act in synergy with IL-1β and LPS to 
enhance NF-κB-mediated cytokine production (Hreggvidsdottir et al., 2009; Garcia-
Arnandis et al., 2010; Wähämaa et al., 2011). 
The synergistic effect of HMGB1 with IL-1β is of particular interest since both 
molecules are regarded as classical cytokine mediators that activate related 
intracellular signalling pathways to mediate a similar range of biological responses. 
Moreover, the HMGB1 and IL-1β proteins often co-exist at the site of injury or 
infection, with both danger signals secreted by activated immune cells in response to 
hepatocyte cell stress or damage.  
HMGB1 and IL-1β synergy is not well defined and the molecular mechanism 
mediating the synergistic response is unknown. In 2008, Sha and colleagues reported 
that FLAG-tagged HMGB1 expressed in the presence of IL-1β has enhanced pro-
inflammatory activity compared to HMGB1 alone. In this study, macrophage and 
neutrophil cells treated with HMGB1, expressed in the presence of IL-1β, had 
enhanced pro-inflammatory cytokine production (Sha et al., 2008). Subsequent 
studies confirmed this finding with HMGB1 and IL-1β also shown to act 
synergistically on SFs isolated from RA and osteoarthritis (OA) patients 
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(Hreggvidsdottir et al., 2009; Garcia-Arnandis et al., 2010; Wähämaa et al., 2011). 
To date, it has been reported that HMGB1 and IL-1β act synergistically to enhance 
the production of multiple inflammatory mediators including IL-6, IL-8, TNF and 
MIP (Sha et al., 2008; Hreggvidsdottir et al., 2009; Garcia-Arnandis et al., 2010; 
Wähämaa et al., 2011). These mediators contribute to the immune response with IL-
6, in particular, known to have multiple biological activities that promote hepatic 
acute phase inflammatory responses and tissue regeneration.   
Although HMGB1 and IL-1β have been shown to act synergistically, there are no 
detailed studies investigating the effects of this interaction within the current 
literature. Therefore, the overall aim of this chapter was to characterise the cellular 
response to HMGB1 and IL-1β synergy. This was investigated by addressing the 
following points:  
1. Accessing the synergistic activity of bacterially expressed recombinant 
HMGB1 and IL-1β proteins.  
2. Investigating the dynamics of the synergistic interaction. Specifically, 
determining the minimal incubation time and optimal conditions required to 
enhance the inflammatory response 
3. Investigating the kinetics of the synergy; do different ratios of HMGB1/ IL-
1β show similar synergistic responses?  
4. Identifying which domain(s) of HMGB1 mediates the synergistic activity 
with IL-1β. This was achieved by investigating whether the three HMGB1 
mutants (Δ30, A box and B box proteins) act synergistically with IL-1β.   
5. Confirming that HMGB1/IL-1β synergy is mediated by the IL-1R 
6. Determining if LPS inhibits the synergistic interaction with IL-1β  
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4.2.  MATERIALS AND METHODS 
LPS-free recombinant HMGB1 (Full length, Δ30, A box and B box) and IL-1β 
proteins were expressed and purified from E.coli as described in Chapter 2, Sections 
2.2 and 2.3. Proteins were characterised as detailed in Chapter 3. The LPS content in 
all proteins was <5 EU per mg of protein.  
SFs were used as a model cell system to investigate HMGB1-IL-1β synergy. Cells 
were cultured from synovial tissue isolated from arthritic patients undergoing joint 
replacement surgery at the Karolinska Institute, Stockholm, Sweden, as described in 
Chapter 2, Section 2.4. Cell experiments were performed as described in Chapter 2, 
Sections 2.4.2 to 2.4.7. IL-6 cytokine levels were quantified by ELISA (Chapter 2, 
Section 2.4.8). All results are expressed as absolute IL-6 content ± SD, with the 
exception of Figure 4.2 where data are expressed as mean IL-6 content ± SEM. Data 
were analysed as described in Chapter 2, Section 2.4.9.   
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4.3.  RESULTS 
4.3.1. HMGB1 and IL-1β act in synergy to increase pro-inflammatory 
cytokine levels in SFs 
The synergistic activity of the recombinant HMGB1 and IL-1β proteins was assessed 
in SFs isolated from four arthritic patients. The patients were aged between 30-71 
years of old and had been clinically diagnosed with either RA or poly-arthritis (Table 
4.1). Cells were treated with 100 ng/mL HMGB1 alone or with HMGB1 that had 
been pre-incubated overnight at 4
o
C with 0.05 or 0.5 ng/mL IL-1β. Cell supernatants 
were collected 24 h after stimulation and the IL-6 release was quantified by ELISA.   
Table 4.13 Summary of patient information SFs were isolated and cultured from 
the synovial tissue of four arthritic patients undergoing joint replacement therapy at 
the Karolinska Institute, Stockholm, Sweden. Background details for each patient are 
provided.  
Cell ID Gender Age Clinical diagnosis 
0-247 Female 71 RA   
0-248 Male 43 Poly-arthritis  
0-253 Female 60 RA   
0-255 Female 30 RA   
 
The results for each patient are provided in Figure 4.1. Un-treated fibroblasts or cells 
treated with HMGB1 or IL-1β alone had no detectable IL-6 release, or IL-6 levels 
that were below the limit of detection for the ELISA assay (9.37 pg/mL; samples 
below this limit were assigned a value of 0.1 pg/mL for statistical analysis). 
However, in all four patients, HMGB1 acted in synergy with both 0.05 and 0.5 
ng/mL IL-1β to substantially enhance the IL-6 release. A similar trend was seen in 
all patients, although the individual cytokine levels differed considerably; for 
example, when treated with 100 ng/mL HMGB1 in combination with 0.5 ng/mL IL-
1β patients 0-247, 0-248, 0-253 and 0-255 had IL-6 levels of 7603 ± 260, 8066 ± 
1030, 15,385 ± 2688 and 28,473 ± 127 pg/mL respectively. To account for the inter-
patient variability, data are also expressed as a percentage of the 100 ng/mL 
HMGB1-0.5 ng/mL IL-1β group in Figure 4.2. Statistical analysis confirmed that 
cells treated with HMGB1 in combination with 0.5 ng/mL IL-1β had significantly 
increased IL-6 secretion when compared to un-treated cells or cells treated with 
HMGB1 or IL-1β alone (p < 0.05). However, the increase observed in fibroblasts 
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treated with HMGB1 and 0.05 ng/mL IL-1β was not found to be statistically 
significant from the control cells. Additionally, the synergistic activity of HMGB1 
with 
15
N-labelled-IL-1β was tested and the results were found to be consistent with 
the data obtained for the un-labelled proteins (Figure 4.25).   
Chapter 4 
 
107 
 
Figure 4.23 HMGB1 and IL-
1β act synergistically to 
enhance the inflammatory 
response in SFs: Individual 
patient data SFs were isolated 
from four arthritic patients and 
treated with HMGB1 alone or 
HMGB1 in combination with 
IL-1β for 24 h. IL-6 cytokine 
levels were quantified by 
ELISA.  A), B), C) & D) show 
data for patients 0-247, 0-248, 
0-253 and 0-255 respectively. 
Untreated fibroblasts or cells 
treated with HMGB1 or IL-1β 
alone had minimal or no 
detectable IL-6 release (<9.37 
pg/mL; SD values < 7.00 
pg/mL). However, treatment 
with 100 ng/mL HMGB1 that 
was pre-incubated with 0.5 
ng/mL IL-1β enhanced the IL-6 
cytokine levels.  n = 1 
experiment/patient performed 
in triplicate wells; data are 
expressed as absolute IL-6 level 
± SD.  
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Figure 4.24 HMGB1 and IL-1β act synergistically to enhance the inflammatory 
response in SFs; combined patient data SFs were isolated from four arthritic 
patients and treated with 100 ng/mL HMGB1 alone or in combination with IL-1β for 
24 h. IL-6 cytokine levels were quantified by ELISA. Un-treated, IL-1β- and 
HMGB1-treated cells had no detectable IL-6 release (IL-6 levels were below the 
limit of detection (9.37 pg/mL) and were assigned a value of 0.1 pg/mL for statistical 
analysis; SEM values for these groups were <0.1%). To account for inter-patient 
variability, data are expressed as a % of the HMGB1/0.5 ng/mL IL-1β group ± SEM. 
Data were analysed for statistical significance using a Kruskal Wallis one-way 
ANOVA on ranks test. Cells treated with HMGB1 in combination with IL-1β had 
significantly increased IL-6 levels (p <0.05). n = four experiments performed in 
triplicate wells.  
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Figure 4.25 HMGB1 acts in synergy with 
15
N-labelled IL-1β to enhance the IL-6 
release from SFs SFs were isolated from two RA patients (0-247 and 0-248) and 
treated with 100 ng/mL HMGB1 or 0.05/0.5 ng/mL IL-1β alone or following 16 h 
co-incubation. Un-treated, IL-1β- and HMGB1-treated cells had no detectable IL-6 
release (IL-6 levels were below the limit of detection (9.37 pg/mL) and were 
assigned a value of 0.1 pg/mL for statistical analysis; SD values for these groups = 
0). n = two experiments performed in triplicate wells. Data are expressed as IL-6 
level ± SD.   
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4.3.2. HMGB1 enhances the cytokine-stimulating activity of IL-1β in a dose-
dependent manner  
Previous studies reporting the synergistic interaction between HMGB1 and IL-1β 
have utilised an excess of the HMGB1 protein in comparison to IL-1β and in the 
previous expeirment the final molar ratio of HMGB1:IL-1β in the cells was 137:1 or 
1370:1, respectively. The aim of this experiment was to determine if HMGB1 
enhances the activity of the IL-1β protein in a dose-dependent manner and to 
investigate whether the synergistic interaction is still relevant at lower molar ratios.  
SFs, isolated from two RA patients (0-253 and 0-255), were treated with increasing 
concentrations of HMGB1 (0-100 ng/mL) that had been pre-incubated with 0.5 
ng/mL IL-1β for 16 h at 4oC. This provided a molar ratio range of from 4:1 to 137:1 
(HMGB1: IL-1β). Cells were stimulated for 24 h and the IL-6 content was quantified 
by ELISA. As previously observed, un-treated cells or cells treated with the 
recombinant proteins alone had minimal or un-detectable IL-6 levels (Figure 4.4). 
Additionally, fibroblasts treated with 3.25-25 ng/mL HMGB1 together with 0. 5 
ng/mL IL-1β (4:1 to 34:1; HMGB1: IL-1β) had low IL-6 cytokine levels (<12 
pg/mL). In contrast, cells from both patients had increased IL-6 levels when treated 
with 50 or 100 ng/mL HMGB1 in combination with I-1β. However, the relationship 
between the molar ratio used and the IL-6 release did not appear to be linear; for 
example, 100 ng/mL HMGB1 with 0.5 ng/mL IL-1β resulted in IL-6 levels of 
10,332 ± 6.25 and 12,983 ± 9.90 pg/mL in patients 0-253 and 0-255, respectively. In 
contrast, treatment with 50 ng/mL HMGB1/ 0.5 ng/mL IL-1β induced IL-6 levels of 
178 ± 0.20 and 145 ± 0.05 pg/mL in patients 0-253 and 0-255, respectively.  
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Figure 4.26 The effect of HMGB1 concentration on the synergistic interaction 
with IL-1β SFs isolated from two RA patients (0-253 and 0-255) were treated with 
increasing concentrations of HMGB1 (0-100 ng/mL) in complex with 0.5 ng/mL IL-
1β. No detectable IL-6 secretion was detected in cells treated with IL-1β alone. 
However, treatment with IL-1β in combination with HMGB1 increased IL-6 levels 
considerably in a dose-dependent manner. n = 1 experiment per patient, performed in 
triplicate wells. Data are expressed as IL-6 value ± SD with all SD values < 10 
pg/mL.  
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4.3.3. Investigating the kinetics of the synergistic interaction between 
HMGB1 and IL-1β 
It has been previously reported that pre-incubation of HMGB1 and IL-1β for 16 h at 
4
o
C is an important prerequisite for the synergistic interaction (Hreggvidsdottir et al., 
2009; Wähämaa et al., 2011). However, Garcia-Arnandis et al (2010) reported that 
simultaneous protein addition also results in enhanced cytokine production. 
Therefore, the aim of this experiment was to determine if pre-incubation of HMGB1 
and IL-1β is necessary for the cellular response and if so, to identify the minimal 
incubation time required.  
SFs from two patients (0-253 and 0-255) were stimulated with HMGB1 that had 
been pre-incubated with IL-1β for 0-24 h prior to cell stimulation. To determine the 
physiological relevance of the interaction, the proteins were incubated at 4
o
C, room 
temperature and 37
o
C. Cell supernatants were collected after 24 h and the IL-6 
release was quantified by ELISA.  As can be seen in Figure 4.27, pre-incubation of 
HMGB1 and IL-1β is not required for the synergistic response and the IL-6 
induction was not dependent upon the incubation time. Additionally, in this 
experiment simultaneous addition of HMGB1 and IL-1β induced an enhanced 
cellular response resulting in IL-6 levels of 2,796 ± 2.17 pg/mL and 2,785 ± 1.56 
pg/mL, in patients 0-253 and 0-255, respectively.  
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Figure 4.27 The effect of pre-incubation on the synergistic interaction between 
HMGB1 and IL-1β SFs from two patients (0-253 (A) and 0-255 (B)) were 
stimulated with 100 ng/mL HMGB1 that had been pre-incubated with 0.5 ng/mL IL-
1β for 0-24 h at 4oC, room temperature or 37oC. Cells were stimulated for 24 h, 
supernatants were collected and the extracellular IL-6 release was quantified by 
ELISA. Data are expressed as absolute IL-6 value ± SD. n = 1 experiment performed 
in triplicate wells. All SD values were < 13 pg/mL. Note: Proteins were incubated as 
a 50 x stock solution (5 µg/mL HMGB1 and 25 ng/mL IL-1β) and diluted in 
OPTIMEM immediately prior to dosing.   
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4.3.4. The Δ30 and B box proteins act in synergy with IL-1β to increase IL-6 
secretion from SFs but the A box does not interact with IL-1β 
To determine which domain of HMGB1 is critical for the synergistic activity 
observed between HMGB1 and IL-1β, SFs from two RA patients (0-253 and 0-255) 
were treated for 24 h with four different HMGB1 constructs – full length HMGB1, 
Δ30, A box or B box - in combination with either 0.05 or 0.5 ng/mL IL-1β. Different 
concentrations of the four constructs were used (100 ng/mL HMGB1, 86 ng/mL 
Δ30, 40 ng/mL A box and 35 ng/mL B box) to maintain the same molar ratio across 
all of the treatment groups (1 IL-1β: 137 HMGB1 or 1 IL-1β: 1370 HMGB1).  
As previously observed, no detectable IL-6 secretion was seen in the supernatants 
obtained from untreated cells. Additionally, all of the recombinant proteins – 
HMGB1, Δ30, A box, B box and IL-1β – failed to elicit a cellular response alone. 
However, full length HMGB1, Δ30 and the B box all acted in synergy with IL-1β to 
noticeably enhance cytokine production in both patients. In SFs isolated from patient 
0-255 treatment with HMGB1, Δ30 or the B box in combination with 0.5 ng/mL IL-
1β resulted in IL-6 cytokine levels of 28,473 ± 127 pg/mL, 18,491 ± 2388 pg/mL 
and 18,710 ± 2792 pg/mL, respectively. A similar response was observed with cells 
isolated from patient 0-253 although to a lesser extent.  
Interestingly, the A box did not act synergistically with either concentration of IL-1β 
and in both patients, treatment with 35 ng/mL A box in combination with 0.5 or 0.05 
ng/mL IL-1β failed to induce detectable IL-6 production. This data would suggest 
that whilst the B box is critical for the interaction between HMGB1 and IL-1β, the A 
box does not contribute to the synergistic activity.  
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Figure 4.28 HMGB1, Δ30 and B box act in synergy with IL-1β to enhance 
cytokine production in SFs but the A box does not. SFs were treated with 
HMGB1, Δ30, A box or B box in combination with 0.5 or 0.05 ng/mL IL-1β for 24 h 
and IL-6 levels were analysed by ELISA (Note: Different concentrations of the 
HMGB1 constructs were used to maintain the same molar ratio). The HMGB1, Δ30 
and B box constructs acted in synergy with IL-1β to increase IL-6 secretion in both 
patients (Black = Patient 0-253 and red = Patient 0-255) but the A box did not, 
indicating that the interaction between HMGB1 and IL-1β is specific to the B box 
domain. Data are expressed as IL-6 value ± SD. n = two experiments, performed in 
triplicate wells.  
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4.3.5. The synergistic activity of HMGB1, Δ30 or the B box with IL-1β is 
mediated via the IL-1 receptor  
To determine if the synergy between HMGB1 and IL-1β is mediated by the IL-1R, 
the previous experiment (described in Section 4.3.4) was repeated in the presence of 
anakinra (Kineret®, a synthetic IL-1RA). SFs from patients 0-253 and 0-255 were 
pre-treated with 5 μg/mL anakinra for 1-2 h prior to cell stimulation. As previously 
observed, in the absence of anakinra, full length HMGB1, Δ30 and the B box all 
acted in synergy with IL-1β to promote an increase in IL-6 levels. However, pre-
treatment with anakinra inhibited the synergistic effect and resulted in minimal or 
un-detectable cytokine levels (Figure 4.7). 
Additionally, cells from patient 0-253 were pre-treated for 1-2 h with detoxified 
LPS, a TLR4 antagonist, and stimulated with 100 ng/mL HMGB1 pre-incubated 
with 0.5 ng/mL IL-1β. Detoxified LPS did not inhibit the enhanced cytokine release 
induced by HMGB1/IL-1β and in the absence and presence of detoxified LPS, SFs 
had IL-6 levels of 10,332 ± 6.25 and 10,498 ± 1.40 pg/mL, respectively.  
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Figure 4.29 The synergistic activity between HMGB1 and IL-1β is mediated via 
the IL-1R A) SFs were pre-treated with 5 μg/mL anakinra, an IL-1RA, for 1-2 h 
prior to cell stimulation. Cells were stimulated with HMGB1, Δ30, A box or B box 
in combination with IL-1β for 24 h and the IL-6 levels were quantified by ELISA. 
(Data for patient 0-253 are shown in black and in red for patient 0-255). n = two 
experiments performed in triplicate wells B) Cells from patient 0-253 were pre-
treated with detoxified LPS, a TLR4 antagonist, prior to stimulation with HMGB1 in 
combination with IL-1β. n = one experiment performed in triplicate wells. All data 
are expressed as IL-6 value ± SD (SD values were < 6.25 pg/mL). 
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4.3.6. HMGB1/IL-1β synergy can be inhibited using sub-optimal 
concentrations of LPS 
HMGB1 is reported to form pro-inflammatory complexes with both IL-1β and LPS 
and it was hypothesised that LPS may inhibit the synergistic interaction. As 
previously observed, un-treated fibroblasts and cells treated with HMGB1 or IL-1β 
alone had minimal or no detectable IL-6 release (Figure 4.30). Additionally, the sub-
optimal LPS concentration used in this experiment (25 pg/mL) did not enhance IL-6 
levels alone or in combination with HMGB1 or IL-1β. To determine if LPS could 
prevent the interaction with IL-1β, 100 ng/mL HMGB1 was pre-incubated with LPS 
for 1 h prior to the addition of 0.5 ng/mL IL-1β. Pre-incubation with LPS partially 
inhibited the HMGB1/IL-1β induced IL-6 release. In the absence of LPS, HMGB1 
and IL-1β induced IL-6 levels of 15,385 ± 2688 pg/mL and 28,473 ± 127 pg/mL in 
patients 0-253 and 0-255, respectively. However, this was reduced to 7371 ± 444.7 
pg/mL and 6370 ± 753.1 pg/mL in the presence of LPS. Additionally, LPS was 
added to HMGB1/IL-1β combinations for 0-2 h post overnight incubation to 
determine if LPS could disrupt the synergistic interaction. In patient 0-253, LPS was 
not able to inhibit HMGB1/IL-1β induced IL-6 release. In cells treated with HMGB1 
and IL-1β that had been incubated with LPS for 1 h post overnight incubation IL-6 
levels of 17,753 ± 809 pg/mL were detected. Inconsistent results were recorded for 
patient 0-255 and IL-6 levels of 14,728 ± 279 pg/mL were detected following the 
addition of LPS for 1 h post overnight incubation with similar results recorded for 2, 
0.5 and 0 h post incubation. These levels were considerably lower than the 28,473 ± 
127 pg/mL IL-6 detected with HMGB1/IL-1β.  
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Figure 4.30 Pre-incubation of HMGB1 with sub-optimal concentrations of LPS 
partially inhibits the synergistic response with IL-1β 100 ng/mL HMGB1 was 
pre-incubated with 25 pg/mL LPS before (1 h) and addition (0-2 h) the addition of 
0.5 ng/mL IL-1β and overnight incubation at 4oC. The HMGB1/IL-1β/LPS 
combinations were used to stimulate SFs from two patients (0-253 and 0-255) for 24 
h. Cell supernatants were collected and IL-6 levels were quantified by ELISA. n = 
two experiments performed in triplicate wells. Data are expressed as absolute IL-6 
value ± SD.   
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4.4.  DISCUSSION 
The overall aim of the work presented in this chapter was to characterise the cellular 
response to the synergistic interaction between HMGB1 and IL-1β. The recombinant 
HMGB1 and IL-1β proteins were shown to act synergistically on SFs to enhance 
cytokine production. Fibroblasts treated with 100 ng/mL HMGB1 that had been pre-
incubated with 0.5 ng/mL IL-1β had significantly increased IL-6 release compared to 
un-treated fibroblasts or cells treated with HMGB1 or IL-1β alone (p < 0.05) (Figure 
4.23 and Figure 4.24). These results are agreement with the findings published by 
Hreggvidsdottir et al (2009). Moreover, recent studies have reported that HMGB1 
and IL-1β also act synergistically to promote PGE2 biosynthesis and to enhance IL-8, 
TNF, and Matrix Metalloproteinase (MMP) production from SFs (Wähämaa et al., 
2011; Leclerc et al., 2013).  
Previous studies investigating the synergistic interaction between HMGB1 and IL-1β 
have utilised an excess of the HMGB1 protein in comparison to IL-1β (1:137 
HMGB1: IL-1β) (Hreggvidsdottir et al., 2009; Wähämaa et al., 2011). To determine 
if the synergistic activity was dose-dependent, SFs were treated with increasing 
concentrations of HMGB1 (0-100 ng/mL) and IL-1β (0.5 ng/mL). The results 
suggest that an excess of the HMGB1 protein may be required for the synergistic 
interaction, with no or minimal IL-6 production detected in cells treated with low 
levels of HMGB1 (3.25-25 pg/mL) and IL-1β (Figure 4.4). In contrast, both 50 and 
100 ng/mL HMGB1 acted in synergy with IL-1β to enhance IL-6 production, 
although this increase was not linear. When the concentration of HMGB1 was 
halved, from 100 to 50 ng/mL, the IL-6 secretion was reduced by up 89-fold (Figure 
4.4). Overall this data suggests that HMGB1 and IL-1β only act synergistically 
during injury or infection, when HMGB1 levels are significantly elevated.   
It has previously been reported that pre-incubation of HMGB1 and IL-1β, for up to 
16 h, may be an important prerequisite for the synergistic response. However, 
simultaneous protein addition to cell cultures has generated conflicting results and 
one of the aims of this chapter was to determine if pre-incubation is required. 
Initially, in agreement with the findings of Hreggvidsdottir et al (2009) and 
Wähämaa et al (2011), simultaneous protein addition induced minimal or no-
detectable IL-6 secretion (Figure 4.2). However, in the time course, simultaneous 
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addition of HMGB1 and IL-1β resulted in extracellular IL-6 levels of up to 2800 
pg/mL (Figure 4.5). This data is concordant with the results reported by García-
Arnandis et al (2010) and suggests that pre-incubation of HMGB1 and IL-1β is not 
required for the synergistic activity. The inconsistent results between experiments 
might, in part, be due to subtle differences in the experimental set up. Initially, the 
stock proteins were diluted and incubated overnight at 4
o
C prior to cell addition. 
However, in subsequent experiments the stock solutions were diluted immediately 
prior to cell treatment and this may have been an important factor given the 
relatively low concentrations that were used in these studies (Li et al., 2004). 
The next aim was to determine which domain of HMGB1 is critical for the 
synergistic activity and SFs were treated with the individual HMGB1 constructs in 
combination with IL-1β. Full length HMGB1, Δ30 and the B box all acted in 
synergy with IL-1β to substantially enhance IL-6 release in both patients (Figure 
4.28): in patient 0-255 this resulted in IL-6 levels of 28,473 ±127 pg/mL, 18,490 ± 
2337 pg/mL and 18,710 ± 2797 pg/mL respectively, and a similar trend was 
observed for patient 0-253. Previous studies have shown that the B box mediates the 
pro-inflammatory activity of full length HMGB1 and these results demonstrate, for 
the first time, that the B box domain is also critical for the synergistic interaction 
with IL-1β. Li et al identified that the amino acids at positions 89-108 are 
indispensable for HMGB1 induced macrophage activation and TNF release (Li et al., 
2003) and further investigation is required to determine if this region also mediates 
the synergistic interaction with IL-1β. Additionally, these results imply that the c-
terminal acidic tail may also contribute to the interaction as treatment with Δ30 in 
combination IL-1β induced lower levels of IL-6 than HMGB1 in combination IL-1β. 
The acidic tail has been previously shown to modulate the acetylation of HMGB1 
(Pasheva et al., 2004) and the interactions with DNA (Sheflin et al., 1993; Stros et 
al., 1994; Muller et al., 2001) and nucleosomes (Bonaldi et al., 2002). These results 
also demonstrate that the A box domain is not required for the synergistic interaction 
and fibroblasts treated with the A box in combination with IL-1β had low IL-6 
secretion, with 7.1 ± 0.9 pg/mL and 23.8 ± 4.2 pg/mL IL-6 detected in patients 0-253 
and 0-255, respectively (Figure 4.28). This is not an unexpected finding, previous 
work has shown that the A box domain is anti-inflammatory and that it can 
competitively inhibit the pro-inflammatory activity of the full length protein. 
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Treatment with recombinant A box has been demonstrated to be beneficial in animal 
models of sepsis, arthritis, pancreatitis, ischemia-reperfusion injury, stroke and 
transplantation (Yang et al., 2004; Huang et al., 2007; Andrassy et al., 2008; 
Muhammad et al., 2008; Yuan et al., 2009; Ostberg et al., 2010). The mode of action 
for the A box inhibition is still not defined and it is not known yet if the A box can 
inhibit the synergistic interaction between HMGB1 and IL-1β. 
Anakinra is a synthetic mimic of the endogenous IL-1RA, which can bind to the IL-
1R but cannot recruit the IL-1RAcP, an essential co-factor, and does not initiate 
intracellular signalling (Figure 1.4) (Arend et al., 1990; Greenfeder et al., 1995). In 
Figure 4.7 it was demonstrated that the synergistic interaction between HMGB1, 
Δ30 or the B box with IL-1β can be inhibited using anakinra pre-treatment, 
indicating that the cellular response is mediated via the IL-1R. In patient 0-255, in 
the absence of anakinra, 35 ng/mL B box with 0.5 ng/mL IL-1β resulted in IL-6 
levels of 18,710 ± 2,791 pg/mL, but in the presence of anakinra this was reduced by 
99% to 12.4 ± 3.5 pg/mL. This finding is in agreement with recently published data 
which indicates that the synergistic activities of HMGB1 are mediated by the partner 
molecule receptor (Hreggvidsdottir et al., 2011). Additionally, it has been previously 
shown that HMGB1 and IL-1β do not act synergistically on PBMCs, which express 
low levels of the IL-1R (Hreggvidsdottir et al., 2009; Leclerc et al., 2013). 
Furthermore, pre-treatment with detoxified LPS, a competitive TLR4 antagonist, 
failed to inhibit the synergistic interaction and cells treated with HMGB1/IL-1β in 
the absence and presence of detoxified LPS had IL-6 levels of 10,332 ± 6.25 pg/mL 
and 10,498 ± 1.40 pg/mL, respectively.  
HMGB1 is also reported to act in synergy with LPS. It has been reported that 
HMGB1 acts as an alternative LPS binding protein, transferring LPS monomers to 
the CD14 molecule to initiate TLR4-mediated pro-inflammatory responses (Youn et 
al., 2008). Recent investigations have identified two potential LPS-binding sites in 
the HMGB1 protein with boxes A and B reported to bind to the polysaccharide and 
lipid moieties of LPS, respectively (Hreggvidsdottir et al., 2009; Youn et al., 2011). 
Consequently, it was hypothesised that suboptimal concentrations of LPS (25 
pg/mL) may inhibit the synergistic interaction with IL-1β.  Pre-incubation of 
HMGB1 with LPS inhibited HMGB1/IL-1β induced IL-6 release by up to 52% 
(Figure 4.30). However, LPS was not able to inhibit HMGB1/IL-1β-induced IL-6 
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production when added after the overnight incubation (Figure 4.8). These findings 
support the hypothesis previously proposed, which suggests that HMGB1 and IL-1β 
promote inflammation by forming a highly active pro-inflammatory complex. 
Moreover, this data suggests that IL-1β and LPS may compete for the same binding 
site on the HMGB1 protein and that the interaction with LPS may block the IL-1β 
binding site and vice versa.  
In conclusion, the work presented within this chapter demonstrates that HMGB1 and 
IL-1β act in synergy, via the IL-1R, to enhance cytokine production from SFs. For 
the first time, these results identify that the B box domain of HMGB1 is critical for 
this interaction. Previous studies have proposed that HMGB1 and IL-1β form a 
binary pro-inflammatory complex that initiates and promotes inflammation and, 
collectively, the findings from this chapter support that hypothesis. However, 
biophysical analysis of the interaction between HMGB1 and IL-1β is lacking within 
the current literature and further investigations are required to elucidate the 
mechanism of action.   
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5.1.  INTRODUCTION 
HMGB1 and IL-1β have been shown to act synergistically to enhance inflammation 
(Sha et al., 2008; Hreggvidsdottir et al., 2009; Garcia-Arnandis et al., 2010; 
Wähämaa et al., 2011) and it has been proposed that this synergistic activity is 
mediated by the formation of a highly active pro-inflammatory complex in which 
HMGB1 and IL-1β directly interact. This hypothesis is supported by previous 
studies which have demonstrated that HMGB1 is able to interact with a diverse 
range of endogenous and exogenous molecules to mediate a range of biological 
activities (Dintilhac and Bernués 2002; Ivanov et al., 2007; Tian et al., 2007; 
Urbonaviciute et al., 2008; Youn et al., 2008; Schiraldi et al., 2012). Additionally, 
two independent groups have reported that an interaction between HMGB1 and IL-
1β can be detected using immunoprecipitation (IP) methods (Sha et al., 2008; 
Ferhani et al., 2010). However, a detailed biophysical analysis of the molecular 
relationship between HMGB1 and IL-1β is not available within the current literature.  
Protein NMR spectroscopy is a powerful biophysical technique that can be used to 
obtain physical, chemical and electronic information about proteins in solution. It is 
routinely used to characterise intermolecular interactions and can be used to identify 
the specific residues involved in a binding interaction. Protein NMR has been 
previously used to investigate the interactions of the HMGB1 protein. The 
interaction between the A and B boxes with the c-terminal acidic tail has been 
elucidated (Watson et al., 2007; Stott et al., 2010). Additionally, the binding to DNA 
and linker histones, which is essential for the physiological role of HMGB1, has 
been extensively characterised using this technique (Stott et al., 2006; Cato et al., 
2008). Furthermore, Schiraldi et al have recently reported that HMGB1 forms a 
heterocomplex with the chemokine, CXCL12. They proposed a model in which one 
molecule of HMGB1 binds to two molecules of CXCL12 via the A and B boxes. 
The complex was shown to have enhanced binding to the CXCR4 receptor and 
increased cell infiltration (Schiraldi et al., 2012).  
Evidence within the literature suggests that HMGB1 may form a similar complex 
with IL-1β. Therefore, the aim of this chapter was to conduct a comprehensive 
biophysical analysis of the interaction between HMGB1 and IL-1β using NMR 
methodologies. Specifically, this work was performed to test the hypothesis that 
 Chapter 5 
 
127 
 
HMGB1 and IL-1β directly interact to form a binary complex and to identify the 
residue(s) involved in the binding interaction. The choice of using NMR for these 
studies is based on the fact that the method is able to detect interactions over a wide 
range of binding affinities. Furthermore, if binding is detected, the binding interface 
between HMGB1 and IL-1 can be determined since the resonance assignments of 
both proteins are available.  
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5.2.  MATERIAL AND METHODS 
LPS-free recombinant HMGB1, Δ30, A box, B box and IL-1β proteins were 
expressed and purified from E.coli as detailed in Chapter 2 and Chapter 3. The 
interaction between IL-1β and each of the individual HMGB1 constructs was 
determined using 2D 
1
H-
15
N HSQC experiments as described in Chapter 2, Section 
2.5.   
 Chapter 5 
 
129 
 
5.3.  RESULTS 
5.3.1. Investigating the intermolecular interaction between HMGB1 and IL-
1β 
Firstly, the interaction between full length HMGB1 and IL-1β was examined using 
NMR spectroscopy. 
1
H-
15
N HSQC spectra were collected on a 600 MHz Bruker 
Avance II spectrometer equipped with triple resonance cryoprobes. To allow a direct 
comparison to be made, the spectra were collected using identical acquisition 
parameters: 32 scans with 160 increments at a resolution in the indirect dimension of 
21.00 Hz. To reproduce the conditions used in the cellular experiments (described in 
Chapter 4) the NMR spectra were collected in PBS at pH 7.2 and the HMGB1 and 
IL-1β proteins were incubated for 16 h at 4oC prior to the experimental analysis.  
Initially, a 
1
H-
15N HSQC spectrum was collected on a 25 μM 15N-labelled IL-1β 
sample in the absence of HMGB1 at 25
o
C. The peaks on the spectrum were well 
resolved and dispersed and indicate that the IL-1β protein was well folded (Figure 
5.31; black spectrum). Next, a 12.5 µM aliquot of the IL-1β protein was incubated 
overnight with 11.5 µM HMGB1; this resulted in a molar ratio of approximately 1:1 
IL-1β: HMGB1. The HSQC spectrum was recorded again and an overlay of the 
spectra for IL-1β alone and in the presence of HMGB1 is presented in Figure 5.31. 
No interaction between HMGB1 and IL-1β was detected, under the conditions 
employed in this experiment, since there were no significant chemical shift 
perturbations for the IL-1β residues following the addition of HMGB1. This is 
illustrated more clearly in Figure 5.32, where a section of the amide region is shown 
in greater detail.  
Next, the IL-1β and HMGB1 proteins were concentrated and the experiment was 
repeated at 10
o
C (or 283 K) using a higher concentration of protein. A HSQC 
spectrum was collected for 100 μM 15N-IL-1β in the absence of HMGB1 (Figure 
5.33; black spectrum) using 64 scans with 250 increments at a resolution in the 
indirect dimension of 12.65 Hz. A 50 µM 
15
N-IL-1β sample was then incubated 
overnight with 195 µM HMGB1 (1:4 molar ratio) and the spectrum were recorded 
again using 256 scans with 384 increments at a resolution in the indirect dimension 
of 12.67 Hz (Figure 5.33; red spectrum). For clarity an expanded section of the 
amide region of the spectra is also provided in Figure 5.4. Small chemical shift 
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perturbations were observed for five of the IL-1β residues in the presence of an 
excess of HMGB1. The deposited NMR spectra for IL-1β was obtained from the 
Biological Magnetic Resonance Bank (BMRB) database (BMRB accession number 
434 (Driscoll et al., 1990; Ulrich et al., 2008)) and it was possible to identify two of 
the residues that displayed small chemical perturbations as histidine 30 (H30) and 
asparagine 129 (N129). Further analysis revealed that these two residues are both 
surface exposed and are in close physical proximity to each other (Figure 5.35). 
However, the identity of the other three residues could not be determined as it was 
not possible to transfer the complete IL-1β assignment from the deposited data to the 
current spectra. This was due to differences in the ionic strength and pH between IL-
1β in PBS and in 100 mM sodium acetate-d3 pH 5.4, the conditions under which the 
assignment was deposited in the BMRB.  
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Figure 5.31 
1
H-
15
N 
HSQC spectra for 
15
N-
IL-1β in the presence 
and absence of full 
length HMGB1 
1
H-
15
N 
HSQC spectra were 
recorded for 
15
N-labelled 
IL-1β in the absence and 
presence of HMGB1 on 
a 600 MHz Bruker 
Avance II spectrometer 
at 25
o
C (298 K) using 
identical acquisition 
parameters (
15
N res = 
21.00 Hz). Spectra were 
recorded on a 25 μM 
15
N-labelled IL-1β alone 
(black) and for a 12.5 
μM 15N-IL-1β sample in 
the presence of 11.5 μM 
HMGB1 (red). No 
significant chemical shift 
changes were noted in 
the presence of HMGB1.  
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Figure 5.32 An expanded 
view of the amide region 
of the 
1
H-
15
N IL-1β HSQC 
spectra in the presence 
and absence of full length 
HMGB1 
1
H-
15
N HSQC 
spectra were recorded for 
15
N-IL-1β in the absence 
and presence of HMGB1 on 
a 600 MHz Bruker Avance 
II at 25
o
C (298 K) using 
identical acquisition 
parameters  (
15
N res = 
21.00 Hz). Spectra were 
recorded on a 25 μM 15N-
labelled IL-1β alone (black) 
and for a 12.5 μM 15N-IL-
1β sample in the presence 
of 11.5 μM HMGB1 (red). 
For clarity an expanded 
section of the backbone 
amide region is shown. No 
significant chemical shift 
changes were detected 
following the addition of 
HMGB1. 
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Figure 5.33 Full 
1
H-
15
N 
HSQC spectra 
recorded for 
15
N-
labelled IL-1β at 10oC 
in absence and 
presence of HMGB1 
HSQC spectra were 
recorded on a 600 MHz 
Bruker Avance II 
spectrometer at 10
o
C 
(283 K) in PBS, pH 7.2, 
using an identical 
resolution in the indirect 
dimension of 12.67 Hz.  
Spectra were recorded 
for 100 μM IL-1β alone 
(black) and for 50 μM 
IL-1β in the presence of 
195 μM HMGB1 (red; 
1:4 molar ratio). Minor 
changes in the chemical 
shift of five peaks were 
observed (as indicated) 
and two of these 
residues could be 
assigned as H30 and 
N129.  
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Figure 5.34 An 
expanded view of the 
amide region of the 
1
H-
15
N IL-1β HSQC 
spectra in the presence 
and absence of full 
length HMGB1 
recorded at 10
o
C HSQC 
spectra were recorded on 
a 600 MHz Bruker 
Avance II spectrometer 
at 10
o
C (283 K) in PBS, 
pH 7.2, using an 
resolution in the indirect 
dimension of 12.67 Hz.  
The black spectra show 
100 µM IL-1β alone and 
the red spectra 
correspond to 50 µM IL-
1β with 195 µM 
HMGB1. An expanded 
region is shown for 
clarity with perturbations 
in the chemical shifts of 
two unassigned residues 
observed within this 
region (as indicated in 
the boxed regions). 
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Figure 5.35 3D structure of the IL-1β protein highlighting the H30 and N129 
residues NMR analysis detected small chemical shift perturbations for the H30 and 
N129 residues in the IL-1β protein in the presence of a 4:1 excess of HMGB1. As 
can be seen these residues are both surface exposed and in close physical proximity 
to each other. Figure was produced using PyMOL (PyMoL).  
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5.3.2. Investigating the intermolecular interaction between ∆30 and IL-1β 
Due to the acidic nature of the C-terminal tail (residues 185-215) it was decided that 
further investigations into the interaction between HMGB1 and IL-1β would be 
carried out using the more stable Δ30 construct. In Chapter 4, it was demonstrated 
that the Δ30 protein acted in synergy with IL-1β to enhance IL-6 release in SFs 
(Chapter 4, Section 4.2.4). NMR spectra were collected on a 10 μM 15N-labelled Δ30 
sample in the absence and presence of 90 μM unlabelled  IL-1β (1:9 molar ratio) on 
an 800 MHz Avance II Bruker spectrometer at 25
o
C (298 K) in PBS at pH 7.2. To 
allow a direct comparison to be made between the spectra, identical acquisition 
parameters were used: 192 scans with 256 increments at a resolution in the indirect 
dimension of 15.80 Hz. An overlay of the 
1
H-
15
N HSQC spectra is presented in 
Figure 5.36. The ∆30 protein appeared to be well folded as the peaks on the HSQC 
spectra were well resolved and dispersed. When an excess of the IL-1β protein was 
added to the sample no significant changes in the chemical shift of the peaks was 
observed. It may appear that some small peaks disappear from spectrum following 
the addition of IL-β, however this is not the case as all of the peaks are present when 
the contour levels are increased. The reduction in the intensity is an unavoidable 
result of dilution effects. For increased clarity and to reduce the background noise 
levels the spectra are presented at reduced contour levels.  
Next, the reverse experiment was conducted with 
1
H-
15
N HSQC spectra recorded for 
100 μM IL-1β in the absence and presence of a three-fold excess of unlabelled ∆30 
protein. The experiment was performed on an 800 MHz Bruker Avance II 
spectrometer in 20 mM phosphate, 100mM potassium chloride, and 10 mM DTT at 
pH 6.8 using comparable acquisition parameters: 4 scans with 210 increments at a 
resolution in the indirect dimension of 16.99 Hz. As shown in Figure 5.7 and Figure 
5.8 minor chemical shift perturbations were observed for a number of the IL-1β 
residues; however, this did not appear to be a specific effect as most of the residues 
on the spectrum displayed some small perturbation. As observed previously (Figure 
5.3), the H30 and N129 residues displayed the greatest chemical perturbations. 
However, it was difficult to replicate these results in subsequent experiments.  
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Figure 5.36 Effect of IL-1β 
on the 
15
N-HSQC spectra of 
Δ30 1H-15N HSQC spectra 
were collected using a 800 
MHz Bruker Avance II 
spectrometer at 25
o
C (298 K) 
on a 10 μM 15N-labelled his-
tagged Δ30 sample in PBS, 
pH 7.2. Spectra were 
recorded for Δ30 alone 
(black) and in the presence of 
90 μM IL-1β (red) using 
identical acquisition 
parameters: NS = 192, 
increments = 256 and 
15
N res 
= 15.80 Hz. No significant 
changes in the chemical shifts 
of the peaks were observed in 
the presence of IL-1β. From 
the spectra presented it would 
appear that some of peaks 
disappear following the 
addition of IL-1β. However, 
this was due the low 
concentration of the 
15
N B 
box protein and all peaks 
were present when the 
contour levels were increased. 
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Figure 5.37 
1
H-
15
N HSQC 
spectra for 
15
N-labelled 
IL-1β before and after the 
addition of a three-fold 
excess of Δ30 NMR spectra 
were collected for 100 μM 
IL-1β in the absence and 
presence of 300 μM Δ30 on 
a Bruker 800 MHz 
spectrometer at 25
o
C (298 
K). Samples were analysed 
in 20mM potassium 
phosphate, 100mM 
potassium chloride and 10 
mM DTT, pH 6.8, using 4 
scans with 210 increments 
at a FID resolution of 16.99. 
Minor chemical shift 
perturbations were observed 
for the majority of residues 
and the residues that 
showed the greatest 
perturbations are indicated.  
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Figure 5.38 An 
expanded view of the 
amide region of the 
1
H-
15
N HSQC spectra 
for 
15
N-labelled IL-1β 
in the absence and 
presence of Δ30 NMR 
spectra were collected 
for 100 μM IL-1β in 
the absence and 
presence of 300 μM 
Δ30 on a Bruker 800 
MHz spectrometer at 
25
o
C (298 K). Samples 
were analysed in 20 
mM potassium 
phosphate, 100 mM 
potassium chloride and 
10 mM DTT, pH 6.8, 
using 4 scans with 210 
increments at a 
resolution in the 
indirect dimension of 
16.99 Hz. Minor 
chemical shift 
perturbations were 
observed.  
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5.3.3. Investigating the intermolecular interaction between the B box and IL-
1β  
In Chapter 4 it was demonstrated that the B box domain of HMGB1 is critical for the 
synergistic interaction with IL-1β. The association between the B box and IL-1β was 
investigated using 2D NMR analysis, to determine if a direct interaction could be 
detected. NMR spectra were collected on an 800 MHz Bruker Avance II 
spectrometer equipped with triple resonance cryoprobes at 25
o
C (298 K) using 
identical acquisition parameters: 192 scans with 256 increments at a resolution in the 
indirect dimension of 15.80 Hz. 
1
H-
15
N HSQC spectra were collected on a 10 μM 
15
N-labelled B box sample before and after the addition of 100 μM IL-1β (B box: IL-
1β ratio of 1:10). Samples were analysed in PBS at pH 7.2 to replicate the cellular 
buffer conditions.  
An overlay of the two spectra is presented in Figure 5.9. In both cases the peaks are 
well defined and dispersed and the spectra are indicative of a folded B box protein.  
Following the addition of an excess of un-labelled IL-1β the HSQC spectra showed 
little variation; no significant change in the chemical shift of the peaks was observed. 
From Figure 5.9 it would appear that some of peaks disappear from the spectrum 
after the addition of IL-1β. However, this was due to the dilution effects of the 15N-B 
box protein used in the experiment and all of the peaks were present when the 
contour levels were increased. However, the spectra are presented at reduced contour 
levels in the Figure for increased clarity as the background noise levels also 
increased significantly.  
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Figure 5.39 
1
H-
15
N HSQC spectra 
for the 
15
N-labelled B box domain 
in the presence and absence of 
IL-1β 1H-15N HSQC spectra were 
collected on a 10 µM 
15
N B box 
sample in PBS, pH 7.2 at 25
o
C (298 
K) in the absence (Black) and 
presence (red) of 100 μM IL-1β 
(
15
N B box: IL-1β ratio of 1:10). 
NMR spectra were collected on a 
Bruker Avance II 800 MHz 
spectrometer using identical 
experimental parameters (NS = 
192, increments = 256 and 
15
Nres = 
15.80 Hz). In the presence of IL-1β, 
no significant change in the 
chemical shift of the peaks was 
observed. From the spectra it would 
appear that some of peaks disappear 
following the addition of IL-1β. 
However, this was due the low 
concentration of the 
15
N B box 
protein and all peaks were present 
when the contour levels were 
increased. 
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5.3.4. Investigating the intermolecular interaction between the A box domain 
of HMGB1 and IL-1β 
1
H-
15N HSQC spectra for a 100 μM 15N-labelled A box sample were collected in the 
absence and presence of 500 μM IL-1β at 25oC in 20 mM potassium phosphate, 100 
mM potassium chloride and 10 mM DTT at pH 6.8 using a 800 MHz Bruker Avance 
II spectrometer. Figure 5.10 shows an overlay of the A box spectra without (black) 
and with (red) IL-1β. In order for a direct comparison to be made the spectra were 
collected using identical acquisition parameters: 8 scans with 150 increments at a 
resolution in the indirect dimension of 21.09 Hz. In both spectra the peaks are well 
defined and dispersed indicating that the A box protein used in the experiment was 
folded. As can be seen, no chemical shift perturbations were observed following the 
addition of an excess of IL-1β.  
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Figure 5.40 
Investigating the 
intermolecular 
interaction between 
15
N A box and IL-1β 
1
H-
15
N HSQC spectra 
were collected for a 
100 μM 15N-labelled 
A box sample in the 
absence (black) and 
presence (red) of 500 
μM IL-1β at 25oC 
(298 K) in 20 mM 
potassium phosphate, 
100 mM potassium 
chloride and 10 mM 
DTT, pH 6.8, on a 
800 MHz Bruker 
Avance II 
spectrometer. No 
significant chemical 
shift changes were 
observed in the 
presence of IL-1β.  
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5.4.  DISCUSSION 
It has been previously demonstrated that HMGB1 and IL-1β act in synergy to 
amplify the inflammatory response and it has been postulated that this effect is 
mediated by the formation of a highly active pro-inflammatory complex in which 
HMGB1 and IL-1β directly interact (Sha et al., 2008; Ferhani et al., 2010; Wähämaa 
et al., 2011). However, there is currently limited evidence to prove that a direct 
association occurs, although it is known that HMGB1 can complex with a diverse 
range of endogenous and exogenous molecules. Two independent groups have 
demonstrated that HMGB1 and IL-1β can be co-purified using IP: in 2008, Sha and 
colleagues reported that IL-1β could be detected along with FLAG-tagged HMGB1 
following FLAG-affinity IP purification (Sha et al., 2008). Additionally, in 2010, 
Ferhani et al (2010) reported that HMGB1/IL-1β complexes could be isolated from 
macrophages treated with recombinant HMGB1 and IL-1β proteins. However, the 
published data for this later study did not include an IL-1β positive control and it is 
possible that the IL-1β protein interacted non-specifically with the anti-HMGB1 
antibody used in the experiment. Therefore, the work presented in this chapter was 
performed to elucidate the molecular interaction between E.coli expressed and 
purified recombinant HMGB1 and IL-1β, and to test the hypothesis that these 
proteins directly interact to form a binary complex that enhances the inflammatory 
response.  
The first experiment was designed to investigate the intermolecular interaction 
between 
15
N-labelled IL-1β and unlabelled full length HMGB1. The specific batch 
of proteins used in this experiment had been previously demonstrated to act 
synergistically on SFs to enhance the release of IL-6 in cells isolated from two RA 
patients (Figure 4.3). Neither protein induced detectable IL-6 secretion alone but 
they acted synergistically to induce IL-6 levels of up to 13,486 ± 2055 pg/mL. The 
NMR experiments performed in this chapter were designed to replicate the cellular 
experimental conditions as closely as possible: the HSQC spectra were collected in 
PBS and the proteins were incubated overnight at 4
o
C prior to sample analysis, as it 
has been previously reported this was a prerequisite for the synergistic activity (Sha 
et al., 2008; Hreggvidsdottir et al., 2009; Wähämaa et al., 2011) although the results 
 Chapter 5 
 
145 
 
from Chapter 4 indicate that pre-incubation may not be necessary. Initially, the 
experiment was conducted at 25
o
C (298 K) and under the conditions examined in 
this thesis no direct protein-protein interaction was detected between IL-1β and 
HMGB1 with no chemical shift perturbations observed for any of the IL-1β residues, 
suggesting that the cellular response is not mediated by the formation of a highly 
active binary complex (Figure 5.31 and Figure 5.32). Somewhat different results 
were obtained when the experiment was repeated at 10
o
C (283 K) as minor chemical 
shift perturbations were observed for five IL-1β residues (Figure 5.3 and Figure 5.4). 
Two of these residues, H30 and N129, were surface exposed and in close proximity 
to each other (Figure 5.35). However, given such small and limited chemical shifts, 
and the difficulties in replicating the results, it is likely that these small perturbations 
are not caused by a direct binding interaction but are the result of subtle pH 
differences, which are likely to affect charged residues.  
In Chapter 4 the Δ30 protein was shown to act synergistically with IL-1β to enhance 
the inflammatory response (Section 4.2.4) and experiments were designed to 
determine if this effect was due to the formation of a binary complex. Initially, 
1
H-
15
N HSQC spectra were collected for a 
15
N-labelled Δ30 sample in the absence and 
presence of a 9-fold excess of unlabelled IL-1β protein. No chemical shift 
perturbations for the Δ30 residues were observed following the addition of IL-1β 
(Figure 5.36) indicating that a detectable binary complex was not formed under the 
conditions utilised in this experiment. It should be noted that it was not practical to 
reproduce the 1:137 (IL-1β: HMGB1 protein) molar ratio used in the cellular 
experiments within the NMR studies. However, the total concentration of the 
HMGB1 constructs used in the NMR experiments exceeds the concentration used in 
the cellular assays. Additionally, an excess of the unlabelled protein was required for 
the experiments and this resulted in an excess of the IL-1β protein being used when 
spectra were collected for 
15
N-labelled HMGB1 proteins. However, the reverse 
experiment was also performed with 
1
H-
15
N HSQC spectra recorded for 
15
N-labelled 
IL-1β in the presence of a three-fold excess of Δ30 protein (Figure 5.7 and Figure 
5.8). Under these conditions minor chemical shift perturbations were observed for 
several of the IL-1β residues, including once again the H30 and N129 peaks. It is 
unlikely that these small chemical shift perturbations are due to a specific binding 
interaction since minor changes were detected for many of the residues. Moreover, 
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the chemical shift of the H30 residue, a charged amino acid, is particularly 
susceptible to pH changes and once again it is likely that the perturbations were due 
to a subtle pH change following the addition of the Δ30 protein.  
Subsequently, NMR experiments were conducted to investigate the interaction 
between IL-1β and the individual A and B box domains. Despite structural 
similarities, the two HMG boxes have opposing functions in vivo: the B box is 
essential for the pro-inflammatory activity of HMGB1 (Li et al., 2003; Yang et al., 
2010) whilst the A box is anti-inflammatory and has been shown to neutralise the 
inflammatory activity of the full length HMGB1 protein in experimental animal 
models (Yang et al., 2004; Andrassy et al., 2008; Yuan et al., 2009; Ostberg et al., 
2010). It was previously observed that the B box is critical for the synergistic 
interaction with IL-1β and that the A box is not required (Chapter 4, Section 4.2.4). 
Therefore, as predicted, the formation of a complex between 
15
N-labelled A box and 
IL-1β was not detected, with no chemical shift perturbations observed in the A box 
spectrum (Figure 5.10). Additionally, no chemical shift perturbations were observed 
in the 
1
H-
15
N HSQC spectrum for the 
15
N-labelled B box protein following the 
addition of a 10-fold excess of IL-1β (Figure 5.9), despite the fact that this 
combination of proteins induced increased IL-6 secretion in vitro (Figure 4.6). Once 
again, this implies that HMGB1 and IL-1β do not directly interact to form a binary 
complex under the conditions used in these experiments.  
From the NMR data presented within this chapter it would appear that the synergistic 
interaction observed between HMGB1 and IL-1β is not mediated by the formation of 
a pro-inflammatory binary complex. Rather, an alternative cellular mechanism is 
needed in which HMGB1 is involved and additional co-factor(s) may be required. 
The HMGB1 and IL-1β proteins signal via a common pathway to initiate 
inflammation, binding to the TLR4 and IL-1R, respectively (Figure 5.11). Both 
receptors belong to the Toll/IL-1R (TIR) family, which is split into three sub-
families: the TLR family, the IL-1 family and the MyD88 family. All of the 
members of the TIR family share a common, highly conserved cytoplasmic motif 
(Gay and Keith 1991), the TIR domain which is essential for the initiation of 
intracellular signalling (Leung et al., 1994). The synergistic interaction between 
HMGB1 and IL-1β is mediated via the IL-1R (Chapter 4; Hreggvidsdottir et al., 
2011). The IL-1R subfamily contains 10 proteins including the type I and II IL-R’s 
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and the IL-1RAcP, a co-factor that is essential for the initiation of intracellular 
signalling. The type I IL-1R and IL-1RAcP are composed of an extracellular region 
made of three immunoglobulin-like domains, a transmembrane domain and a 
cytoplasmic TIR domain, which contains approximately 215 residues (Sims et al., 
1989). The type II IL-1R has a truncated 29-residue TIR domain, cannot initiate cell 
signalling and acts as a decoy receptor for IL-1 (McMahan et al., 1991).  
IL-1 signalling is mediated by the MyD88/IRAK/TRAF6 pathway and the TIR 
domains play a central role in initiating the cellular response (Figure 5.11). IL-1 
binds to the type I IL-1R and recruits the IL-1RAcP resulting in the formation of a 
heterodimeric signalling complex (Greenfeder et al., 1995). The TIR domains within 
the IL-1R and the IL-1RAcP interact, inducing a conformational change (Martin and 
Wesche 2002) leading to the recruitment of the MyD88 and Tollip/IRAK proteins 
(Muzio et al., 1997). Under normal conditions, the activity of IRAK-1 is sequestered 
by the Tollip protein; this association is lost when IRAK-1 is recruited to receptor 
complex (Burns et al., 2000). IRAK-1 is phosphorylated (Burns et al., 2000; Kollewe 
et al., 2004) and released into the cytoplasm, where it associates with the TAB2 and 
TRAF6 proteins (Jiang et al., 2002). TRAF6 is poly-ubiquitinated and active TRAF6 
can interact with the TAK-1, which in turn activates the NF-κB, p38 and c-JNK 
pathways (Wang et al., 2001). NF-κB activates a diverse range of pro-inflammatory 
genes including the IL-6 gene (Libermann and Baltimore 1990). Our findings 
suggest that additional molecules may be involved in mediating HMGB1/IL-1β 
synergy. There is currently no evidence within the literature to suggest that HMGB1 
can directly bind to and activate the IL-1R. However, HMGB1 and IL-1β may form 
a tertiary complex with the IL-1R or IL-1RAcP to enhance intracellular signalling 
and future studies will investigate this hypothesis.  
 Chapter 5 
 
148 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.41 TIR family signal transduction pathway HMGB1 and IL-1β bind to 
the TLR4 and type I IL-1R (IL-1R1) proteins, respectively. Engagement of the 
receptor activates the MyD88/IRAK/TRAF6 intracellular signalling pathway. This 
results in activation of NF-κB-mediated gene transcription and the c-JNK and p38 
signalling pathways.  
 
In conclusion, the data presented within this chapter definitively shows that the 
synergistic effect between HMGB1 and IL-1β, observed in the cellular experiments, 
is not due to the formation of a binary complex between the two pro-inflammatory 
proteins. Despite performing the NMR experiments in various ways, there was no 
significant evidence to support the formation of a pro-inflammatory complex 
between IL-1β and either full length HMGB1, Δ30 or the B box. This suggests that 
HMGB1 and IL-1β elicit an inflammatory response via a novel cellular mechanism 
in which HMGB1 is required and additional proteins are involved.  Future work will 
focus on discovering what these other proteins might be.  
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6.1.  BACKGROUND 
HMGB1 is an important mediator of inflammation which acts to alert the immune 
system to tissue stress and injury. It mediates cytokine production (Andersson et al., 
2000), chemotaxis (Orlova et al., 2007), cell proliferation, dendritic cell and T-cell 
activation (Dumitriu et al., 2005), cell differentiation (Melloni et al., 1995) and 
autophagy (Tang et al., 2010). HMGB1 has been implicated in the pathogenesis of 
multiple inflammatory diseases including immune-mediated DILI, where it is a 
potential mechanistic biomarker and a target for therapeutic intervention. However, 
despite intense research the pro-inflammatory role of HMGB1 remains unresolved. 
Several studies have demonstrated that HMGB1 interacts with multiple unrelated 
ligands to enhance the inflammatory response, although currently these interactions 
are poorly defined. The overall aim of the work presented in this thesis was to 
specifically characterise the interaction between HMGB1 and IL-1β. This was 
achieved by:  
 Developing and optimising methods for the production of LPS-free and 
isotopically-labelled recombinant HMGB1, Δ30, A box, B box and IL-1β 
proteins. The characterisation of these proteins in Chapter 3 enabled their use 
in further studies in Chapters 4 and 5, where a dual cellular and biophysical 
strategy was employed to study the synergistic response between HMGB1 
and IL-1β. 
 Performing an extensive cellular characterisation of the interaction between 
HMGB1 and IL-1β using established cell assays. In Chapter 4, SFs were used 
as a model cell system to investigate the cellular response to HMGB1 and IL-
1β. These studies identified which domain of HMGB1 mediates the 
interaction and investigated the clinical relevance of the synergy by exploring 
the dynamics and kinetics of the response.  
 Conducting an extensive biophysical analysis of the interaction between 
HMGB1 and IL-1β using NMR methodologies. The experiments described in 
Chapter 5 were undertaken to test the hypothesis that HMGB1 and IL-1β 
directly interact to form a binary pro-inflammatory complex. These are the 
first biophysical studies to investigate the interaction between HMGB1 and 
IL-1β.   
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The findings from these studies help to clarify the pro-inflammatory function of 
HMGB1 and are relevant to multiple inflammatory diseases where HMGB1 has been 
implicated as a pathogenic mediator.   
6.2.  HMGB1 AS AN INFLAMMATORY MEDIATOR OF DILI 
There is an ever increasing awareness of the involvement of innate immunological 
responses during DILI. It is now widely accepted that DAMPs are released as a 
direct consequence of hepatic cellular dysfunction and death in response to a toxic 
insult. Amongst all DAMPs, HMGB1 is the most studied protein. HMGB1 drives 
inflammation during tissue injury or infection and is increasingly being identified as 
a pathogenic mediator of immune-mediated DILI, with elevated levels of up to 100 
ng/mL reported during clinical APAP-induced hepatotoxicity (Antoine et al., 2012; 
Antoine et al., 2013). Additionally, HMGB1-targeted therapies have been reported to 
be beneficial in experimental animal models of DILI. Neutralising HMGB1 
antibodies reduce hepatic inflammation and increase survival during APAP-induced 
DILI (Antoine et al., 2010), although the clinical potential of HMGB1-inhibition in 
hepatotoxicity is, as yet, unknown.  
The renewed interest in HMGB1 biology has driven the need for a large quantity of 
recombinant HMGB1 protein. To facilitate this work, Chapter 3 describes the 
development and optimisation of methods for the production of recombinant 
HMGB1, Δ30, A box, B box and IL-1β proteins. To enable further cellular and 
biophysical studies in Chapters 4 and 5, the recombinant proteins were both LPS free 
and isotopically-labelled. To our knowledge, at the start of this work no other study 
had considered both of these factors when producing recombinant HMGB1 proteins.  
Extracellular HMGB1 has been reported to act in synergy with multiple un-related 
endogenous and exogenous molecules to modulate the inflammatory response (Table 
6.14). These interactions are ligand-specific as HMGB1 does not act synergistically 
with TNFα, RANKL, IL-18 or PolyI:C (Hreggvidsdottir et al., 2009). HMGB1 
interactions with IL-1β, IL-1α, LPS and CpG-ODN are pro-inflammatory promoting 
the production and release of multiple cytokine mediators including IL-6, IL-8, TNF 
and MMP (Hreggvidsdottir et al., 2009; Wähämaa et al., 2011).  
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There is currently limited data available on the synergistic interaction between 
HMGB1 and IL-1β and prior to this study the kinetics of the interaction had not been 
well defined. In Chapter 4 an extensive in vitro analysis was undertaken to 
characterise the cellular response. SFs were isolated from RA patients and used as a 
model cell system. The results show that HMGB1 acts synergistically with IL-1β to 
initiate and enhance the inflammatory response following infection or injury when 
HMGB1 levels are significantly elevated. Full length HMGB1, Δ30 and the B box, 
but not the A box, all acted in synergy with IL-1β, via the IL-1R, to enhance 
cytokine production in these cells (Figure 4.6 and Figure 4.7). The B box was 
essential for the synergistic interaction with IL-1β (Figure 4.6), although further 
studies are needed to identify the critical residues involved. Previous studies have 
shown that a minimal 20-residue peptide (residues 89-108) (Figure 1.7) from within 
the B box domain is required for HMGB1-induced cytokine production and this 
region may be involved in the synergistic activity with IL-1β (Li et al., 2003).  
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Table 6.14 Overview of the key synergistic interactions of the HMGB1 protein HMGB1 interacts with multiple molecules to modulate the 
inflammatory response. The main findings from the work presented in this thesis are shown in the boxed region.  
Partner molecule Key findings  Receptor 
Relevance of 
PTMs 
Key reference(s) 
PRO-INFLAMMATORY 
LPS Enhances cytokine production 
LPS interacts with A and B boxes  
Alternative LBP-binding protein  
TLR4  (Youn et al., 2008; 
Hreggvidsdottir et al., 
2009; Wähämaa et al., 
2011; Youn et al., 2011) 
IL-1β  Enhances cytokine production 
B box domain of HMGB1 is critical 
Not due to the formation of a pro-
inflammatory binary complex  
Mediated via an alternative cellular 
mechanism  
IL-1R Redox independent  Chapter 4 & 5 
(Hreggvidsdottir et al., 
2009; Hreggvidsdottir et 
al., 2011; Wähämaa et 
al., 2011) 
 
IL-1α Enhances cytokine production IL-1R  (Wähämaa et al., 2011) 
CXCL12 Promotes the recruitment of inflammatory 
cells to damaged tissue 
HMGB1 forms a heterocomplex with 
CXCL12 as shown by NMR 
CXCR4 CXCL12 binds 
fully reduced 
HMGB1 
(Schiraldi et al., 2012) 
Nucleosomes  Enhance cytokine production  
Increases expression of co-stimulatory 
molecules on macrophages and dendritic cells  
TLR2  (Urbonaviciute et al., 
2008) 
Nucleic acids Enhances cytokine production  TLR9  (Ivanov et al., 2007) 
ANTI-INFLAMMATORY 
CD24/Siglec-10 Ternary complex (HMGB1/CD24/Siglec-10)  
Negatively regulates HMGB1-induced NF-κB 
activation and cytokine production   
CD24/Siglec-10  (Chen et al., 2009) 
Chapter 6 
 
155 
 
6.3.  DIFFERENT MOLECULAR FORMS OF HMGB1 PRESENT 
DURING DILI AND THEIR SYNERGISTIC INTERACTIONS 
It is now known that HMGB1 can undergo multiple post-translational modifications 
(PTMs) (Table 6.2). These PTMs regulate the release and function of HMGB1, with 
multiple molecular forms reported to be present during the inflammatory response. 
Emerging evidence suggests that different molecular forms of HMGB1 may function 
as informative mechanistic indicators of DILI.  
Acetylation of HMGB1 is a prerequisite for protein secretion from activated immune 
cells and analysis of the acetylation status can provide insights into the mechanisms 
of DILI. Antoine and colleagues have shown that hypo-acetylated HMGB1, derived 
from necrotic cells, is an early marker of hepatocyte cellular dysfunction and cell 
death.  In experimental rodent models, hypo-acetylated HMGB1 levels are 
significantly elevated from 3 h post APAP treatment, peaking at 5 h and returning to 
control values within 10 h. In contrast, hyper-acetylated HMGB1, a marker of cell 
activation and inflammation, is first significantly increased at 5 h post-treatment with 
levels remaining elevated for up to 24 h after APAP-administration (Antoine et al., 
2009; Antoine et al., 2012). A recent clinical analysis of 84 patients presenting with 
acute liver failure to two major hospitals in the UK and USA has reported similar 
findings (Antoine et al., 2012). Moreover, from these patients it appears that 
quantification of the hyper-acetylated form of HMGB1 may be a predictive 
biomarker of the clinical outcome (Antoine et al., 2012). 
Recent studies have demonstrated that the redox status of the three cysteine residues 
regulates HMGB1 receptor binding and bioactivity (Table 6.16). ‘Cytokine-
inducing’ HMGB1 requires a C23-C45 disulphide bond and a reduced C106 residue 
(di-sulphide HMGB1) (Yang et al., 2011). The C106 residue is located within the B 
box domain and is critical for TLR4-binding. The results from Chapter 4 show that 
this region is also required for the synergistic interaction with IL-1β, although the 
effects of oxidation and other PTMs on HMGB1 synergy are still largely unknown. 
Recently, Park et al have shown that the C23-C45 di-sulphide bond reduces the 
binding affinity for cisplatin modified DNA (Park and Lippard 2011). Furthermore, 
it appears that all-thiol HMGB1 form a heterocomplex with CXCL12 that signals via 
the CXCR4 receptor to promote chemotaxis (Schiraldi et al., 2012). 
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Table 6.15: The functional importance of post-translational modifications in the 
HMGB1 protein 
PTM Target residue(s) Significance References 
Acetylation  All lysine (K) 
residues are 
susceptible but K28, 
K29, K30, K180, 
K182, K183, K184 
& K185 are 
frequently 
acetylated in vivo  
  
Prerequisite for the 
active secretion from 
immune cells (Including 
macrophages and 
monocytes). 
Acetylation of K2 and 
K11 is required for 
binding to distorted 
DNA.  
(Bonaldi et 
al., 2003; 
Assenberg et 
al., 2008) 
Oxidation C23, C45 & C106 Regulates pro-
inflammatory activity 
C106 is critical for 
TLR4 binding  
(Yang et al., 
2011) 
(Venereau et 
al., 2012) 
Methylation K42 Promotes cytoplasmic 
accumulation 
(Ito et al., 
2007) 
Phosphorylation S35, S39, S42, S46, 
S53 and S181 
Promotes cytoplasmic 
accumulation 
(Youn and 
Shin 2006) 
 
LC-MS/MS analysis of a batch of the recombinant HMGB1 produced in Chapter 3 
revealed that the three cysteine residues were all oxidised (Figure 3.18). The 
biological function of C106- or fully-oxidised HMGB1 is still unknown (Table 6.3) 
and in agreement with previous findings, this recombinant HMGB1 did not induce 
IL-6 release in PBMCs or SFs alone (Figure 3.17 & Figure 4.1) (Yang et al., 2011). 
However, in Chapter 4, the recombinant HMGB1 was able to act synergistically with 
IL-1β to significantly enhance IL-6 production (Figure 4.1). This suggests that the 
synergistic activities of HMGB1 with IL-1 are independent of the oxidation status, 
TLR4 binding capability and the intrinsic cytokine-inducing activity. These results 
are in agreement with similar findings recently reported by Wähämaa and colleagues 
(Wähämaa et al., 2011) and suggest that an ‘inactive cytokine-inducing’ HMGB1 
molecule may still be able to promote inflammation in the presence of IL-1β or other 
co-factors. However, to confirm this finding the synergistic activity between C106A 
and C106S HMGB1 mutants and IL-1β will need to be determined. 
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Table 6.16 Redox-state dependent functions of HMGB1 released during DILI Table adapted from (Yang et al., 2013). 
Molecular form 
 
Role in DILI 
 
Source Schematic representation 
Cytokine-
inducing  
(TLR4 binding) 
Chemoattractant 
activity 
All-thiol HMGB1 
 
Promotes resolution 
and regeneration  
Necrosis 
 
No Yes 
Di-sulphide 
HMGB1 
 
Promotes 
Inflammation 
Necrosis and 
pyroptosis 
 
Yes No 
C106-oxidised 
HMGB1 
 
Unknown function Apoptosis  
 
No No 
Fully-oxidised 
HMGB1 
 
Unknown function Apoptosis 
 
No No 
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6.4.  EXPLORING THE INTERACTION BETWEEN HMGB1 AND IL-1Β  
Biophysical analysis of the interaction between HMGB1 and IL-1β is not available 
within the current literature, although several publications have alluded to the 
formation of a pro-inflammatory binary complex. Protein NMR spectroscopy is a 
powerful technique used to investigate intermolecular interactions. In Chapter 5, an 
extensive biophysical analysis of the interaction between HMGB1 and IL-1β was 
conducted using NMR methodologies. The NMR findings conclusively show that 
HMGB1 and IL-1β do not directly interact to form a binary complex, under the 
conditions employed in these experiments. Despite the fact that the full length 
HMGB1, Δ30 and B box proteins had all been shown to act synergistically with IL-
1β in the cellular assays described in Chapter 4 (Figure 4.6). This suggests that 
HMGB1 and IL-1β act via an alternative mode of action to synergistically enhance 
cytokine production during inflammation, although further studies are required to 
identify this pathway. Moreover, the results indicate that additional proteins involved 
in IL-1 signalling may be required for the synergistic interaction    
6.5.  FUTURE INVESTIGATIONS; ELUCIDATING THE MECHANISM 
OF ACTION FOR HMGB1/IL-1Β SYNERGY  
Future studies will investigate alternative mechanisms that may mediate the 
synergistic activity between HMGB1 and IL-1β. The findings presented in this thesis 
suggest that the interaction may require additional proteins. One possibility is that 
HMGB1 may form a ternary complex with IL-1β and the IL-1R or IL-1RAcP 
(Figure 6.42). It has recently been reported that HMGB1 forms a similar trimolecular 
complex with CD24, a glycosylated GDP-anchored membrane protein, and Siglec10 
(or the mouse homologue Siglec-G), an inhibitory membrane receptor (Chen et al., 
2009). It has been proposed that HMGB1 and CD24 first form a binary complex 
which, in turn, interacts with Siglec10. Chen et al have shown that the B box domain 
of HMGB1 is critical for this interaction. However, further biophysical experiments 
are needed to elucidate the specific binding site. In contrast, to the synergy between 
HMGB1 and IL-1β the ternary complex with CD24 and Siglec10 is anti-
inflammatory, with the CD24 and Siglec10 proteins suppressing HMGB1-mediated 
NF-κB activation. Recent studies have shown that the HMGB1/CD24/Siglec10 
pathway protects against DILI and sepsis with CD24 and SiglecG knockout mice 
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displaying an increased susceptibility to APAP-induced hepatotoxicity (Chen et al., 
2009; Chen et al., 2011). This appears to be due to enhanced intracellular signalling 
in the absence of CD24 and SiglecG and administration of HMGB1-antibodies is 
beneficial in these models. This demonstrates a critical role for CD24 and Siglec10 
in dampening the immune response to HMGB1. In contrast, a similar ternary 
complex between HMGB1, IL-1β and the IL-1R or IL-1RAcP would be pro-
inflammatory, promoting inflammation in response to a toxic insult.  
Additionally, it is also possible that HMGB1 may form a ternary complex with an 
alternative cellular protein prior to the interaction with the IL-1R receptor (Figure 
6.42). This may result in enhanced intra-cellular signalling when compared IL-1β 
signalling alone. However, further experiments are required to test these hypotheses.  
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Figure 6.42 Overview of the potential mechanisms that may mediate the 
synergistic activity between HMGB1 and IL-1β The potential mechanism that has 
been investigated in this work is shown in the red box region. Based on the findings 
presented in this thesis, this mechanism can be excluded. Future experiments will 
investigate alternative mechanisms of action as outlined in the black box regions.      
6.6.  CONCLUDING REMARKS 
In summary, the work presented in this thesis has used combined cellular and NMR 
methodologies to characterise the synergistic interaction between HMGB1 and IL-
1β. The results show that the two proteins act synergistically to enhance cytokine 
production during the inflammatory response. Furthermore, these findings 
demonstrate that the B box domain of HMGB1 is critical for this effect. However, 
this is not due to the formation of a binary complex between HMGB1 and IL-1β, as 
shown by the NMR experiments. Instead, it appears that this occurs via an 
alternative cellular mechanism in which HMGB1 is required and other molecules 
may be involved. Future work will focus on identifying these other proteins. Overall 
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these studies help to clarify the pro-inflammatory role of extracellular HMGB1 
released from stressed or dying hepatocytes during DILI. Moreover, these findings 
are relevant to multiple inflammatory diseases, where HMGB1 has been implicated 
as an important pathogenic mediator.  
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